

BIOGRAPHICAL SKETCH

**Borja Ibáñez**

Madrid, 9<sup>th</sup> June 1975 (46 years)

E-mail

[bibanez@cnic.es](mailto:bibanez@cnic.es)

[bibanez@fjd.es](mailto:bibanez@fjd.es)

[bibanez@secardiología.es](mailto:bibanez@secardiología.es)

POSITION TITLE

- **Full Professor** Cardiovascular Research.
- **Director Clinical Research** Department, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Spain.
- Staff Catheterization Laboratory, **Cardiology Department**, Fundación Jiménez Díaz Hospital, Madrid, Spain.

EDUCATION/TRAINING

INSTITUTION AND LOCATION

DEGREE

YEAR (s)

FIELD OF STUDY

Universidad Complutense de Madrid, Spain

MD

1993-1999

Medicine

Universidad Autónoma de Madrid, Spain

PhD

2010

Medicine

**Index**

Index .....	1
Biosketch .....	2
Positions and Certifications.....	3
Honors and Awards .....	3
Peer Review Activities .....	5
Memberships and Committees .....	6
Clinical Practice Guidelines .....	7
Teaching activities .....	7
Organization of Scientific Meetings.....	8
Chapters in books (Total=23).....	8
Publications (Total=327) .....	12
Metrics updated June 2022.....	60
Research Support .....	61
Patents.....	65
Invited presentations to international conferences (selected from > 70).....	66
Mentorship and Training: PhD thesis and postdoctoral fellows.....	71

## Biosketch

Borja Ibanez (Madrid, 1975). Medical Doctor (Universidad Complutense de Madrid), and PhD (Universidad Autónoma de Madrid). Cardiology training at Fundación Jiménez Díaz University Hospital in Madrid. After completing MD and Cardiology training in Madrid, I moved to Mount Sinai School of Medicine, NY, USA to perform a 3 years training in basic and translational research. After returning to Spain, I started my independent career in 2009 as Group Leader at the CNIC. Since then I devote a 20% dedication to clinical cardiology at University Hospital Fundación Jiménez Díaz. This clinical activity is critical for my overall research plan since it allows me to be updated on the clinical needs and bring clinical questions to the lab to better understand pathophysiological processes and/or to find new therapeutic targets. I am also PI of a consolidated group of the national CIBER Cardiovascular. My primary scientific interest is to study myocardial diseases. I have devoted much efforts of my group to study acute myocardial infarction (ischemia/reperfusion injury), both at the basic research level (eg J Am Coll Cardiol 2016) and clinical levels even leading multicenter clinical trials where therapies identified by us in the lab have been proven beneficial to patients (eg Circulation 2013, Lancet 2019, NEJM 2021). We have identified the critical role of neutrophil's beta1 adrenergic receptor activation during reperfusion injury (eg Nature Commun 2017, Eur Heart J 2020). We use non-invasive imaging as a tool to better understand biological processes occurring in the heart during disease conditions in a longitudinal and in-vivo conditions. By using this technology, we have unraveled novel processes involved in irreversible damage during myocardial infarction, such as the dynamics of post-reperfusion myocardial inflammation/healing (eg Circ Res 2017). More recently, I started a line dedicated to study the role mitochondrial dynamics in heart failure (Science 2015). The knowledge we gained about mitochondrial biology in myocardial disease allowed us to better understand anthracycline-induced cardiotoxicity (eg J Am Coll Cardiol 2019). Within my ongoing ERC CoG grant, we have identified remote ischemic conditioning as an intervention protecting the heart from anthracycline-induced cardiotoxicity by preventing mitochondrial fragmentation and dysregulated autophagy (Cardiovasc Res 2020). Based on these data, I am leading a multinational randomized clinical trial that will enroll 600 cancer patients undergoing chemotherapy to test this novel intervention as a means to reduce the incidence of heart failure in cancer survivors.

According to Web of Science (WOS, November 2020), I have published 254 scientific articles, 50% as main author, which have received 12903 citations (50.8 cites per article). My H-index is 46. I have written 22 chapters in books, some of them in reference textbooks of clinical cardiology or cardiovascular development. I have obtained overlapping competitive funding from national and international agencies since I became independent. Among them, I am recipient of an *ERC Consolidator* grant (2018 call) and I am coordinator of a *H2020-HEALTH* (2019 call), and several H2020 consortium grants. I am inventor of 4 patents.

To tackle scientific questions from disparate angles, I have built a highly multidisciplinary group including basic researchers, clinicians, physicists, and engineers. I have directed 23 doctoral thesis (plus 4 ongoing), and supervised 5 postdoctoral fellows (including one Marie Curie Individual Global Fellowship).

I am Associate Editor at the Journal of American College of Cardiology and I am member of several editorial boards. I actively participate in grant evaluations at the international level and I served as President of the Cardiovascular Panel for the ISCiii FIS funding scheme.

I have participated in several European Society of Cardiology (ESC) Clinical Practice Guidelines, serving as Chairman of the ESC Clinical Practice of ST-Elevated Acute Myocardial Infarction in 2017.

## Positions and Certifications

- 6/2000-6/2005: Clinical Fellowship in Cardiology, Fundación Jiménez Díaz Hospital, Universidad Autónoma de Madrid (Professor Farré), Madrid, Spain.
- 6/2005-5/2008: Research Fellowship, Atherothrombosis Research Unit (Professor JJ Badimon), Cardiovascular Institute (Professor V Fuster), Mount Sinai School of Medicine, New York, NY, USA.
- 5/2008-4/2009: Assistant Professor, Interventional Cardiology Laboratory, Cardiology Department, Fundación Jiménez Díaz, Madrid, Spain.
- 4/2009-5/2014: Associate Professor, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
- 5/2009-8/2015: Clinical Cardiologist- Staff in Interventional Cardiology, Cardiovascular Institute, Hospital Clínico San Carlos, Madrid, Spain.
- 6/2014-Present: Full Professor, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
- 9/2015-Present: Clinical Cardiologist- Staff in Interventional Cardiology, Fundación Jiménez Díaz Hospital, Universidad Autónoma, Madrid, Spain.
- 1/2015-Present: Director Clinical Research Department, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
- 06/2017- Accreditation in Interventional Cardiology by the Spanish Society of Cardiology (Interventional Cardiology section).
- 10/2017- ANECA certification as Professor (“acreditado como profesor contratado doctor y como profesor de Universidad privada por la ANECA”).

## Honors and Awards

- **Forbes list 2021 “best 100 physicians in Spain” (Top cardiologist).** <https://forbes.es/listas/132988/los-100-mejores-medicos/> 2021
- **Recipient of the order of merit “Cruz Azul Zendal-Balmis”** granted by the “Orden Gran Cruz Azul de Emergencias” for his contribution in the fight against COVID-19 pandemics. October 2021
- **Forbes list 2020 “best 100 physicians in Spain” (Top cardiologist).** 2020
- **Winner (Ex Aequo) 3<sup>rd</sup> Edition “Fundación Jesús Serra Investigación Clínica” award,** “Nutritional approaches for cancer therapy cardiotoxicity”. June 2021
- **Winner 6<sup>th</sup> Edition “CONSTANTES Y VITALES” award,** Category “Young Talent in Biomedical Research”. November 2020
- **Forbes list 2019 “best 100 physicians in Spain” (Top 10 cardiologist).** 2019
- **Winner 2019 Best Senior Investigator Quironsalud.**
- **Winner 2018 Best Senior Investigator Quironsalud.**
- **Winner of XII Banco Sabadell Foundation “Award in Biomedical Research”** for the innovative contribution in the battle against cardiovascular diseases through the translation of basic and technological knowledge to the prevention and treatment of this condition. July 2017
- **College of Physicians of Cordoba National Research Award 2014 Winner** for the work “Effect of early metoprolol on infarct size in ST-segment elevation myocardial infarction patients undergoing primary PCI: the METOCARD-CNIC trial”. Ibanez B et al.
- **European Resuscitation Council Award Best Presentation 2014 (2<sup>nd</sup> place).** International European Resuscitation Symposium “Resuscitation 2014”, Bilbao May 2014. “Pre-hospital metoprolol administration in killip-class i-ii anterior st-segment elevation acute myocardial infarction is safe and reduces infarct size and adverse events. Insights from the metocard-cníc trial”. A Mateos-Rodríguez, I García-Lunar, JM García-Ruiz,

- G Pizarro, J Valenciano-Rodriguez, P Huertas, R Fernandez-Jimenez, A Garcia-Alvarez, L Fernandez-Friera, JA Iglesias-Vazquez, MJ Fernandez-Campos, B Ruiz-Mateos, J Bravo, A Fernandez-Ortiz, A Albarran, A Iñiguez, E Corral, C Macaya, Valentin Fuster, V Sanchez Brunete-Ingelmo, **B Ibañez**.
- **Spanish Society of Cardiology Winner Award Best Presentation 2013.** National Spanish Cardiology Congress, Valencia, Spain. October 2013; Sociedad Española de Cardiología. Ganador Mejor comunicación 2013. Sevilla " Estimulación adrenérgica B3 como nueva alternativa terapéutica en hipertensión pulmonar aguda y crónica" A García-Álvarez, D Pereda, M Nuño-Ayala, R F-Jiménez, D Sanz-Rosa, JM García-Ruiz, V Fuster, y **B Ibañez**.
  - **Spanish Society of Cardiology Winner Award Best Presentation 2012.** National Spanish Cardiology Congress, Sevilla, Spain. October 2012; Sociedad Española de Cardiología. Ganador Mejor comunicación 2012. Sevilla "Receptor  $\beta_3$ -adrenérgico: nueva diana terapéutica para reducir el tamaño del infarto. Estudio traslacional con resonancia magnética" JM García-Ruiz, D Sanz-Rosa, J García-Prieto, A García-Alvarez, L Fernandez-Friera, M Nuño-Ayala, V Fuster y **B Ibañez**.
  - **Spanish Society of Cardiology Winner Award Oral Communication 2011.** Annual Meeting of The Spanish Society of Cardiology, Murcia. The transcription factor NF-Y is activated during atherosclerosis and restenosis post-stent and is essential for PDGF-BB-induced mitogenesis in vascular smooth muscle cells C. Silvestre, P.Fernández, Ó.Pello, R.Viana, C.Indolfi, C.Rodríguez, R.Rodríguez-Calvo, P.Martín-Fuentes, M.Solanas-Barca, F.Civeira, G.Bauriedel, R.Hutter, V.Fuster, **B.Ibañez**, FJ.Chaves, J.Martínez-González, V.Andrés
  - **Winner (Ex Aequo) of the First Scientific Research Award from the Princess of Girona Foundation** for the contribution in the field of cardiology research. July 2010
  - **ESC Young Investigator Award in Thrombosis Finalist.** European Society of Cardiology Congress, Barcelona, Spain. September 2009; "Despite similar cholesterol removing abilities, recombinant HDL-Milano exerts greater anti-inflammatory properties than wild type-HDL" **B Ibanez**, G. Cimmino, C. Giannarelli, A. Pinero, CG Santos-Gallego, G. Vilahur, V. Fuster, L. Badimon, JJ. Badimon.
  - **Spanish Society of Cardiology Winner Award Best Presentation 2008.** National Spanish Cardiology Congress, Bilbao, Spain. October 2008; "El HDL-recombinante (apoA-I<sub>Milano</sub>) tiene un efecto estabilizador de la placa de ateroma marcadamente superior al del HDL-nativo" **B Ibanez**, G Vilahur, A Pinero, G Cimmino, V Fuster, L Badimon, JJ Badimón.
  - **Spanish Society of Cardiology Winner Award Best Presentation 2007.** National Spanish Cardiology Congress, Madrid, Spain. October 2007; "La administración aguda de HDL-recombinante (apoA-I Milano) induce una regresión y estabilización acelerada de la placa aterosclerótica" **B Ibanez**, G Vilahur, A Pinero, CG Santos-Gallego, L Badimón, V Fuster, JJ Badimón.
  - **ESC Young Investigator Award in basic Science Finalist.** European Society of Cardiology Congress, Vienna, Austria. September 2007; "Atherosclerotic plaque regression and stabilization following short term treatment with ApoA-I<sub>Milano</sub>" **B Ibanez**, G. Vilahur, G. Cimmino, WS. Speidl, A. Pinero, MU. Zafar, BG. Choi, I. Sorokin, V. Fuster, JJ. Badimon.
  - **Siemens Outstanding Academic Award (S.O.A.R) Finalist.** Second scientific meeting of the Society of Cardiovascular Computed Tomography (SCCT). July 5-8 2007 Washington DC. Utility of 64-Slice Computed Tomography to Monitor Changes in Atheroma Volume. **Borja Ibanez**.
  - **AHA Young Investigator Award Finalist.** 34<sup>th</sup> Annual Meeting, North American Society for Cardiac Imaging, Las Vegas, 6-10 October 2006. Cardiac Magnetic Resonance Imaging (MRI) is a Useful Tool for the Evaluation of Post-Ischemic Stunned Myocardium. Histopathological Validation in a Porcine Model.

**Borja Ibanez**, Gemma Vilahur, Susanna Prat, Javier Sanz, Walter S Speidl, M. Urooj Zafar, Brian G Choi, Giovanni Cimmino, Gregg Goldschlager, Valentin Fuster, Bernardo Nadal-Ginard, Juan J. Badimon.

- **Spanish Society of Cardiology Runner-up Best Presentation 2003.** XXXVIII National Spanish Cardiology Congress, Sevilla, Spain. October 2003; “Tako-tsubo: First non Japanese Series of a Novel Cardiomyopathy” **B Ibanez**, P Marcos-Alberca, Felipe Navarro, Miguel Orejas, C de Diego, J Higuera, J de la Paz, J Farré.
- **Winner 2nd “Siemens” Award.** Course and annual echocardiography meeting, Hospital General Universitario Gregorio Marañón, Madrid, Spain. June 2003. Case: “Auricular Mass: Another Myxoma?” **B Ibanez**, M Orejas, P Marcos-Alberca, R Rabago, M Rey.
- **Winner 1st “Siemens” Award.** Course and annual echocardiography meeting, Hospital General Universitario Gregorio Marañón, Madrid, Spain. June 2002. Case: “Auricular masses: are all mixomas?” **B Ibanez**, M Orejas, P Marcos-Alberca, R Rabago, M Rey.

## Peer Review Activities

### SCIENTIFIC JOURNALS

- Associate Editor Journal of American College of Cardiology (mar 2014-present).
- Specialty Editor, European Heart Journal (2020-present)
- Guest Editor EHJ- Acute Cardiovascular Care (2020-present)
- Guest Editor Basic Res Cardiol (2018-present).
- Guest Editor JACC: Cardiovascular Imaging (2020-present)
- Guest Editor JACC- Basic to Translational Science (2017-present)
- Member of Editorial Board of EHJ-Acute Cardiovascular Care
- Member of Editorial Board Basic Research Cardiology
- Member of Editorial Board JACC: CardioOncology
- Member of Editorial Board Journal of Cardiovascular Translational Research
- Member of Editorial Board REC Interventional Cardiology.
- Ad-hoc Reviewer for: Lancet, Eur Heart J, J Am Coll Cardiol, Circulation, Circulation Research, Circulation: CV Imaging, Basic Research Cardiology, Heart, JACC interventions, JACC: Cardiovascular Imaging, Cardiovascular Research, European Radiology, British Medical Journal (BMJ), Biomaterials, JAHA.

### FUNDING AGENCIES

- National
- President of the Cardiovascular Disease Panel of the “Health Research Projects (FIS)” Funding Agency from the National Institute of Health Carlos III (2018 & 2019)
- Adjunct to the president of the Cardiovascular Disease Panel of the “Health Research Projects (FIS)” Funding Agency from the National Institute of Health Carlos III (2014-2017)

- Panel member-evaluator for the “Health Research Projects (FIS)” Funding Agency from the National Institute of Health Carlos III (2013-2019)
- Panel member (“comisionado”) of the DPT panel (diagnostic, prognostic and therapeutic tools) from the “Agencia Estatal de Investigación” (AEI), Ministry of Science and Innovation (2020-2021)
- Ad hoc reviewer for the Spanish Agency for Evaluation and Prospective (ANEP).
- Ad hoc reviewer for Spanish Society of Cardiology annual grants.

#### International

- Ad hoc reviewer for UK Medical Research Council (MRC)
- Ad hoc reviewer for the MUI-START program from the Medical University of Innsbruck.
- Ad hoc reviewer for the Argentinian “Fondo para la Investigación Científica y Tecnológica” (FONCYT), Argentina.
- Ad hoc reviewer for the “PICT (Proyectos de Investigación Científica y Tecnológica, Ministerio de Ciencia, Tecnología e Innovación Productiva de la República Argentina”, Argentina.
- Committee member for **ESC** Grants 2016-2018
- Member of the European Association of Cardiovascular Imaging (EACVI), European Society of Cardiology (ESC), Research Grants Grading Committee 2018

## Memberships and Committees

- Fellow of the European Society of Cardiology (FESC).
- Member **ESC** Congress Programme Committee (CPC) for ESC Congress 2019, Paris
- Member **ESC** Congress Programme Committee (CPC) for ESC Congress 2020, Amsterdam
- Member of the **ESC** Credentials Committee 2016-2018
- Member of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
- Member of the European Society of Cardiology (ESC) Working group on Myocardial Function
- Member of the ESC Council of Cardiooncology

- Permanent member of the Spanish Society of Cardiology.
- Working Group on Ischemic Heart Disease of the Spanish Society of Cardiology.
- Working Group on Experimental Cardiology of the Spanish Society of Cardiology.
- Working Group on Interventional Cardiology of the Spanish Society of Cardiology.

#### BOARDS MEMBERSHIP:

- Member of the Scientific Advisory Board (SAB) of the Frans Van de Werf Fund, Leuven, Belgium (2019-present)
- Member of the SAB of the forthcoming ICON 'Interfaculty Center for endocrine and cardiovascular disease network modelling and clinical transfer', Ludwig-Maximilians University Munich, Germany (2018-present)
- Member of the SAB of the CRC1116 Research Program, Düsseldorf, Germany (2019-present)
- Member of the SAB of the “Instituto de Investigación Sanitaria Hospital Gregorio Marañón (*IIISGM*), Spain (2019-present).
- Member of the Jury for the Banc Sabadell awards in Biomedical Science (2020-present).

#### JURY OF DOCTORAL THESIS:

- Soumaya Ben-Aicha (President of the Jury). University of Barcelona (UB). June **2020**.

- José Angel Nicolás Ávila. University Autonoma de Madrid. **2020**
- Xin Li. Universidad Complutense de Madrid. October **2018**.
- Marta Roche. University Autónoma Madrid. September **2017**.
- Isaac Martínez Bendayan. University of Santiago Compostela. September **2017**.
- Elisa Ramírez Bustillo. Universidad Autónoma de Madrid. **2015**
- Javier Higuera. Universidad Autónoma de Madrid. **2014**
- Marta Carmen Guadamillas Mora. Universidad Complutense de Madrid. **2012**
- Leticia Fernandez-Friera. Universidad de Cantabria. **2011**

## Clinical Practice Guidelines

- **Chairman** of the 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
- Board member of the ESC Clinical Practice Guidelines (**CPG**) Committee (2022-present).
- Member of the writing committee of the “ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic”
- Official document reviewer 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease.
- Official document reviewer 2018 ESC/EACTS Guidelines on myocardial revascularization
- Official document reviewer 2018 ESC/ACC/AHA/WHF Fourth universal definition of myocardial infarction.
- Official document reviewer 2019 ESC/ERS ESC Guidelines for the diagnosis and management of acute pulmonary embolism.
- Official document reviewer 2020 ESC Guidelines on Acute Coronary Syndromes (ACS) in Patients Presenting without Persistent ST-Segment Elevation.
- Secretary of the Spanish Society of Cardiology Committee for Clinical Practice Guidelines Commentaries (2018 & 2019).

## Teaching activities

- ANECA certification as Professor (“acreditado como profesor contratado doctor y como profesor de Universidad privada por la ANECA”).
- Lecturer at Master’s degree, BMM9 module, Universidad Autonoma de Madrid, Spain. 2010-present.
- Lecturer at bachelor degree in Medicine, Universidad Autonoma de Madrid, Spain. Course 2017-2018.
- Director training program, National Network for Biomedical Research in Cardiovascular Diseases (CIBERCV), Spain. 2017-present.
- Lecturer at PhD course in ischemia/reperfusion (“218-06/01 Ischemia-reperfusion injury and organ protection”). Aarhus University, Denmark. Course 2013-2014.
- Lecturer at Master Course in Advance Heart Failure (“Master teórico-práctico en insuficiencia cardiaca crítica y avanzada (micca)”). Lesson “Estudio de las causas y mecanismos de la insuficiencia mitral grave”. Universidad Complutense Madrid. Course 2018-2019.
- Lecturer at Master course in advanced care of patients in anesthesia, resuscitation and treatment of pain (“Máster Universitario en Cuidados Avanzados del Paciente en Anestesia, Reanimación y Tratamiento del Dolor”). Subject “Metodología de Investigación Cuantitativa”. Lesson “Proyecto de investigación. Pertinencia, Planteamiento, Teoría y marco de la investigación”. Universidad Autónoma de Madrid. Course 2020-2021

- Co-Director of Master in cardio-oncology (“Experto Universitario en El Manejo Global de la Cardiotoxicidad en el Paciente Oncológico”). Universidad Cardenal Herrera CEU. Course 2020-2021
- Faculty at the University Master “Cuidados Avanzados del Paciente en Anestesia, Reanimación y Tratamiento del Dolor”, Universidad Autonoma de Madrid, Spain. 2021-present.

## Organization of Scientific Meetings

- Director of the annual Course “Cardiovascular pathophysiology: from symptoms to genes”. Spanish Society of Cardiology / National Center for Cardiovascular Research Joint Program, Madrid, Spain. 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019.
- Co-Director Course “: NY MOUNT SINAI EXPERIENCE: Spanish Society of Cardiology / National Center for Cardiovascular Research Exchange Cardiology Program”, NY USA. 2011
- Director of the International symposium “Post-myocardial infarction tissue characterization by CMR” Madrid Spain. Dec 2017.
- Member of the Scientific Committee, Biannual meeting of the Ischemic cardiomyopathy section, Spanish Society of Cardiology. 16<sup>th</sup> Ed, Seville 2014, 17<sup>th</sup> Ed. Malaga 2016, 18<sup>th</sup> Ed. Santiago 2018, 19<sup>th</sup> Ed. Santander 2020.
- Member of the Scientific Committee “ESC in Asia” meeting. Joint meeting European Society of Cardiology (ESC) & Asian Pacific Society of Cardiology (APSC). Singapore Nov 2019.
- Member of the Scientific Committee “ESC 2019”. Joint meeting European Society of Cardiology (ESC) & World Congress of Cardiology. Paris, Aug-Sept 2019
- Member of the Scientific Committee “ESC 2020”. **Annual meeting of the European Society of Cardiology (ESC)**. Amsterdam, Aug 2020

## Chapters in books (Total=23)

1. **Borja Ibanez**, Antonio Vidal-Puig,  
Cell Biological Bases for Pathology & Disease - An Overview (Chapter 276)  
In: Ralph A. Bradshaw, Gerald W. Hart, and Philip D. Stahl, editors.  
**Borja Ibanez, SECTION EDITOR**  
ENCYCLOPEDIA OF CELL BIOLOGY. SECOND EDITION.  
vol. 6, pp. 492-494. Oxford: Elsevier  
Amsterdam: Elsevier Ltd; **2023**.  
ISBN: 978-0-12-821624-8
2. **Borja Ibanez**, Manesh Patel, Inés García-Lunar, Usman Baber, Jonathan Halperin, Valentin Fuster,  
ST-elevation myocardial infarction (STEMI) (Chapter 18)  
In: Valentin Fuster, Jagat Narula, Prashant Vaishnav, Martin B. Leon, David J. Callans, and John S. Rumsfeld, editors.  
Hurst’s The Heart (15th Edition).  
New York: McGraw-Hill; **2021**.  
ISBN: 978-1264257560



3. Gemma Vilahur, Valentin Fuster, **Borja Ibanez**  
Pathogenesis of coronary thrombosis and myocardial infarction (Chapter 17)  
In: Valentin Fuster, Jagat Narula, Prashant Vaishnav, Martin B. Leon, David J. Callans, and John S. Rumsfeld, editors.  
Hurst's The Heart (15th Edition).  
New York: McGraw-Hill; **2021**.  
ISBN: 978-1264257560
4. Jagat Narula; Renu Virmani; Navneet Narula; **Borja Ibanez**; Valentin Fuster  
Pathological Basis of Atherosclerotic Coronary Artery Disease (Chapter 16)  
In: Valentin Fuster, Jagat Narula, Prashant Vaishnav, Martin B. Leon, David J. Callans, and John S. Rumsfeld, editors.  
Hurst's The Heart (15th Edition).  
New York: McGraw-Hill; **2021**.  
ISBN: 978-1264257560
5. **Borja Ibanez**, Stefan James.  
ST-segment elevation myocardial infarction (Chapter 38).  
In: Marco Tubaro, Pascal Vranckx, Susanna Price, Christiaan Vrints, and Eric Bonnefoy, Editors  
ESC Textbook of Intensive and Acute Cardiovascular Care (Third Edition)  
Oxford University Press; **2021**  
ISBN: 9780198849346
6. Gonzalo Pizarro, Rodrigo Fernández-Jiménez, **Borja Ibanez**.  
Prevention of Microvascular Obstruction by Addressing Ischemia Reperfusion Injury—Part B: Cardioprotective  
Therapies (Chapter 15.B).  
In: Giampaolo Niccoli & Ingo Eitel, Editors  
Coronary Microvascular Obstruction in Acute Myocardial Infarction: From Mechanisms to Treatment.  
London: Academic Press; **2018**.  
ISBN: 978-0-12-812528-1
7. **Borja Ibanez**, Sigrun Halvorsen.  
Treatment of ST-segment elevation acute coronary syndromes (Chapter 29.10).  
In: A. John Camm, Thomas F. Lüscher, Gerald Maurer, and Patrick W. Serruys, Editors  
ESC Textbook of Cardiovascular Medicine (Third Edition).  
Oxford University Press; **2018**  
ISBN: 9780198784906
8. Rodrigo Fernández-Jiménez, Brian D. Hoit, Richard A. Walsh, Valentin Fuster, **Borja Ibanez**  
Normal physiology of the Cardiovascular System. (Chapter 5)  
In: Valentin Fuster, Robert Harrington, Jagat Narula, Zubin Eapen, editors.  
Hurst's The Heart (14th Edition).  
New York: McGraw-Hill; **2016**.  
ISBN: 978-0071843249
9. Juan Badimon, **Borja Ibanez**, Valentin Fuster, Lina Badimon  
Coronary thrombosis: local and systemic factors. (Chapter 33)  
In: Valentin Fuster, Robert Harrington, Jagat Narula, Zubin Eapen, editors.  
Hurst's The Heart (14th Edition).  
New York: McGraw-Hill; **2016**.  
ISBN: 978-0071843249
10. Maria E Romero, Rodrigo Fernandez-Jimenez, Elena Ladich, Valentin Fuster, **Borja Ibanez**, Renu Virmani.

Pathology of Myocardial Infarction and Sudden Death. (Chapter 37)  
In: Valentin Fuster, Robert Harrington, Jagat Narula, Zubin Eapen, editors.  
Hurst's The Heart (14th Edition).  
New York: McGraw-Hill; **2016**.  
ISBN: 978-0071843249

11. **Borja Ibanez**, Gerd Heusch, David García-Dorado, Derek Yellon.  
Molecular and Cellular Mechanisms of Myocardial Ischemia-Reperfusion Injury. (Chapter 38).  
In: Valentin Fuster, Robert Harrington, Jagat Narula, Zubin Eapen, editors.  
Hurst's The Heart (14th Edition).  
New York: McGraw-Hill; **2016**.  
ISBN: 978-0071843249

12. Rodrigo Fernández-Jiménez, Victor Tapson, Valentin Fuster, **Borja Ibanez**  
Pulmonary thromboembolism. (Chapter 75).  
In: Valentin Fuster, Robert Harrington, Jagat Narula, Zubin Eapen, editors.  
Hurst's The Heart (14th Edition).  
New York: McGraw-Hill; **2016**.  
ISBN: 978-0071843249

13. **Borja Ibanez**, Mauro Giacca.  
Advanced therapies to treat cardiovascular diseases. Controversies and perspectives.  
In: Jose M Pérez-Pomares, Robert Kelly  
ESC Textbook of Cardiovascular Development.  
Oxford University Press; **2016**  
ISBN: 9780199566990

14. Beatriz López-Melgar, Leticia Fernández-Friera, Gonzalo Pizarro, Valentin Fuster, **Borja Ibanez**.  
Assessment of atherosclerotic plaques with magnetic resonance imaging.  
In: Escaned J, Serruys PW, editors.  
Coronary Stenosis: Imaging, Structure and Physiology.  
Europa Edition; **2015**.  
ISBN: 978-2913628564

15. Fernando Herranz, Carlos Perez-Medina, Izaskun Bilbao, Marina Benito, **Borja Ibañez**, Valentin Fuster,  
Jesús Ruiz-Cabello.  
Nanoplatfrom-Based Cardiovascular Molecular Imaging. Chapter 9 (267-303 pp).  
In: Shishir Sinha & Naveen Kumar Navani, editors.  
Nanotechnology: Bioimaging & Vol. 12.  
Studium Press, LLC Houston, USA; **2013**.  
ISBN: 978-1626990128

16. Juan J. Badimon, **Borja Ibanez**, Valentin Fuster, Lina Badimon.  
Coronary Thrombosis: Local and Systemic Factors.  
In: Fuster V, O'Rourke RA, Walsh RA, Poole-Wilson PA, editors.  
Hurst's The Heart (13th Edition).  
New York: McGraw-Hill; **2010**.  
ISBN: 978-0071636469

17. Gonzalo Pizarro, Valentin Fuster MD, Luis Jesús Jiménez-Borreguero, **Borja Ibanez**.

Assessment of atheromatous plaques with magnetic resonance imaging.  
In: Escaned J, Serruys PW, editors.  
Coronary Stenosis: Imaging, Structure and Physiology.  
Europa Edition; **2010**.  
ISBN: 978-2-913628-56-4

18. Juan Badimon, **Borja Ibanez**.  
Diagnosis of Atherosclerosis by Imaging. In: García et al, editors.  
New York, **2009**.  
ISBN: XXX

19. Juan J. Badimon, **Borja Ibanez**, Antonio de Miguel.  
Vascular thrombosis.  
In: Worthley et al, editors. Sidney; **2009**.  
ISBN: XXXX

20. Javier Higuera, Felipe Navarro, **Borja Ibanez**.  
Treatment of bifurcation lesions.  
In: Martín Moreiras, Cruz González, editors.  
Manual de hemodinámica e intervencionismo coronario; **2008**.  
ISBN:13- 9788486671808

21. **Borja Ibanez**, Felipe Navarro, Jerónimo Farré.  
Tako-tsubo syndrome: Paradigm of acute coronary syndrome with normal coronary arteries.  
In: Moreno R, editor. Madrid; **2007**.  
ISBN: XXXX

22. Juan J. Badimon, **Borja Ibanez**, Gemma Vilahur.  
Pathophysiology of arterial thrombosis.  
In: Gresele P, Fuster F, Lopez JA, Page CP, Vermeylen J, editors.  
Platelets in cardiovascular and haematologic disorders: a clinical handbook.  
Cambridge University Press; **2007**.  
ISBN: 978-0521881159

23. Juan J. Badimon, **Borja Ibanez**, Valentin Fuster, Lina Badimon.  
Coronary Thrombosis: Local and Systemic Factors (Chapter 53).  
In: Fuster V, O'Rourke RA, Walsh RA, Poole-Wilson PA, editors.  
Hurst's The Heart (12th Edition).  
New York: McGraw-Hill; **2007**.  
ISBN: 978-0071499286

## Publications (Total=327)

\*corresponding author

### 1. Address Cardiovascular Health in Middle Age: Time to Remove the Blindfold.

Fuster V, and Ibanez B.

*J Am Coll Cardiol* 2023;81:705-707.

IF 27,2

D1

editorial

### 2. Neutrophil $\beta 1$ adrenergic receptor blockade blunts stroke-associated neuroinflammation

Clemente-Moragón A, Oliver E, Calle D, Cussó L, Gómez M, Pradillo JM, Castejón R, Rallón N, Benito JM, Fernández-Ferro JC, Carneado-Ruíz J, Moro MA, Sánchez-González J, Fuster V, Cortés-Canteli M, Desco M, Ibáñez B\*.

*Br J Pharmacol* 2023; 180:459-47.

IF 9,5

D1

article

### 3. Magnetic resonance imaging reference values for cardiac morphology, function and tissue composition in adolescents

Real C, XXXXXXXXXXXX.

*EClinicalMedicine* 2023 (In Press).

IF 17,0

D1

article

### 4. Discussion forum response from authors to letter regarding article, ' Motivational interview and imaging of subclinical atherosclerosis for cardiovascular disease prevention: a winning combination?'

Garcia-Lunar I, Ibanez B, and Fuster V.

*Eur Heart J*. 2023 (In press)

IF 35,9

D1

editorial

### 5. Oral anticoagulants: A plausible new treatment for Alzheimer's disease?

Toribio-Fernandez R, Ceron C, Tristão-Pereira C, Fernandez-Nueda I, Perez-Castillo A, Fernandez-Ferro J, Moro M.A, Ibáñez B, Fuster V, Cortes-Canteli M\*.

*Br J Pharmacol* 2023 (In Press).

IF 9,5

D1

review

### 6. $\beta 3$ -adrenergic agonist treatment in chronic pulmonary hypertension secondary to heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial

García-Álvarez A\*, Blanco I, García-Lunar I, Jordà P, Rodríguez JJ, Fernández-Friera L, Zegri I, Nuche J, Gomez-Bueno M, Prat S, Pujadas S, Sole E, Garcia-Cossio MD, Rivas M, Torrecilla E, Pereda D, Sanchez J, García-Pavía P, Segovia J, Delgado J, Mirabet S, Fuster V, Barberá JA, Ibáñez B.

*Eur J Heart Fail*. 2023 (In Press).

IF 17,3

D1

article

### 7. Reperfusion in ST-elevation myocardial infarction: delays have dangerous ends

Coughlan JJ and Ibanez B\*.

*Eur Heart J* 2023;44:529-531

IF 35,9

D1

editorial

**8. A human hereditary cardiomyopathy shares a genetic substrate with bicuspid aortic valve**

Siguero-Álvarez M, Salguero-Jiménez A, Grego-Bessa J, de la Barrera J, MacGrogan D, Prados B, Sánchez-Sáez F, Piñeiro-Sabarís R, Felipe-Medina N, Torroja C, José Gómez M, Sabater-Molina M, Escribá R, Richaud-Patin I, Iglesias-García O, Sbroggio M, Callejas S, O'Regan DP, McGurk KA, Dopazo A, Giovino G, **Ibañez B**, Monserrat L, María Pérez-Pomares J, Sánchez-Cabo F, Pendas AM, Raya A, Gimeno-Blanes JR, de la Pompa JL.

**Circulation.** 2023;147:47-65 IF 39,9 D1 article

**9. The quest for the mechanism responsible for the cardiovascular benefits of novel antidiabetic agents**

Medina-Hernández D, Galán-Arriola C, and **Ibanez B\***.

**REC: CardioClinics** 2023;58(1):4-6 IF XX X editorial

**10. Beta-3 adrenergic receptor overexpression reverses aortic stenosis–induced heart failure and restores balanced mitochondrial dynamics.**

Pun A, Clemente-Moragón A, Villena-Gutierrez R, Gomez M, Sanz-Rosa D, Díaz-Guerra A, Prados B, Medina JP, Montó F, Ivorra MD, Márquez-López C, Cannavo A, Bernal JA, Koch, WJ, Fuster V, de la Pompa JL, Oliver E, and **Ibanez B\***.

**Basic Res Cardiol** 2022; 117:62 (pages 1-25). IF 12,4 D1 article

**11. The Therapeutic Benefit of Vasodilators in Acute Heart Failure: Absence of Evidence or Evidence of Absence?**

JJ Coughlan, and **B Ibanez\***.

**EHJ: Acute Cardiovascular Care** 2022;11:861-864 IF4,8 Q2 editorial

**12. A polypill treatment strategy in secondary cardiovascular prevention**

Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, Sanchez PL, Marin Ortuño F, Vazquez Rodriguez JM, Domingo-Fernández A, Lozano I, Roncaglioni MC, Baviera M, Foresta A, Ojeda-Fernandez L, Colivicchi F, Di Fusco SA, Doehner W, Meyer A, Schiele F, Ecarnot F, Linhart A, Lubanda JC, Barcsi G, Merkely B, Ponikowski P, Kasprzak M, Fernandez Alvira JM, Andres V, Bueno H, Collier T, Van de Werf F, Perel P, Rodriguez-Manero M, Alonso Garcia A, Proietti M, Schoos MM, Simon T, Fernandez Ferro J, Lopez N, Beghi E, Bejot Y, Vivas D, Cordero A, **Ibañez B**, Fuster V.

**New Engl J Med.** 2022; 387: 967-977 IF 176,1 D1 article

**13. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery.**

Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, De Hert S, de Laval I, Geisler T, Hinterbuchner L, **Ibanez B**, Lenarczyk R, Mansmann UR, McGreavy P, Mueller C, Muneretto C, Niessner A, Potpara TS, Ristić A, Sade LE, Schirmer H, Schüpke S, Sillesen H, Skulstad H, Torracca L, Tutarel O, Van Der Meer P, Wojakowski W, Zacharowski K.

*Eur Heart J* 2022;43:3826-3924

IF 35,9

D1

article

14. **Lp(a): are antithrombotic therapies the key to event reduction?**

Devesa A, **Ibanez B**, Fuster V.

*J Am Coll Cardiol* 2022;80:1299-1301.

IF 27,2

D1

editorial

15. **Bleeding and embolic risk in patients with atrial fibrillation and cancer**

Raposeiras-Roubin S, Abu-Assi E, Fernández Sanz T, Barreiro Pardal C, Muñoz Pousa I, Melendo Viu M, Domínguez Erquicia P, Ledo Piñeiro A, Lizancos Castro A, González Bermúdez I, Rosselló X, **Ibáñez B**, Íñiguez Romo A.

*Rev Esp Cardiol* 2022:S1885-5857(22)00237-7

IF 7,1

Q1

article

16. **Short-term mortality differs between men and women according to the presence of previous cardiovascular disease: Insights from a nationwide STEMI cohort**

González-Del-Hoyo M, Rodríguez-Leor O, Cid-Álvarez AB, de Prado AP, Ojeda S, Serrador A, López-Palop R, Martín-Moreiras J, Rumoroso JR, Cequier Á, **Ibáñez B**, Cruz-González I, Romaguera R, Raposeiras-Roubin S, Moreno R, Rossello X.

*Int J Cardiol* 2022;367:90-98

IF 4,0

Q2

article

17. **Remote Ischaemic Conditioning: defining critical criteria for success: Report from the 11th Hatter Cardiovascular Workshop.**

Bell RM, Basalay M, Bøtker HE, Beikoghli Kalkhoran S, Carr RD, Cunningham J, Davidson SM, England TJ, Giesz S, Ghosh AK, Golfroush P, Gourine AV, Hausenloy DJ, Heusch G, **Ibanez B**, Kleinbongard P, Lecour S, Likhna K, Ntsekhe M, Ovize M, Salama AD, Vilahur G, Walker JM, Yellon DM.

*Basic Res Cardiol* 2022; 117:39.

IF 12,4

D1

review

18. **Post-myocardial infarction risk prediction: Does ventricular shape matter?**

Pizarro G, and **Ibanez B\***

*JACC: Cardiovascular Imaging*. 2022;15:1575-1577

IF 16,1

D1

editorial

19. **The impact of type 2 immunity and allergic diseases in atherosclerosis**

Fernández-Gallego N, Castillo-González R, Méndez-Barbero N, López-Sanz C, Obeso D, Villaseñor A, Escribese MM, López-Melgar B, Salamanca J, Benedicto-Buendía A, Jiménez-Borreguero LJ, **Ibáñez B**, Sastre J, Berver MT, Vega F, Blanco C, Barber D, Sánchez-Madrid F, de la Fuente H, Martín P, Esteban V, Jiménez-Saiz R.

*Allergy* 2022;77:3249-3266

IF 14,7

D1

review

20. **Effects of a comprehensive lifestyle intervention on cardiovascular health: the TANSNIP-PESA trial**

García-Lunar I, van der Ploeg HP, Fernández Alvira JM, van Nassau F, Castellano Vázquez JM, van der

Beek AJ, Rossello X, Fernández-Ortiz A, Coffeng J, van Dongen JM, Mendiguren JM, **Ibáñez B**, van Mechelen W, Fuster V.

**Eur Heart J** 2022;43:3732-3745 IF 35,9 D1 article

21. **The intima-media thickness age is over: the time of multiterritorial subclinical plaque quantification has come.**

**Ibanez B**, García-Lunar I, Fuster V.

**J Am Coll Cardiol** 2022;79:1983-1985. IF 27,2 D1 editorial

22. **Regional analysis of inflammation and contractile function in reperfused acute myocardial infarction by in vivo 19F cardiovascular magnetic resonance in pigs.**

Bönnner F, Gastl M, Nienhaus F, Rothe M, Jahn A, Pfeiler S, Gross U, Schultheiss HP, **Ibanez B**, Kozerke S, Szendroedi J, Roden M, Westenfeld R, Schrader J, Flögel U, Heusch G, Kelm M.

**Basic Res Cardiol** 2022; 117:21. IF 12,4 D1 article

23. **Bone Marrow Activation in Response to Metabolic Syndrome and Early Atherosclerosis**

Devesa A, Lobo-González M, Martínez-Milla J, Oliva B, García-Lunar I, Mastrangelo A, España S, Sanz J, Mendiguren JM, Bueno H, Fuster JJ, Andrés V, Fernández-Ortiz A, Sancho D, Fernández-Friera L, Sanchez-Gonzalez J, Rossello X, **Ibanez B\***, Fuster V\*. **\*co-corresponding authors**

**Eur Heart J** 2022;43:1809-1828 IF 35,9 D1 article

24. **Unbiased plasma proteomics discovery of biomarkers for improved detection of subclinical atherosclerosis**

Núñez E, Fuster V, Gómez-Serrano M, Valdivielso JM, Fernández-Alvira JM, Martínez-López D, Rodríguez JM, Bonzon-Kulichenko E, Calvo E, Alfayate A, Bermudez-Lopez M, Escola-Gil JC, Fernández-Friera L, Cerro-Pardo I, Mendiguren JM, Sánchez-Cabo F, Sanz J, Ordovás JM, Blanco-Colio LM, García-Ruiz JM, **Ibáñez B**, Lara-Pezzi E, Fernández-Ortiz A, Martín-Ventura JL, Vázquez J.

**EBioMedicine**. 2022; 76:103874. doi: 10.1016/j.ebiom.2022.103874 IF 11,2 Q1 article

25. **Targeting inflammation to improve long-term outcome in ST-segment elevation myocardial infarction survivors.**

**Ibanez B**.

**Eur Heart J Acute Cardiovasc Care**. 2022;11:124-126 IF 4,8 Q2 review

26. **New 3-Dimensional Volumetric Ultrasound Method for Accurate Quantification of Atherosclerotic Plaque Volume**

López-Melgar B, Mass V, Nogales P, Sánchez-González J, Entrekin R, Collet-Billon A, Rossello X, Fernández-Friera L, Fernández-Ortiz A, Sanz J, Bentzon JF, Bueno H, Ibáñez B, Fuster V.

**JACC: Cardiovascular Imaging**. 2022;15:1124-1135 IF 16,1 D1 article

**27. Nutrition status, obesity and outcomes in patients with atrial fibrillation.**

Raposeiras-Roubin S, Abu-Assi E, Lizancos Castro A, Barreiro Pardal C, Melendo Viu M, Cespón Fernández M, Blanco Prieto S, Rosselló X, **Ibáñez B**, Filgueiras-Rama D, Íñiguez Romo A.

*Rev Esp Cardiol* 2022;75:825-832. IF 7,1 Q1 article

**28. Analysis of the management of ST-segment elevation myocardial infarction in Spain. Results from the ACI-SEC Infarction Code Registry.**

Rodríguez-Leor O, Cid-Álvarez AB, Pérez de Prado A, Rosselló X, Ojeda S, Serrador A, López-Palop R, Martín-Moreiras J, Rumoroso JR, Cequier Á, **Ibáñez B**, Cruz-González I, Romaguera R, Raposeiras S, Moreno R; investigators of the Infarction Code Working Group of the Interventional Cardiology Association of the Spanish Society of Cardiology.

*Rev Esp Cardiol* 2022;75:669-680. IF 7,1 Q1 article

**29. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)**

Rossello X, Raposeiras-Roubin S, Latini R, Dominguez-Rodriguez A, Barrabés JA, Sánchez PL, Anguita M, Fernández-Vázquez F, Pascual-Figal D, De la Torre Hernandez JM, Ferraro S, Vetrano A, Pérez-Rivera JA, Prada-Delgado O, Escalera N, Staszewsky L, Pizarro G, Agüero J, Pocock S, Ottani F, Fuster V, **Ibanez B\***, REBOOT-CNIC investigators.

*Eur Heart J Cardiovasc Pharmacother* 2022;8:291-301. IF 11,2 Q1 article

**30. Reliability, reproducibility and advantages of measuring carotid total plaque area**

Azarpazhooh MR, Mathiesen E, Rundek T, Romanens M, Adams A, Armando L, Perez H, Villafañe H, Garcia NH, **Ibáñez B**, Bogiatzi C, Tabrizi R, Fuster V, Spence JD.

*J Am Soc Echocardiogr* 2022;35:530-532 IF 7,7 Q1 article

**31. Coronary microcirculation damage in anthracycline cardiotoxicity**

Galán-Arriola C, Vilchez-Tschischke JP, Lobo M, López GJ, de Molina-Iracheta A, Pérez-Martínez C, Villena-Gutiérrez R, Macías Á, Díaz-Rengifo IA, Oliver E, Fuster V, Sánchez-González J, **Ibanez B\***

*Cardiovasc Res.* 2022;118:531-541. IF 14,2 D1 article

**32. Cardioprotective effect of the short-acting betablocker Esmolol in experimental ischemia/reperfusion**

Nuche J, Huertas S, Galán-Arriola C, López-Ayala P, Lobo M, and **Ibanez B\***.

*Rev Esp Cardiol* 2022;75:527-529. IF 7,0 Q1 article

**33. Rationale and Design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.**

Amat-Santos IJ, Sánchez-Luna JP, Abu-Assi E, Melendo Viu M, Cruz-Gonzalez I, Nombela-Franco L, Muñoz García AJ, García Blas S, de la Torre Hernandez JM, Romaguera R, Sánchez-Recalde Á, Díez Gil



JL, López Otero D, Gheorge L, **Ibáñez B**, Iñiguez Romo A, Raposeiras-Roubín S; Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) investigators.

**Eur J Heart Fail.** 2022;24:581-588. IF 17,3 D1 article

34. **The quest for an early marker of anthracycline-induced cardiotoxicity**

**Ibáñez B\***, Moreno-Arciniegas A. \*corresponding author

**JACC Basic Transl Sci.** 2022;7:11-13. IF 9,5 Q1 article

35. **Goat milk exosomes as natural nanoparticles for detecting inflammatory processes by optical imaging.**

Santos-Coquillat A, González MI, Clemente-Moragón A, González-Arjona M, Albaladejo-García V, Peinado H, Muñoz J, Ximénez Embún P, **Ibáñez B**, Oliver E, Desco M, Beatriz Salinas.

**Small.** 2022; 18(6): e2105421. IF 15,2 D1 article

36. **ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: Part 1 – Epidemiology, pathophysiology and diagnosis**

Task Force for the management of COVID-19 of the European Society of Cardiology (B Ibanez listed as author of the Task Force).

**Eur Heart J** 2022;43:1033-1058 IF 35,9 D1 article

37. **ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: Part 2 – Care pathways, treatment and follow-up**

Task Force for the management of COVID-19 of the European Society of Cardiology (B Ibanez listed as author of the Task Force).

**Eur Heart J** 2022;43:1059-1103 IF 35,9 D1 article

38. **Rationale and design of the BA-SCAD (Beta-blockers and Antiplatelet agents in patients with Spontaneous Coronary Artery Dissection) randomized clinical trial.**

Alfonso F, de la Torre Hernández JM, **Ibáñez B**, Sabaté M, Pan M, Gulati R, Saw J, Angiolillo DJ, Adlam D, Sánchez-Madrid F.

**Rev Esp Cardiol** 2022;75:515-522. IF 4,8 Q2 article

39. **Prevalence and prognostic value of monoclonal gammopathy in heart failure patients with preserved ejection fraction: A prospective study.**

Devesa Arbiol A, Rodríguez Olleros C, Kaçi X, Askari E, Camblor Blasco A, Pello Lázaro AM, Gómez Talavera S, Gómez Octavio J, Lapeña G, Navarro F, Tuñón J, **Ibáñez B**, Aceña Á.

**Cardiol J** 2022;29:216-227. IF 3,5 Q3 article

40. **Trade-off between the effects of embolic versus bleeding events on mortality in elderly patients with atrial fibrillation.**

Raposeiras-Roubín S, Abu-Assi E, Cespón Fernández M, Blanco Prieto S, Barreiro Pardo C, Domínguez-Erquicia P, Melendo Viu M, Bonanad Lozano C, Rosselló X, Ibáñez B, Íñiguez Romo A

*Rev Esp Cardiol* 2022;75:334-342. IF 7,0 Q2 article

**41. Intramyocardial Hemorrhage: the final frontier for preventing heart failure post-myocardial infarction**

Berry C, and **Ibanez B**

*J Am Coll Cardiol* 2021;79:49-51. IF 27,2 D1 editorial

**42. Mitral valve prolapse morphofunctional features by cardiovascular magnetic resonance: more than just a valvular disease.**

Romero Daza A, Chokshi A, Pardo P, Maneiro N, Guijarro Contreras A, Larrañaga-Moreira JM, **Ibáñez B**, Fuster V, Fernández Frieria L, Solís J, Sanz J.

*J Cardiovasc Magn Reson.* 2021;23:107. IF 6,9 Q1 article

**43. Biological plausibility behind the benefits of intravenous metoprolol in severe COVID-19**

Santos A, Martínez-Milla J, Pérez-Calvo C, and **Ibanez B\***

*J Am Coll Cardiol* 2021; 79:e13-e14. IF 24,1 D1 letter

**44. Metoprolol in critically ill patients with COVID-19**

Clemente-Moragón A, Martínez-Milla J, Oliver E, Santos A, Flandes J, Fernández I, Rodríguez-González L, Serrano Del Castillo C, Ioan AM, López-Álvarez M, Gómez-Talavera S, Galán-Arriola C, Fuster V, Pérez-Calvo C, **Ibáñez B\***.

*J Am Coll Cardiol* 2021;78:1001-1011. IF 27,2 D1 article

**45. Time-efficient three-dimensional transmural scar assessment provides relevant substrate characterization for ventricular tachycardia features and long-term recurrences in ischemic cardiomyopathy.**

Merino-Caviedes S, Gutierrez LK, Alfonso-Almazán JM, Sanz-Estébanez S, Cordero-Grande L, Quintanilla JG, Sánchez-González J, Marina-Breyse M, Galán-Arriola C, Enríquez-Vázquez D, Torres C, Pizarro G, **Ibáñez B**, Peinado R, Merino JL, Pérez-Villacastín J, Jalife J, López-Yunta M, Vázquez M, Aguado-Sierra J, González-Ferrer JJ, Pérez-Castellano N, Martín-Fernández M, Alberola-López C, Filgueiras-Rama D.

*Sci Rep.* 2021;11:18722 IF 5,0 Q2 article

**46. What's Behind the HbA1c Value?**

Rossello X, **Ibanez B**, Fuster V.

*J Am Coll Cardiol* 2021; 78:e119. IF 27,2 D1 letter

**47. Triglycerides and residual atherosclerotic risk**

Raposeiras-Roubin S, Rossello X, Oliva B, Fernández-Friera L, Mendiguren JM, Andres V, Bueno H, Sanz J, Martínez de Vega V, Abu-Assi E, Iñiguez A, Fernández-Ortiz A, **Ibanez B\***, and Fuster V\*. **\*co-corresponding authors**

*J Am Coll Cardiol* 2021;77: 3031-3041. IF 27,2 D1 article

48. **Intravenous metoprolol during ongoing STEMI ameliorates markers of ischemic injury: a METOCARD-CNIC trial electrocardiographic study**

Díaz-Munoz R, Valle-Caballero MJ, Sanchez-Gonzalez J, Pizarro G, García-Rubira JC, Escalera N, Fuster V, Fernández-Jiménez R, **Ibanez B\***

*Basic Res Cardiol* 2021; 116:45. IF 12,4 D1 article

49. **Closing the Glycemic Divide: The Time for Preventive Cardiology Is Now.**

Shapiro MD, **Ibanez B**

*J Am Coll Cardiol* 2021;78:465-467 IF 27,2 D1 article

50. **Novel device-based therapies to improve outcome in ST-segment elevation myocardial infarction**

De Maria GL, Garcia-Garcia HM, Scarsini R, Finn A, Sato Y, Virmani R, Bhindi R, Ciofani JL, Nuche J, Ribeiro HB, Mathias W, Yerasi C, Fischell TA, Otterspoor L, Ribichini F, **Ibañez B**, Pijls NHJ, Schwartz RS, Kapur NK, Stone GW, Banning AP

*Eur Heart J Acute Cardiovasc Care.* 2021;10:687-697. IF 4,8 Q2 review

51. **Statin use is associated with reduced mortality after respiratory viral infection**

Franco-Peláez JA, Esteban-Lucia L, Zambrano Chacón MLÁ, Pello-Lázaro AM, Venegas Rodriguez AM, Nieto Roca L, García-Talavera CS, Kallmeyer Mayor A, Villar Alvarez F, Fernandez Roblas R, Gonzalez-Lorenzo O, Tuñón J, **Ibañez B**, Aceña A

*ERJ Open Res.* 2021;7:00365-2020. IF 4,2 Q2 article

52. **Glycated hemoglobin and subclinical atherosclerosis in people without diabetes**

Rossello X, Raposeiras-Roubin S, Oliva B, Sánchez-Cabo F, García-Ruiz JM, Caimari F, Mendiguren JM, Lara- Pezzi E, Bueno H, Fernández-Friera L, Fernández-Ortiz A, Sanz J, **Ibanez B\***, and Fuster V\*. **\*co-corresponding authors**

*J Am Coll Cardiol* 2021;77:2777-91 IF 27,2 D1 article

53. **Prevalence of transthyretin amyloidosis in patients with heart failure with preserved ejection fraction and no left ventricular hypertrophy**

Devesa A, Cambor Blasco A, Pello Lázaro AM, Elham Askari E, Lapeña G, Gómez-Talavera S, Taibo Urquía M, Rodríguez Olleros C, Tuñón J, **Ibañez B\***, Aceña A\*. **\*co-corresponding authors**

*ESC Heart Fail.* 2021;8:2856-2865 IF 3,6 Q2 article

54. **Progression of Early Subclinical Atherosclerosis (PESA) Study.**

**Ibanez B**, Fernández-Ortiz A, Fernández-Friera L, García-Lunar I, Andrés V, and Fuster V.

*J Am Coll Cardiol* 2021;78:156–79. IF 27,2 D1 review

55. **2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTEMI-ACS guideline group**

Schiele F, Aktaa S, Rossello X, Ahrens I, Claeys MJ, Collet JP, Fox KAA, Gale CP, Huber K, Iakobishvili Z, Keys A, Lambrinou E, Leonardi S, Lettino M, Masoudi FA, Price S, Quinn T, Swahn E, Thiele H, Timmis A, Tubaro M, Vrints CJM, Walker D, Bueno H; ESC Scientific Document Group, Halvorsen S, Jernberg T, Jortveit J, Blöndal M, **Ibanez B**, Hassager C.

*Eur Heart J Acute Cardiovasc Care.* 2021;10: 224-233 IF 4,8 Q2 review

56. **The Edge of Time in Acute Myocardial Infarction**

Dauerman HL and **Ibanez B**

*J Am Coll Cardiol* 2021;77:1871-1874. IF 27,2 D1 editorial

57. **The art of prescribing beta-blockers after myocardial infarction**

Desta L, Raposeiras-Roubin S, **Ibanez B\***

*Circ Cardiovasc Interv.* 2021; 14(4):e010720 IF 7,5 Q1 editorial

58. **A Novel Circulating MicroRNA for the Detection of Acute Myocarditis**

Blanco-Domínguez R, Sánchez-Díaz R, de la Fuente H, Jiménez-Borreguero LJ, Matesanz-Marín A, Relaño M, Jiménez-Alejandre R, Linillos-Pradillo B, Tsilingiri K, Martín-Mariscal ML, Alonso-Herranz L, Moreno G, Martín-Asenjo R, García-Guimaraes MM, Bruno KA, Dauden E, González-Álvaro I, Villar-Guimerans LM, Martínez-León A, Salvador-Garicano AM, Michelhaugh SA, Ibrahim NE, Januzzi JL, Kottwitz J, Iliceto S, Plebani M, Basso C, Baritussio A, Seguso M, Marcolongo R, Ricote M, Fairweather D, Bueno H, Fernández-Friera L, Alfonso F, Caforio ALP, Pascual-Figal DA, Heidecker B, Lüscher TF, Das S, Fuster V, **Ibáñez B**, Sánchez-Madrid F, Martín P.

*New Engl J Med.* 2021;384:2014-2027. IF 176,1 D1 article

59. **Good night, sleep tight**

García-Lunar I, Fuster V, and **Ibanez B\***

*Eur Heart J* 2021; 42:2100-2102 IF 35,9 D1 editorial

60. **Variations in T2 mapping-assessed area at risk after experimental ischemia/reperfusion**

Gómez-Talavera S, Fernández-Jiménez R, Galán-Arriola C, Agüero J, López-Martín GJ, González ML, López-Ayala P, Vilchez-Tschischke JP, Sánchez-González J, **Ibanez B\***

*J Cardiovasc Transl Res.* 2021;14:1040-1042 IF 3,2 Q3 article

61. **Clinical validation of 3D-ultra-fast CMR protocol including single breath-hold 3D sequences**  
Gómez-Talavera S, Fernandez-Jimenez R, Fuster V, Nothnagel ND, Kouwenhoven M, Clemence M, García-Lunar I, Gómez-Rubín MC, Navarro F, Pérez-Asenjo B, Fernández-Friera L, Calero MJ, Orejas M, Cabrera JA, Desco M, Pizarro G, **Ibanez B\***, and Sánchez-González J\*. **\*co-corresponding authorship**  
*JACC: Cardiovascular Imaging*. 2021;14:1742-1754. IF 16,1 D1 article
62. **Cardiac mitochondrial transplantation: the force awakens**  
**Ibanez B\***, Villena-Gutiérrez R. **\*corresponding author**  
*J Am Coll Cardiol* 2021;77:1989-1992. IF 27,2 D1 editorial
63. **The year in cardiovascular medicine: acute coronary syndromes and intensive cardiac care**  
**Ibanez B\***, Roque D, Price S. **\*corresponding author**  
*Eur Heart J* 2021;42:884-895 IF 35,9 D1 article
64. **Physical Activity-Related Left Ventricular Trabeculation - More Uncertainty Than Ever**  
de la Chica JA; García-Lunar I; Oliva B; Fuster V; and **Ibáñez B\***.  
*J Am Coll Cardiol* 2021;77:663-665 IF 27,2 D1 letter
65. **Effect of COMBinAtion Therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI)**  
García Del Blanco B, Otaegui I, Rodríguez-Palomares JF, Bayés-Genis A, Fernández-Nofrerías E, Vilalta Del Olmo V, Carrillo X, **Ibáñez B**, Wörner F, Casanova J, Pueo E, González-Juanatey JR, López-Pais J, Bardají A, Bonet G, Fuertes M, Rodríguez-Sinovas A, Ruiz-Meana M, Inserte J, Barba I, Gómez-Talavera S, Martí G, Serra B, Bellera N, Ojeda-Ramos M, Cuellar H, Valente F, Carmona MÁ, Miró-Casas E, Marsal JR, Sambola A, Lidón RM, Bañeras J, Elizaga J, Padilla F, Barrabés JA, Hausenloy DJ, Ferreira-González I, García-Dorado D.  
*Basic Res Cardiol* 2021; 116: 4 IF 12,4 D1 article
66. **Subclinical atherosclerosis and brain metabolism in midlife. The PESA study**  
Cortes-Canteli M, Gispert JD, Salvadó G, Toribio-Fernandez R, Tristao-Pereira C, Falcon C, Oliva B, Mendiguren JM, Fernandez-Friera L, Sanz J, Garcia-Ruiz JM, Fernandez-Ortiz A, Sanchez-Gonzalez J, **Ibanez B**, Molinuevo JL, and Fuster V.  
*J Am Coll Cardiol* 2021;77:888–98 IF 27,2 D1 article
67. **Effect of sildenafil on right ventricular performance in an experimental large-animal model of postcapillary pulmonary hypertension**  
Santiago-Vacas E, García-Lunar I, Solanes N, Dantas AP, Ascaso M, Jimenez-Trinidad FR, Ramirez J, Fernández-Friera L, Galán C, Sanchez-Gonzalez, Sabate M, Perez-Villa F, Rigol M, Pereda D, **Ibanez B**, and Garcia-Alvarez A.  
*Transl Res* 2021;228:64-75 IF 7,0 D1 article

**68. Remote Ischemic Preconditioning Ameliorates Anthracycline-induced Cardiotoxicity and Preserves Mitochondrial Integrity**

Galán-Arriola G, Villena-Gutiérrez R, Higuero-Verdejo MI, Díaz-Rengifo IA, Pizarro G, López GJ, de Molina-Iracheta A, Pérez-Martínez C, García RD, González-Calle D, Lobo M, Sánchez PL, Oliver E, Córdoba R, Fuster V, Sánchez-González J, **Ibanez B\***

**Cardiovasc Res.** 2021;117:1132-1143 IF 14,2 D1 article

**69. Beta-blocker effect on ST-segment: a prespecified analysis of the EARLY-BAMI randomised trial.**

Fabris E, Hermanides R, Roolvink V, **Ibanez B**, Ottervanger JP, Pizarro G, van Royen N, Mateos-Rodriguez A, Dambrink JH, Albarran A, Fernández-Avilés F, Botas J, Remkes W, Hernandez-Jaras V, Kedhi E, Zamorano J, Alfonso F, García-Lledó A, van Leeuwen M, Nijveldt R, Postma S, Kolkman E, Gosselink M, de Smet B, Rasoul S, Lipsic E, Piek JJ, Fuster V, van 't Hof AW.

**Open Heart** 2020;7(2):e001316. doi: 10.1136/openhrt-2020-001316. IF XX Q article

**70. Metoprolol exerts a non-class effect against ischemia-reperfusion injury by abrogating exacerbated inflammation**

Clemente-Moragón A; Gómez M; Villena-Gutiérrez R; Lalama DV; García-Prieto J; Martínez F; Sánchez-Cabo F; Fuster V; Oliver E\*; and **Ibañez B\***.

**Eur Heart J** 2020;41:4425-4440 IF 30,0 D1 article

**71. Neurohormonal Modulation as a Therapeutic Target in Pulmonary Hypertension.**

García-Lunar I, Pereda D, **Ibanez B**, García-Álvarez A.

**Cells.** 2020 Nov 22;9(11):E2521. doi: 10.3390/cells9112521. IF 6,6 Q2 review

**72. Myocardial infarction in times of COVID-19.**

**Ibañez B\***.

**Rev Esp Cardiol** 2020; 73:975-977 IF 4,8 Q2 editorial

**73. In-hospital outcomes of COVID-19 ST-elevation myocardial infarction patients.**

Rodriguez-Leor O, Cid Alvarez AB, de Prado AP, Rossello X, Ojeda S, Serrador A, López-Palop R, Martín-Moreiras J, Rumoroso JR, Cequier A, **Ibañez B**, Cruz-González I, Romaguera R, Moreno R.

**EuroIntervention.** 2020;16:1426-1433. IF 6,5 Q1 article

**74. Prevalence and correlates of cardiovascular health among early adolescents enrolled in the SII Program in Spain: a cross-sectional analysis**

Fernandez-Jimenez R, Santos-Beneit G, de Cos-Gandoy A, Fernández-Alvira JM, Tresserra-Rimbau A, Storniole C, Domènech M, Laveriano-Santos EP, Bodega P, de Miguel M, Rodríguez C, Carvajal I, **Ibañez B**, Estruch R, Lamuela-Raventós RM, Fuster V

**Eur J Prev Cardiol.** 2020 In Press (doi: 10.1093/eurjpc/zwaa096) **IF 7,8** **D1** **article**

**75. Identification of a peripheral blood gene signature predicting aortic valve calcification.**

MacGrogan D, Martínez-Poveda B, Desvignes JP, Fernandez-Friera L, Gomez MJ, Gil Vilariño E, Callejas Alejano S, García-Pavía P, Solis J, Lucena J, Salgado D, Collod-Bérout G, Faure E, Théron A, Torrents J, Avierinos JF, Montes L, Dopazo A, Fuster V, **Ibáñez B**, Sánchez-Cabo F, Zaffran S, de la Pompa JL.

**Physiol Genomics** 2020;52:563-574. **IF 3,1** **Q3** **article**

**76. A network of macrophages supports mitochondrial homeostasis in the heart**

Nicolás-Ávila JA, Lechuga-Vieco AV, Esteban-Martínez L, Sánchez-Díaz M, Díaz-García E, Santiago DJ, Rubio-Ponce A, Li JL, Balachander A, Quintana JA, Martínez-de-Mena R, Castejón-Vega B, Pun-García A, Través PG, Bonzón-Kulichenko E, García-Marqués F, Cussó L, A-González N, González-Guerra A, Roche-Molina M, Martín-Salamanca S, Crainiciuc G, Guzmán G, Larrazabal J, Herrero-Galán E, Alegre-Cebollada J, Lemke G, Rothlin CV, J-Borreguero LJ, Reyes G, Castrillo A, Desco M, Muñoz-Cánoves P, **Ibáñez B**, Torres M, Ng LG, Priori SG, Bueno H, Vázquez J, Cordero MD, Bernal JA, Enríquez JA, Hidalgo A.

**Cell** 2020;183:94-109. **IF 41,6** **D1** **article**

**77. The Value of Mouse Models of Rare Diseases: A Spanish Experience**

Murillo-Cuesta S, Artuch R, Asensio F, de la Villa P, Dierssen M, Enríquez JA, Fillat C, Fourcade S, **Ibáñez B**, Montoliu L, Oliver E, Pujol A, Salido E, Vallejo M and Varela-Nieto I

**Front. Genet.** 2020;11:583932. **IF 4,6** **Q2** **review**

**78. New cancer diagnosis after bleeding in anticoagulated patients with atrial fibrillation**

Raposeiras Roubin S, Abu Assi E, Barreiro Pardo C, Cespón Fernandez M, Muñoz Pousa I, Cobas Paz R, Parada JA, Represa Montenegro M, Melendo Miu M, Blanco Prieto S, Rosselló X, **Ibáñez B**, Íñiguez Romo A.

**J Am Heart Assoc.** 2020;9:e016836. **IF 5,5** **Q1** **article**

**79. Myocardial injury determination improves risk stratification and predicts mortality in COVID-19 patients.**

Lorente-Ros A, Monteagudo Ruiz JM, Rincón LM, Ortega Pérez R, Rivas S, Martínez-Moya R, Sanromán MA, Manzano L, Alonso GL, **Ibáñez B**, Zamorano JL.

**Cardiol J.** 2020;7:489-496. **IF 2,7** **Q3** **article**

**80. Intravenous  $\beta$ -blockers in STEMI: what you are about to do, do it quickly**

**Ibanez B\***

**Eur Heart J Acute Cardiovasc Care.** 2020;9:459-461 **IF4,7** **Q2** **article**

**81. ISCHEMIA trial: The long-awaited evidence to confirm our prejudices.**

Cortés C, Johnson TW, Silber S, Buszman PP, Poerner TC, Lavarra F, **Ibáñez B**, Kim Y, Mischke K,

Jaguszewski M, Gutiérrez-Chico JL.

*Cardiol J* 2020;27(4):336-341.

IF 2,7

Q3

editorial

**82. Association Between Body Size Phenotypes and Subclinical Atherosclerosis**

Rossello X, Fuster V, Oliva B, Sanz J, Fernández-Friera L, López-Melgar B, Mendiguren JM, Lara- Pezzi E, Bueno H, Fernández-Ortiz A, **Ibanez B**, Ordovás JM

*J Clin Endocrinol Metab.* 2020;105(12):dgaa620.

IF 6,0

Q1

article

**83. Left ventricular Non Compaction and Vigorous Physical Activity**

de la Chica JA; Gómez-Talavera S; García-Ruiz JM; García-Lunar I; Oliva B; Fernández-Alvira JM; López-Melgar B; Sánchez-González J; de la Pompa JL; Mendiguren JM; Martínez de Vega V; Fernández-Ortiz A; Sanz J; Fernández-Friera L; **Ibáñez B\***; Fuster V. **\*Corresponding author**

*J Am Coll Cardiol* 2020;76:1723–1733.

IF 24,1

D1

article

**84. Five-Year Outcomes and Prognostic Value of Feature-Tracking Cardiovascular Magnetic Resonance in Patients Receiving Early Pre-reperfusion Metoprolol in Acute Myocardial Infarction**

Podlesnikar T, Pizarro G, Fernandez-Jimenez R, Montero-Cabezas JM, Saanchez-Gonzalez J, Bucciarelli-Ducci C, Ajmone-Marsan N, Frasci Z, Bax JJ, Fuster V, **Ibanez B**, Delgado V

*Am J Cardiol* 2020;133:39-47.

IF 2,8

Q3

article

**85. Machine learning improves cardiovascular risk definition for young, asymptomatic individuals**

Sánchez-Cabo F, Rossello X, Fuster V, Benito F, Manzano JP, Silla JC, Fernández-Alvira JM, Oliva B, Fernández-Friera L, López-Melgar B, Mendiguren JM, Sanz J, Ordovás JM, Andrés V, Fernández-Ortiz A, Bueno H, **Ibáñez B**, García-Ruiz JM, Lara-Pezzi E.

*J Am Coll Cardiol* 2020;76:1674-1685.

IF 24,1

D1

article

**86. Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience**

Rodriguez-Leor O, Cid-Alvarez B, Perez de Prado A, Rossello X, Ojeda S, Serrador A, Lopez-Palop R, Martin-Moreiras J, Rumoroso JR, Cequier A, **Ibáñez B**, Cruz-Gonzalez I, Romaguera R, and Moreno R

*Rev Esp Cardiol.* 2020;73:994-1002.

IF 4,8

Q2

article

**87. Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension**

Nuche J, Segura de la Cal T, Jiménez López Guarch C, López-Medrano F, Pérez-Olivares Delgado C, Arribas-Ynsaurriaga F, Delgado JF, **Ibáñez B**, Oliver E, and Escribano Subías P

*Diagnostics.* 2020;10:548

IF 3,7

Q2

review

**88. Metoprolol blunts the time-dependent progression of infarct size**



Lobo-González M; Galán-Arriola C; Rossello X; González-Del-Hoyo M; Vilchez JP; Higuero-Verdejo MI; García-Ruiz JM; López-Martín GJ; Sánchez-González J; Oliver E; Pizarro G; Fuster V; **Ibañez B\***

**Basic Res Cardiol** 2020;115(5):55 IF 17,2 D1 article

89. **Coexistence of transmural and lateral wavefront progression of myocardial infarction in the human heart**

Lorca R, Jiménez-Blanco M, García-Ruiz JM, Pizarro G, Fernández-Jiménez R, García-Álvarez A, Fernández-Friera L, Lobo-González M, Fuster V, Rossello X, and **Ibañez B\***

**Rev Esp Cardiol.** 2020;S1885-5857(20)30336-4 IF 4,8 Q2 article

90. **The pharmaceutical solvent N-methyl-2-pyrrolidone (NMP) attenuates inflammation through Krüppel-like factor 2 activation to reduce atherogenesis**

Roche-Molina M, Hardwick B, Sanchez-Ramos C, Sanz-Rosa D, Gewert D, Cruz FM, Gonzalez-Guerra A, Andres V, Palma JA, **Ibanez B**, Mckenzie G, and Bernal JA.

**Sci Rep.** 2020;10:11636 IF 4,4 Q1 article

91. **Prevalence and prognostic significance of malnutrition in patients with acute coronary syndrome.**

Raposeiras Roubin S, Abu Assi E, Cespón Fernandez M, Barreiro Pardo C, Lizancos Castro A, Parada JA, Pérez DD, Blanco Prieto S, Rossello X, **Ibanez B**, Íñiguez Romo A.

**J Am Coll Cardiol.** 2020 Aug 18;76(7):828-840 IF 24,1 D1 article

92. **Effect Left ventricular functional recovery of infarcted and remote myocardium after ST-segment elevation myocardial infarction (METOCARD-CNIC randomized clinical trial substudy)**

Podlesnikar T, Pizarro G, Fernández-Jiménez R, Montero-Cabezas JM, Sánchez-González J, Bucciarelli-Ducci C, Ajmone N, Fras Z, Bax JJ, Fuster V, **Ibañez B**, Delgado V.

**J Cardiovasc Magn Reson.** 2020;22:44. IF 5,4 Q1 article

93. **T cells with dysfunctional mitochondria induce multimorbidity and premature senescence.**

Desdín-Micó G, Soto-Heredero G, Aranda JF, Oller J, Carrasco E, Gabandé-Rodríguez E, Blanco EM, Alfranca A, Cussó L, Desco M, **Ibañez B**, Gortazar AR, Fernández-Marcos P, Navarro MN, Hernaez B, Alcamí A, Baixauli F, Mittelbrunn M.

**Science** 2020;368:1371-1376 IF 47,7 D1 article

94. **Decreased salivary lactoferrin levels are specific to Alzheimer's disease**

González-Sánchez M, Bartolome F, Antequera D, Puertas-Martín V, González P, Gómez-Grande A, Llamas-Velasco S, Herrero-San Martín A, Pérez-Martínez D, Villarejo-Galende A, Atienza M, Palomar M, Cantero JL, Perry G, Orive G, **Ibañez B**, Bueno H, Fuster V, Carro E.

**EBioMedicine.** 2020;57:102834 IF 8,1 Q1 article

**95. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial.**

Kristensen AMD, Bovin A, Zwisler AD, Cerqueira C, Torp-Pedersen C, Bøtker HE, Gustafsson I, Veien KT, Thomsen KK, Olsen MH, Larsen ML, Nielsen OW, Hildebrandt P, Foghmar S, Jensen SE, Lange T, Sehested T, Jernberg T, Atar D, [Ibanez B](#), Prescott E.

*Trials*. 2020 May 23;21(1):415 **IF 2,3** **Q4** **article**

**96. Ramipril in High Risk Patients with COVID-19.**

Amat-Santos IJ, Santos-Martinez S, López-Otero D, Nombela-Franco L, Gutiérrez-Ibanes E, Del Valle R, Muñoz-García E, Jiménez-Díaz VA, Regueiro A, González-Ferreiro R, Benito T, Sanmartin-Pena XC, Catalá P, Rodríguez-Gabella T, Delgado-Arana JR, Carrasco-Moraleja M, [Ibañez B](#), San Román JA.

*J Am Coll Cardiol* 2020;76:268-276. **IF 24,1** **D1** **article**

**97. Single breath-hold saturation-recovery 3D cardiac T1 mapping via compressed SENSE at 3T**

Ferreira da Silva T, Galan-Arriola C, Montesinos P, López-Martín GJ, Desco M, Fuster V, [Ibañez B](#)\*, Sanchez-Gonzalez J\*. **\*Co-corresponding authors**

*MAGMA* 2020;33:865-876 **IF 2,3** **Q2** **article**

**98. The Obstacle Course of Reperfusion for STEMI in the COVID-19 Pandemics**

Roffi M, Guagliumi G, [Ibanez B](#)

*Circulation* 2020;141:1951-1953 **IF 29,7** **D1** **editorial**

**99. P2Y12 Inhibitors Monotherapy after short course of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: a meta-analysis of randomized clinical trials including 29.089 patients.**

Bianco M, Careggio A, Destefanis P, Luciano A, Perrelli MG, Quadri G, Rossini R, Campo G, Vizzari G, D'Ascenzo F, Anselmino M, Biondi-Zoccai G, [Ibañez B](#), Montagna L, Varbella F, and Cerrato E.

*Eur Heart J Cardiovasc Pharmacother*. 2020;7:196-205 **IF 6,6** **Q1** **article**

**100. Potential molecular pathways related to pulmonary artery aneurysm development. Lessons to learn from the aorta**

Nuche J, Palomino-Doza J, Ynsaurriaga FA, Delgado JF, [Ibañez B](#), Oliver E, Subías PE

*Int J Mol Sci*. 2020 Apr 4;21(7). pii: E2509 **IF 5,9** **Q1** **review**

**101. Translational large animal model of hibernating myocardium: characterization by serial multimodal imaging**

Martínez-Milla J; Galán-Arriola C; Carnero C; Cobiella J; Pérez-Camargo D; Bautista-Hernández V; Rigol M; Solanes N; Villena-Gutierrez R; Lobo M; Mateo J; Vilchez-Tschischke JP; Salinas B; Cussó L; López GJ; Fuster V; Desco M; Sanchez-González J; [Ibanez B](#)\*.

*Basic Res Cardiol* 2020;115:33 **IF 17,2** **D1** **article**

102. **Plasma metabolic signature of atherosclerosis progression and colchicine treatment in rabbits**  
Izidoro M, Cecconi A, Panadero M, Mateo J, Godzien J, Vilchez JP, López-González A, Ruiz-Cabello J, **Ibáñez B**, Barbas C, Rupérez F.  
*Sci Rep.* 2020; 10:7072. doi: 10.1038/s41598-020-63306-y IF 4,4 Q1 article
103. **Short-term Progression of Multiterritorial Subclinical Atherosclerosis**  
López-Melgar B, Fernández-Friera L, Oliva B, García-Ruiz JM, Sánchez-Cabo F, Bueno H, Mendiguren JM, Lara-Pezzi E, Andrés V, **Ibáñez B**, Fernández-Ortiz A, Sanz J, Fuster V.  
*J Am Coll Cardiol* 2020;75:1617-1627. IF 24,1 D1 article
104. **T2 Mapping Early Identifies Anthracycline-Induced Cardiotoxicity in Elderly Patients With Cancer.**  
Martin-Garcia A, Diaz-Pelaez E, Lopez-Corral L, Sanchez-Pablo C, Macias de Plasencia G, Galan-Arriola C, Sanchez-Gonzalez J, Cruz JJ, **Ibanez B**, Sanchez PL.  
*JACC: Cardiovascular Imaging.* 2020;13:1630-1632. IF 14,8 D1 article
105. **Impact of malnutrition in the embolic-haemorrhagic trade-off of elderly patients with atrial fibrillation.**  
Raposeiras-Roubín S, Abu-Assi E, Paz RC, Rosselló X, Barreiro Pardo C, Piñón Esteban M, Pascual CR, García Comesaña J, González-Carrero López A, Caneiro-Queija B, Cespón-Fernández M, Muñoz-Pousa I, Domínguez-Erquicia P, Domínguez-Rodríguez LM, Carpintero A, García E, **Ibanez B**, Iñiguez-Romo A.  
*Europace* 2020;22:878-887. IF 5,2 Q1 article
106. **Design of the "β3-adrenergic agonist treatment in chronic Pulmonary Hypertension secondary to Heart Failure" trial.**  
Garcia-Lunar I, Blanco I, Fernandez-Friera L, Prat-González S, Jorda P, Sanchez-Gonzalez J, Pereda D, Pujadas S, Rivas-Lasarte M, Solé-González E, Vázquez J, Blazquez Z, Garcia-Picart J, Caravaca Perez P, Escalera N, Garcia-Pavia P, Delgado Jimenez J, Segovia-Cubero J, Fuster V, Roig E, Barberá JA, **Ibáñez B\***, García-Alvarez A\*. **Co-corresponding authors.**  
*JACC: Basic to Translational Research.* 2020;5:317-327 IF 8,6 Q1 article
107. **Identification of the culprit artery in inferior myocardial infarction through the 12-lead electrocardiogram**  
Ruiz-Mateos B, García-Borbolla R, Nunez-Gil I, Almendro-Delia M, Vivas D, Seoane-García T, Cristo-Ropero MJ, Izquierdo-Bajo A, Madrona-Jimenez L, Fernandez-Ortiz A, Hidalgo-Urbano R, **Ibanez B**, Garcia-Rubira JC.  
*Coronary Artery Disease* 2020;31:20-26 IF 1,4 Q4 article
108. **Complement C5 Protein as a Marker of Subclinical Atherosclerosis.**

Martínez-López D, Roldan-Montero R, García-Marqués F, Nuñez E, Jorge I, Camafeita E, Minguez P, Rodríguez de Córdoba S, López-Melgar B, Lara-Pezzi E, Fernández-Ortiz A, **Ibáñez B**, Valdivielso JM, Fuster V, Michel JB, Blanco-Colio LM, Vázquez J, Martín-Ventura JL.

*J Am Coll Cardiol* 2020; 75:1926-1941. IF 24,1 D1 article

**109. Effects of Colchicine on Atherosclerotic Plaque Stabilization: a Multi-modality Imaging Study in an Animal Model.**

Cecconi A, Cecconi A, Vilchez-Tschischke JP, Mateo J, Sanchez-Gonzalez J, España S, Fernandez-Jimenez R, Lopez-Melgar B, Fernández Friera L, López-Martín GJ, Fuster V, Ruiz-Cabello J, **Ibanez B\***.

*J Cardiovasc Transl Res.* 2020;4:150-160. IF 3,3 Q2 article

**110. R2 prime (R2') magnetic resonance imaging for post-myocardial infarction intramyocardial hemorrhage quantification**

Rosello X; Lopez-Ayala P; Fernández-Jiménez R; Oliver E; Galán-Arriola C; de Molina-Iracheta A; Agüero J; López GJ; Lobo-Gonzalez M; Vilchez-Tschischke JP; Fuster V; Sánchez-González J, **Ibanez B\***

*Eur Heart J Cardiovasc Imaging* 2020; 21: 1031–1038 IF 6,9 Q1 article

**111. And fibrinolysis became pharmacoinvasive**

**Ibanez B\***

*Eur Heart J* 2020;41:855-857 IF 30,0 D1 editorial

**112. Lipidomic profiling identifies signatures of metabolic risk.**

Yin X, Willinger CM, Keefe J, Liu J, Fernández-Ortiz A, **Ibáñez B**, Peñalvo J, Adourian A, Chen G, Corella D, Pamplona R, Portero-Otin M, Jove M, Courchesne P, van Duijn CM, Fuster V, Ordovás JM, Demirkan A, Larson MG, Levy D.

*EBioMedicine.* 2020;51:102520. IF 8,1 Q1 article

**113. Myocardial function and structure improvement with Sacubitril-Valsartan in cancer therapy-induced cardiomyopathy**

Martin-Garcia A, Diaz-Pelaez E, Martin-Garcia A, Sánchez-González J, **Ibanez B**, Sanchez PL

*Rev Esp Cardiol.* 2020; 73:268-269. IF 4,7 Q1 article

**114. Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction.**

Raposeiras-Roubin S, Abu-Assi E, Cespón-Fernández M, **Ibáñez B**, García-Ruiz JM, D'Ascenzo F, Simao Henriques JP, Saucedo J, Caneiro-Queija B, Cobas-Paz R, Muñoz-Pousa I, Wilton SB, González Juanatey JR, Kikkert WJ, Núñez-Gil I, Ariza-Solé A, Song X, Alexopoulos D, Liebetrau C, Kawaji T, Gaita F, Huczek Z, Nie SP, Yan Y, Fujii T, Correia L, Kawashiri MA, Kedev S, Southern D, Alfonso E, Terol B, Garay A, Zhang D, Chen Y, Xanthopoulou I, Osman N, Möllmann H, Shiomi H, Giordana F, Kowara M, Filipiak K, Wang X, Fan JY, Ikari Y, Nakahayashi T, Sakata K, Yamagishi M, Kalpak O, Íñiguez-Romo A.

- Rev Esp Cardiol.* 2020 73:114-122. IF 4,7 Q1 article
115. **CIBER-CLAP (CIBERCV Cardioprotection Large Animal Platform): A multicenter preclinical network for testing reproducibility in cardiovascular interventions.**  
Rossello R; Rodriguez-Sinovas A; Vilahur G; Crisóstomo1 V; Jorge I; Zaragoza C; Zamorano JL; Bermejo J; Ordoñez A; Boscá L; Vázquez J; Badimón L; Sánchez-Margallo FM; Fernández-Avilés F; Garcia-Dorado D; **Ibanez B\***  
*Sci Rep.* 2019;9:20290 IF 4,0 Q1 article
116. **Transition of Macrophages to Fibroblast-like Cells in Healing Myocardial Infarction**  
N Haidera, L Boscá, HR Zandbergene, JC Kovacic, N Narula, S González-Ramos, M Fernandez-Velasco, S Agrawal, M Paz-García, S Gupta, K DeLeon-Pennelli, V Fuster, **B Ibañez**, J Narula  
*J Am Coll Cardiol* 2019;74:3124-3135. IF 20,6 D1 article
117. **Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.**  
Hausenloy DJ, Kharbanda RK, Møller UK, Ramlall M, Aarøe J, Butler R, Bulluck H, Clayton T, Dana A, Dodd M, Engstrom T, Evans R, Lassen JF, Christensen EF, Garcia-Ruiz JM, Gorog DA, Hjort J, Houghton RF, **Ibanez B**, Knight R, Lippert FK, Lønborg JT, Maeng M, Milasinovic D, More R, Nicholas JM, Jensen LO, Perkins A, Radovanovic N, Rakhit RD, Ravkilde J, Ryding AD, Schmidt MR, Riddervold IS, Sørensen HT, Stankovic G, Varma M, Webb I, Terkelsen CJ, Greenwood JP, Yellon DM, Bøtker HE; CONDI-2/ERIC-PPCI Investigators.  
*Lancet* 2019; 394:1415-1424 IF 60,4 D1 article
118. **Long-term dabigatran treatment delays Alzheimer's disease pathogenesis in the TgCRND8 mouse model**  
Cortes-Canteli M, Kruyer A, Fernandez-Nuedaa I, Marcos-Diaz A, Ceron C, Richards AT, Jno-Charles OC, Rodriguez I, Callejas S, Norris EH, Sanchez-Gonzalez J, Ruiz-Cabello J, **Ibanez B**, Strickland S, and Fuster V.  
*J Am Coll Cardiol* 2019;74:1910-1923 IF 20,6 D1 article
119. **Monoclonal Gammopathy of Uncertain Significance and Transthyretin Cardiac Amyloidosis.**  
Devesa-Arbiol A, Aceña-Navarro Á, Pello-Lázaro AM, Orejas Orejas M, Askari E, Merino Á, Lapeña G, Navarro Del Amo F, **Ibañez B**, Tuñón-Fernández J.  
*Circ Cardiovasc Imaging.* 2019 Sep;12(9):e009493. IF 5,7 Q1 case report
120. **Optimized Treatment of ST-Elevation Myocardial Infarction.**  
Niccoli G, Montone RA, **Ibanez B**, Thiele H, Crea F, Heusch G, Bulluck H, Hausenloy DJ, Berry C, Stiermaier T, Camici PG, Eitel I.  
*Circ Res.* 2019;125:245-258 IF 14,5 D1 review

121. Present and future of medical journals

**Ibanez B\***, Rodés-Cabau J. \*corresponding author

*REC Interv Cardiol.* 2019;1:11-12 IF- -- editorial

122. Quantitative assessment of myocardial blood flow and extracellular volume fraction using <sup>68</sup>Ga-DOTA-PET: a feasibility and validation study in large animals

Velasco C, Mota-Cobián A, Mota RA, Pellico J, Herranz F, Galán-Arriola C, **Ibáñez B**, Ruiz-Cabello J, Mateo J, España S.

*J Nucl Cardiol* 2020;27:1249-1260 IF 3,7 Q2 article

123. CMR endpoints selection in myocardial infarction experimental and clinical trials: from pathophysiology to outcomes. *JACC Scientific Expert Panel.*

**Ibanez B\***; Aletras AH; Arai AE; Arheden H; Bax J; Berry C; Bucciarelli-Ducci C; Croisille P; Dall'Armellina E; Dharmakumar R; Eitel I; Fernández-Jiménez R; Friedrich MG; García-Dorado D; Hausenloy DJ; Kim R; Kozerke S; Kramer CM; Salerno M; Sánchez-González J; Sanz J; Fuster V\*. \*Co-corresponding authors.

*J Am Coll Cardiol* 2019;74:238–56 IF 20,6 D1 article

124. Procedural-related coronary atrial branch occlusion during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction and atrial arrhythmias at follow-up.

Montero Cabezas JM, Abou R, Goedemans L, Agüero J, Schalij MJ, Ajmone Marsan N, Fuster V, **Ibáñez B**, Bax JJ, Delgado V.

*Catheter Cardiovasc Interv.* 2020;;95:686-693 IF 2,0 Q3 article

125. Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study.

Castellano JM, Verdejo J, Ocampo S, Rios MM, Gómez-Álvarez E, Borrayo G, Ruiz E, **Ibáñez B**, Fuster V; SORS investigators.

*Arch Med Res.* 2019 Jan;50(1):31-40 IF 2,1 Q3 article

126. Does socioeconomic status influence the risk of subclinical atherosclerosis? a mediation model

Redondo-Bravo L, Fernández-Alvira JM, Górriz J, Mendiguren JM, Sanz J, Fernandez-Friera L, Garcia-Ruiz JM, Fernández-Ortiz A, **Ibanez B**, Bueno B, Fuster V

*J Am Coll Cardiol* 2019;74:526-535 IF 20,6 D1 article

127. Elevation of ST-segment in aVR is predictive of cardiogenic shock but not of multivessel disease in inferior myocardial infarction.

Ruiz-Mateos B, Almendro-Delia M, Nunez-Gil IJ, García-Borbolla R, Vivas D, Seoane-García T, Lorenzo-

- Lopez B, Garcia-Gonzalez N, Fernandez-Ortiz A, Hidalgo-Urbano R, **Ibanez B**, Garcia-Rubira JC.  
*J Electrocardiol.* 2019;58:63-67. IF 0,9 Q4 article
128. **Prevención primordial cardiovascular: la inteligencia resuelve problemas, la sabiduría los evita.**  
Santos-Beneit, **Ibanez B\***.  
*JACC Spanish Edition.* 2019;9:77-80. IF - - editorial
129. **Role of betablockers in cardiovascular disease in 2019.**  
Martínez-Milla J, Raposeiras-Roubin S, Pascual-Figal D, **Ibanez B\***.  
*Rev Esp Cardiol.* 2019;72:844-852. IF 4,7 Q1 review
130. **Contemporary differences between men and women with acute coronary syndromes: CIAM multicenter registry.**  
Plaza-Martín M, Sanmartín-Fernández M, Álvarez-Álvarez B, Andrea R, Seoane-García T, González-D'Gregorio J, Hernández-Betancor I, Rozado J, Carrasco-Ávalos F, Del Mar Alameda-Ortiz M, Gómez-Talavera S, Sanchís J, Anguita Sánchez M, Peral-Disdier V, **Ibáñez B**, Del Prado Díaz S, Zamorano Gómez JL.  
*J Cardiovasc Med.* 2019;20:525-530 IF 1,2 Q4 article
131. **A simplified formula to calculate fractional flow reserve in sequential lesions circumventing the measurement of coronary wedge pressure: The APIS-S pilot study.**  
Gutiérrez-Chico JL, Cortés C, Jaguszewski M, Schincariol M, Amat-Santos IJ, Franco-Peláez JA, Zuk G, Cieciewicz D, Wojakowski W, Navarro F, Tu S, **Ibáñez B**.  
*Cardiol J.* 2019 2019;26:310-321. IF 1,7 Q3 article
132. **CMR and tissue characterization - don't forget the strain!**  
Galán-Arriola C, Sánchez-González J, **Ibanez B\***  
*J Am Coll Cardiol* 2019; 73:3356-63 IF 20,6 D1 letter
133. **Left ventricular remodeling is no longer a relevant outcome after myocardial infarction**  
**Ibanez B\***, Rossello X. \*corresponding author  
*JACC: Cardiovascular Imaging.* 2019;12:2457-2459 IF 12,7 D1 article
134. **Rationale and design of the school-based SII Program to face obesity and promote health among Spanish adolescents: a cluster-randomized controlled trial**  
Fernandez-Jimenez R, Santos-Beneit G, Tresserra-Rimbau A, Bodega P, de Miguel M, de Cos-Gandoy A, Rodríguez C, Carral V, Orrit X, Haro D, Carvajal I, **Ibáñez B**, Storniolo C, Domènech M, Estruch R, Fernández-Alvira JM, Lamuela-Raventós RM, Fuster V.  
*Am Heart J* 2019;215:27-40. IF 4,2 Q2 article

135. **Pathophysiology and therapy of myocardial ischemia-reperfusion syndrome.**

X Rossello, M Lobo-González, **B Ibanez\***.

***EHJ: Acute Cardiovascular Care*** 2019;8:443-456 IF4,7 Q2 review

136. **In-Vivo Ratiometric Optical Mapping Enables High-Resolution Cardiac Electrophysiology in Pig Models.**

Lee P, Quintanilla JG, Alfonso-Almazán JM, Galán-Arriola C, Yan P, Sánchez-González J, Pérez-Castellano N, Pérez-Villacastín J, **Ibañez B**, Loew LM, Filgueiras-Rama D.

***Cardiovasc Res.*** 2019; 115:1659-1671. IF 8,2 D1 article

137. **Breakfast is a marker for cardiovascular risk prediction.**

**Ibanez B\***, Fernández-Alvira JM. \*corresponding author

***J Am Coll Cardiol*** 2019;73: 2033-2035 IF 20,6 D1 editorial

138. **Vascular Inflammation in Subclinical Atherosclerosis Detected by Hybrid PET/MRI in the PESA study**

Fernández-Friera L, Fuster V, López-Melgar B, Oliva B, Sánchez-González J, Macías A, Pérez-Asenjo B, Zamudio D, Alonso-Farto JC, España S, Mendiguren J, Bueno H, García-Ruiz JM, **Ibañez B**, Fernández-Ortiz A, Sanz J.

***J Am Coll Cardiol*** 2019;73:1371-1382 IF 20,6 D1 article

139. **Early intravenous beta-blockers in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction A patient-pooled meta-analysis of randomized clinical trials**

Hoedemaker NP, Roolvink V, de Winter RJ, van Royen N, Fuster V, García-Ruiz JM, Er F, Gassanov N, Hanada K, Okumura K, **Ibañez B**, van 't Hof AW, Damman P.

***EHJ: Acute Cardiovascular Care*** 2019 (In Press) IF3,8 Q2 article

140. **Sequential bone marrow-cell delivery of VEGFA/S1P improves vascularization and limits adverse cardiac remodeling after myocardial infarction in mice.**

Zak MM, Gkontra P, Clemente C, Squadrito ML, Ferrarini A, Mota RA, Oliver E, Rocha S, Agüero J, Vazquez J, De Palma M, **Ibañez B**, Arroyo AG.

***Hum Gene Ther.*** 2019 Feb 21. doi: 10.1089/hum.2018.194. IF 4,3 Q1 article

141. **From Heart to Head, Thrombi to Emboli, and Inferences to Extrapolation.**

Narula J, **Ibanez B**, Fuster V.

***J Am Coll Cardiol*** 2019;73:1000-3 IF 20,6 D1 editorial



**142. Comments on the 2018 ESC/EACTS Guidelines for Miocardial Revascularization**

**Ibáñez B\***, Bautista-Hernandez V\*, Alfonso F, Berga-Congost G, Bueno H, Carnero M, Cid-Álvarez BA, de la Torre Hernández JM, Franco-Peláez JA, Ojeda S. **\*co-corresponding authors.**

*Rev Esp Cardiol.* 2019;72:16-20 **IF 4,7** **Q1** **article**

**143. A neutrophil timer coordinates immune defense and vascular protection**

Adrover JM, del Fresno C, Crainiciuc G, Cuartero MI, Casanova-Acebes M, Weiss LA, Huerga Encabo H, Silvestre-Roig C, Rossaint J, Cossío I, Lechuga-Vieco AV, García-Prieto J, Gómez-Parrizas M, Quintana JA, Gómez-Moreno D, Martín-Salamanca S, SZ Chong, Evrard M, Balabanian K, López J, Bidzhekov K, Bachelerie F, Abad-Santos F, Muñoz-Calleja C, Zarbock A, Soehnlein O, Weber C, Guan Ng L, Lopez-Rodriguez C, Sancho D, Moro MA, **Ibáñez B**, and Hidalgo

*Immunity* 2019;51:966-967 **IF 22,6** **D1** **article**

**144. Effect of pulmonary artery denervation in postcapillary pulmonary hypertension: results of a randomized controlled translational study**

García-Lunar I; Pereda D; Santiago E; Solanes N; Nuche J; Ascaso M; Bobí J; Sierra F; Dantas AP; Galán-Arriola C; San Antonio R; Sánchez-Quintana D; Sánchez-González J; Barberá JA; Rigol M; Fuster V; **Ibáñez B**; Sabaté M; García-Álvarez A.

*Basic Res Cardiol* 2019;114(2):5 **IF 12,0** **D1** **article**

**145. Rationale and Design of the SII Program for Health Promotion in Elementary Students Aged 6 to 11 years: a Cluster Randomized Trial**

Santos-Beneit G; Bodega P; de Miguel M; Rodríguez C; Carral V; Orrit X; Haro D; Carvajal I; de Cos-Gandoy A; Peñalvo JL; Gómez-Pardo E; Oliva B; **Ibáñez B**; Fernández-Alvira JM; Fernández-Jiménez R; Fuster V

*Am Heart J* 2019;210:9-17 **IF 4,2** **Q2** **article**

**146. Definition of a cell surface signature for human cardiac progenitor cells after comprehensive comparative transcriptomic and proteomic characterization.**

Torán JL, López JA, Gomes-Alves P, Aguilar S, Torroja C, Trevisan-Herraz M, Moscoso I, Sebastião MJ, Serra M, Brito C, Cruz FM, Sepúlveda JC, Abad JL, Galán-Arriola C, **Ibanez B**, Martínez F, Fernández ME, Fernández-Aviles F, Palacios I, R-Borlado L, Vázquez J, Alves PM, Bernad A.

*Sci Rep.* 2019;9:4647 **IF 4,0** **Q1** **article**

**147. The Interleukin-1 Axis and the Risk of Death in Acutely Decompensated Heart Failure.**

Pascual-Figal D; Bayes-Genís A, Asensio López MC, Hernandez-Vicente A, Garrido-Bravo I, Pastor-Perez F, Díez J, **Ibanez B**; and Lax A.

*J Am Coll Cardiol* 2019;73:1016-25 **IF 20,6** **D1** **article**

**148. Generation and characterization of a novel knockin minipig model of Hutchinson-Gilford progeria syndrome.**

Dorado B, Pløen G, Baretino A, Macías A, Gonzalo P, Andrés-Manzano M, González-Gómez C, Galán-Arriola C, Alfonso J, Lobo M, López-Martín G, de Molina A, Sánchez R, Gadea J, Sánchez-González J, Liu Y, Callesen H, Filgueiras D, **Ibañez B**, Sørensen C, Andres V.

*Cell Discov* 2019;5:16. IF 6,3 Q1 article

**149. Three-dimensional cardiac fibre disorganization as a novel parameter for ventricular arrhythmia stratification after myocardial infarction: insights from the pig model .**

Leon DL; López-Yunta M; Alfonso-Almazán JM; Marina-Breysse M; Quintanilla JG; Sánchez-González J; Galán-Arriola C; Castro-Núñez F; González-Ferrer JJ; **Ibañez B**; Pérez-Villacastín J; Pérez-Castellano N; Fuster V; Jalife J; Vázquez M; Aguado-Sierra J; Filgueiras-Rama D.

*Europace* 2019 (In Press) IF 4,0 Q2 article

**150. Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity.**

Galán-Arriola C; Lobo-González M; Vilchez-Tschischke JP; López GJ; de Molina-Iracheta A; Pérez-Martínez C; Agüero J, Fernández-Jiménez R; Martín-García A; Oliver E; Villena-Gutierrez R; Pizarro G; Sánchez PL; Fuster V; Sánchez-González J; and **Ibanez B\***.

*J Am Coll Cardiol* 2019 ;73:779–91 IF 20,6 D1 article

**151. A Polypill strategy at the Heart of cardiovascular secondary prevention.**

**Ibanez B\***, Castellano JM, Fuster V. \*corresponding author.

*Heart* 2019;105:9-10. IF 5,2 Q1 editorial

**152. Implications of bipolar voltage mapping and magnetic resonance imaging resolution in biventricular scar characterization after myocardial infarction.**

López-Yunta M, León DG, Alfonso-Almazán JM, Marina-Breysse M, Quintanilla JG, Sánchez-González J, Galán-Arriola C, Cañadas-Godoy V, Enríquez-Vázquez D, Torres C, **Ibañez B**, Pérez-Villacastín J, Pérez-Castellano N, Jalife J, Vázquez M, Aguado-Sierra J, Filgueiras-Rama D.

*Europace* 2019 ;21:163-174. IF 4,0 Q2 article

**153. Multi-target strategies to reduce myocardial ischemia/reperfusion injury.**

Davidson SM, Ferdinandy P, Andreadou I, Bøtker HE, Heusch G, **Ibañez B**, Ovize M, Schulz R, Yellon DM, Hausenloy DJ, Garcia-Dorado D.

*J Am Coll Cardiol* 2019;73:89–99 IF 20,6 D1 review

**154. Transition from post-capillary pulmonary hypertension to combined pre- and post-capillary pulmonary hypertension in swine: A key role for endothelin"**

van Duin RWB, Stam K, Cai Z, Uitterdijk A, Garcia-Alvarez A, **Ibanez B**, Danser AH, Reiss I, Duncker DJ, and Merkus D.

*J Physiol* 2019; 597:1157-73 IF 4,5 Q1 article

**155. Discussion forum response from authors to letter regarding article, 'Three questions regarding the 2017 ESC STEMI guidelines'.**

**Ibanez B\***, James SK\*.

*Eur Heart J.* 2019 Apr 14;40(15):1242. IF 22,7 D1 editorial

**156. Effect of Early Metoprolol during ST-Segment Elevation Myocardial Infarction on Left Ventricular Strain: Feature Tracking Cardiovascular Magnetic Resonance Substudy from the METOCARD-CNIC trial**

Podlesnikar T, Pizarro G, Fernández-Jiménez R, Montero-Cabezas JM, Sánchez-González J, Bucciarelli-Ducci C, Ajmone N, Frasz Z, Bax JJ, Fuster V, **Ibáñez B**, Delgado V.

*JACC: Cardiovascular Imaging.* 2019;12:1188-1198. IF 12,7 D1 article

**157. oxLDL receptor in lymphocytes prevents atherosclerosis and predicts subclinical disease**

Tsilingiri K, de la Fuente H, Relaño M, Sánchez-Díaz R, Rodríguez R, Crespo J, Sánchez-Cabo F, Dopazo A, Alonso-Lebrero JL, Vara A, Vázquez J, Casasnovas JM, Alfonso F, **Ibáñez B**, Fuster V, Martínez-González J, Martín P, Sánchez-Madrid F.

*Circulation* 2019;139:243-255. IF 23,6 D1 article

**158. Association of sleep duration and quality with subclinical atherosclerosis: insights from the PESA study**

Domínguez F; Fuster V; Fernández-Alvira JM; Fernández-Friera L; López Melgar B; Blanco-Rojo R; Fernández-Ortiz A; García-Pavía P; Sanz J; Mendiguren JM; **Ibáñez B**; Bueno H; Lara-Pezzi E; Ordovás JM.

*J Am Coll Cardiol* 2019;73:134-44 IF 20,6 D1 article

**159. Psychiatric symptoms and gender related differences in patients with myocardial infarction with non-obstructive coronary arteries.**

Dominguez-Rodriguez A, Avanzas P, Baez-Ferrer N, **Ibáñez B**, Morera-Fumero AL, Abreu-Gonzalez P.

*Rev Esp Cardiol.* 2019;72:686-688 IF 4,6 Q1 article

**160. The microRNA-29/PGC1 $\alpha$  regulatory axis is critical for metabolic control of cardiac function.**

Caravia XM, Fanjul V, Oliver E, Roiz-Valle D, Morán-Álvarez A, Desdín-Micó G, Mittelbrunn M, Cabo R, Vega JA, Rodríguez F, Fueyo A, Gómez M, Lobo-González M, Bueno H, Velasco G, Freije JMP, Andrés V, **Ibáñez B\***, Ugalde AP\*, and López-Otín C\*. \*Co-corresponding authors

*PLoS Biol* 2018;16:e2006247 IF 8,4 D1 article

**161. The 10th Hatter Institute workshop on cellular protection: evaluating new directions in the setting of myocardial infarction, ischaemic stroke and cardio-oncology.**

Davidson SM, Arjun S, Basalay MV, Bell RM, Bromage DI, Bøtker HE, Carr R, Cunningham J, Ghosh A,

Heusch G, **Ibanez B**, Kleinbongard P, Lecour S, Maddock H, Ovize M, Walker M, Wiart M, Yellon DM.

**Basic Res Cardiol** 2018;113:43 IF 6,5 Q1 review

**162. Long-term efficacy of losartan vs atenolol to prevent aortic dilation and clinical complications in Marfan syndrome. Losartan vs atenolol in Marfan syndrome.**

Teixido-Tura G, Forteza A, Rodríguez-Palomares J, González-Mirelis J, Gutiérrez L, Sánchez V, **Ibáñez B**, García-Dorado D, Evangelista.

**J Am Coll Cardiol** 2018;72:1613-1618. IF 18,6 D1 article

**163. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection.**

Bøtker HE, Hausenloy D, Andreadou I, Antonucci S, Boengler K, Davidson SM, Deshwal S, Devaux Y, Di Lisa F, Di Sante M, Efentakis P, Femminò S, García-Dorado D, Giricz Z, **Ibanez B**, Iliodromitis E, Kaludercic N, Kleinbongard P, Neuhäuser M, Ovize M, Pagliaro P, Rahbek-Schmidt M, Ruiz-Meana M, Schlüter KD, Schulz R, Skyschally A, Wilder C, Yellon DM, Ferdinandy P, Heusch G.

**Basic Res Cardiol** 2018;112:17 (pages 1-17) IF 6,5 Q1 article

**164. Infarct Size Reduction by Targeting Ischemic Injury: Back to Square One.**

Rossello X, **Ibanez B\***.

**Circ Res.** 2018 Apr 13;122(8):1041-1043 IF 15,9 D1 editorial

**165. Integrating the results of the CULPRIT-SHOCK trial in the 2017 ESC ST-elevation myocardial infarction guidelines: viewpoint of the task force.**

**Ibanez B\***, Halvorsen S, Roffi M, Bueno H, Thiele H, Vranckx P, Neumann FJ, Windecker S, James S\*.  
**\*Co-corresponding authors**

**Eur Heart J** 2018;39:4239-4242. IF 24,9 D1 viewpoint

**166. Mirabegron, a clinically approved  $\beta_3$  adrenergic receptor agonist, does not reduce infarct size in a swine model of reperfused myocardial infarction**

Rossello X, Piñero A, Fernández-Jiménez, Sánchez-González J, Pizarro G, Galán-Arriola C, Lobo-Gonzalez M, Vilchez JP, García-Prieto J, García-Ruiz JM, Garcia-Alvarez A, Sanz-Rosa D, **Ibanez B\***.

**J Cardiovasc Transl Res.** 2018;11:310-318. IF 2,8 Q2 article

**167. Treatment of atrial fibrillation in patients with enhanced sympathetic tone by pulmonary vein isolation or pulmonary vein isolation and renal artery denervation: clinical background and study design : The ASAF trial: ablation of sympathetic atrial fibrillation.**

de Jong MR, Hoogerwaard AF, Adiyaman A, Smit JJJ, Ramdat Misier AR, Heeg JE, van Hasselt BAAM, Van Gelder IC, Crijns HJGM, Lozano IF, Toquero Ramos JE, Javier Alzueta F, **Ibáñez B**, Rubio JM, Arribas F, Porres Aracama JM, Brugada J, Mont L, Elvan A.

**Clin Res Cardiol.** 2018 Jul;107:539-547. IF 4,9 Q1 article

168. **Take a deep (nitric oxide) breath and follow the reverse translational research pathway.**

Lobo M, and **Ibanez B\***.

*Eur Heart J* 2018;39:2726-2729 IF 24,9 D1 editorial

169. **Soluble ST2 is not released in the coronary circulation during ST-elevation myocardial infarction.**

Pérez-Martínez MT, Lacunza-Ruiz J, García de Lara J, Noguera-Velasco JA, Lax A, Hernández-Vicente A, Asensio-López MC, Januzzi JL, **Ibañez B**, Pascual-Figal DA.

*J Am Coll Cardiol* 2018;72:1429-1430 IF 18,6 D1 article

170. **2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).**

**Borja Ibanez\***, Stefan James\*, Stefan Agewall, Manuel J. Antunes, Chiara Bucciarelli-Ducci, Héctor Bueno, Alida L. P. Caforio, Filippo Crea, John A. Goudevenos, Sigrun Halvorsen, Gerhard Hindricks, Adnan Kastrati, Mattie J. Lenzen, Eva Prescott, Marco Roffi, Marco Valgimigli, Christoph Varenhorst, Pascal Vranckx, Petr Widimsky. \***Chairpersons, corresponding authors.**

*Eur Heart J* 2018; 39: 119-177 IF 24,9 D1 article

171. **Deciphering microvascular changes after myocardial infarction through 3D fully automated image analysis.**

Gkontra P, Norton KA, Žak MM, Clemente C, Agüero J, **Ibañez B**, Santos A, Popel AS, Arroyo AG.

*Scientific Reports* 2018 30;8:1854 IF 4,0 Q1 article

172. **Transplantation of allogeneic pericytes improves myocardial vascularization and reduces interstitial fibrosis in a swine model of reperfused acute myocardial infarction**

Alvino VV, Fernández-Jiménez R, Rodríguez-Arabaloaza I, Slater S, Mangialardi G, Avolio E, Spencer H, Culliford L, Hassan S, Sueiro Ballesteros L, Herman A, Ayaon L, Galán-Arriola C, Sánchez-González J, Hennessey H, Delmege C, Ascione R, Emanuelli C, Angelini G\*, **Ibanez B\***, and Madeddu P\*. \* **Co-corresponding authors.**

*J Am Heart Assoc.* 2018 Jan 22;7(2). Pii: e006727. IF 4,7 Q1 article

173. **One year clinical outcome of early administration of intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary reperfusion. One year results from the EARLY-BAMI trial.**

Roolvink V, Ottervanger JP, **Ibañez B**, Dambrink JH, Gosselink M, Kedhi E, van Royen N, Lipsic E, Remkes W, Piek J, Fuster V, van 't Hof A.

*Eurointervention.* 2018;14:688-691 IF 4,0 Q2 article

**174. Left atrial remodeling after acute myocardial infarction: novel insights into the role of atrial infarction.**

Aguero J, Galan-Arriola C, Fernandez-Jimenez R, Sanchez-Gonzalez J, Ajmone N, Delgado V, Solis J, Lopez-Martín, GJ, de Molina-Iracheta A, Hajjar RJ, Bax JJ, Fuster V, and **Ibanez B\***.

*J Am Coll Cardiol* 2017;70:2878–89 IF 18,7 D1 article

**175. CANTOS: a gigantic proof-of-concept trial.**

**Ibáñez B**, and Fuster V

*Circ Res.* 2017;121:1320-1322. IF 15,2 D1 editorial

**176. Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors.**

Fernández-Friera L, Fuster V, López-Melgar B, Oliva B, García-Ruiz JM, Mendiguren J, Bueno H, Pocock S, **Ibáñez B**, Fernández-Ortiz A, Sanz J.

*J Am Coll Cardiol* 2017; 70: 2979-2991 IF 18,7 D1 article

**177. Predicting Subclinical Atherosclerosis in Low-Risk Individuals: Ideal Cardiovascular Health Score and Fuster-BEWAT Score.**

Fernández-Alvira JM, Fuster V, Pocock S, Sanz J, Fernández-Friera L, Laclaustra M, Fernández-Jiménez R, Mendiguren J, Fernández-Ortiz A, **Ibáñez B**, Bueno H.

*J Am Coll Cardiol* 2017;70:2463-2473 IF 18,7 D1 article

**178. Comments on the 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.**

Fernando Alfonso, Alessandro Sionis, Héctor Bueno, **Borja Ibáñez**, Manel Sabaté, Ángel Cequier, José Barrabés, Juan Sanchis, Emad Abu-Assi, and Jaime Aboal.

*Rev Esp Cardiol.* 2017;70:1039-45 IF 5,2 Q1 editorial

**179. Current state of basic and translational cardiovascular research in Spain.**

Lara-Pezzi E, Andrés V, Fernández-Avilés F, Fuster V, and **Ibáñez B\***

*Circ Res.* 2017; 121:1036-1039 IF 15,2 D1 editorial

**180. Proteomic footprint of myocardial ischemia/reperfusion injury: Longitudinal study of the at-risk and remote regions in the pig model.**

Binek A, Fernández-Jiménez R, Jorge I, Camafeita E, López JA, Bagwan N, Galán-Arriola C, Pun A, Agüero J, Fuster V, **Ibanez B\***, Vazquez J\*. **\*Co-corresponding authors.**

*Scientific Reports* 2017;7:12343 IF 4,1 Q1 article

**181. The importance of breakfast in atherosclerosis disease: Insights from the PESA Study**

Uzhova I, Fuster V, Fernández-Ortiz A, Ordovás JM, Sanz J, Fernández-Friera L, López-Melgar B, Mendiguren JM, **Ibáñez B**, Bueno H, Peñalvo JL.

*J Am Coll Cardiol* 2017;70:1833-1842 IF 18,7 D1 article

**182. Dynamic Edematous Response of the Human Heart to Myocardial Infarction: Implications for Assessing Myocardial Area at Risk and Salvage**

Fernández-Jiménez R, Barreiro-Perez M, Martín-García A, Sánchez-González J, Agüero J, Galán-Arriola C, García-Prieto J, Díaz-Peláez E, Vara P, Martínez I, Zamarró I, Garde B, Sanz J, Fuster V, Sánchez PL, **Ibanez B\***.

*Circulation* 2017;136:1288–1300. IF 18,9 D1 article

**183. Effect of Ischemia Duration and Protective Interventions on the Temporal Dynamics of Tissue Composition After Myocardial Infarction.**

Fernández-Jiménez R, Galán-Arriola C, Sánchez-González J, Agüero J, López-Martín G, Gómez-Talavera S, García-Prieto J, Benn A, de Molina A, Barreiro-Perez M, Martín-García A, García-Lunar I, Pizarro G, Sanz J, Sánchez P, Fuster V, **Ibanez B\***.

*Circ Res* 2017;121:439-450 IF 15,2 D1 article

**184. Randomized Clinical Trials Evaluating the Effectiveness of Drugs Targeting Mitochondrial Function on Reperfusion Injury: a Meta-Analysis.**

Campo G, Morciano G, Lincoff MA, Gibson MC, Kitakaze M, Lonborg J, Ahluwalia A, Ishii H, Frenneaux M, Ovize M, Galvani M, Atar D, **Ibanez B**, Cerisano G, Biscaglia S, Neil BJ, Asakura M, Engstrom T, Jones DA, Pavasini R, Ferrari R, Pinton P, Ottani F.

*Int J Cardiol* 2017; 244:59-66 IF 4,0 Q2 article

**185.  $\beta$ 1AR-blockade prevents post-ischemic myocardial decompensation via  $\beta$ 3AR-dependent protective sphingosine-1 phosphate signaling**

Cannavo A, Rengo G, Liccardo D, Pun A, Gao E, George AJ, Gambino G, Rapacciuolo A, Leosco D, **Ibanez B**, Ferrara N, Paolucci N, Koch WJ.

*J Am Coll Cardiol* 2017; 70:182-192 IF 18,7 D1 article

**186. Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention.**

Campo G, Pavasini R, Morciano G, Lincoff MA, Gibson M, Kitakaze M, Lonborg J, Ahluwalia A, Ishii H, Frenneaux M, Ovize M, Galvani M, Atar D, **Ibanez B**, Cerisano G, Biscaglia S, Neil BJ, Asakura M, Engstrom T, Jones DA, Dawson D, Ferrari R, Pinton P, Ottani F.

*Data Brief.* 2017 Jul 18;14:197-205

**187. Predictors of intramyocardial hemorrhage after reperfused ST-elevation myocardial infarction**

Amier RP, Tijssen RYG, Teunissen PFA, Fernández-Jiménez R, Pizarro G, García-Lunar I, Bastante T, van de Ven PM, Beek AM, Smulders MW, Bekkers S, van Royen N, **Ibanez B**, Nijveldt R.

- J Am Heart Assoc.* 2017;6 (8):e005651 IF 4,5 Q1 article
188. **Subclinical Subclinical Atherosclerosis Burden by 3D Ultrasound in Mid-Life. The PESA study**  
López-Melgar B; Fernández-Friera L; Oliva B; García-Ruiz JM; Peñalvo JL; Gómez-Talavera S; Sánchez-González J; Mendiguren JM; **Ibáñez B**; Fernández-Ortiz A; Sanz J; Fuster V.  
*J Am Coll Cardiol* 2017;70:301-313. IF 18,7 D1 article
189. **Influence of the amount of myocardium subtended to a coronary stenosis on the index of microcirculatory resistance. Implications for the invasive assessment of microcirculatory function in ischemic heart disease.**  
Echavarría-Pinto M, van de Hoef T, Nijjer S, Gonzalo N, Nombela Franco L, **Ibáñez B**, Sen S, Petraco R, Jimenez-Quevedo P, Nunez-Gil I, Cerrato E, Salinas P, Quiros A, García-García HM, Fernandez Ortiz A, Macaya C, Davies J, Piek J, Escaned J  
*Eurointervention.* 2017;13:944-952. IF 4,4 Q2 article
190. **The Swing of  $\beta$ -Blockers: time for a System Reboot.**  
**Ibáñez B\***; Raposeiras-Roubin S; García-Ruiz, JM. \*Corresponding author  
*J Am Coll Cardiol* 2017;69:2721-24 IF 18,7 D1 editorial
191. **Lung ultrasound as a translational approach for non-invasive assessment of heart failure with reduced or preserved ejection fraction in mice**  
Villalba-Orero M, López-Olañeta MM, González-López E, Padrón-Barthe L, Gómez-Salineró JM, García-Prieto J, Wai T, García-Pavía P, **Ibáñez B**, Jiménez-Borreguero LJ, Lara-Pezzi E.  
*Cardiovasc Res* 2017;113:1113-23. IF 6,3 Q1 article
192. **Neutrophil stunning by metoprolol reduces infarct size**  
J García-Prieto, R Villena-Gutiérrez, M Gómez, E Bernardo, A Pun-García, I García-Lunar, G Crainiciuc, R Fernández-Jiménez, V Sreeramkumar, R Bourio-Martínez, JM García-Ruiz, A Serrano del Valle, D Sanz-Rosa, G Pizarro, A Fernández-Ortiz, A Hidalgo, V Fuster, **B Ibanez\***.  
*Nature Commun* 2017;8:14780. IF 12,4 D1 article
193. **Intracoronary Administration of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Improves Myocardial Perfusion but not Left Ventricle Function, in a Translational Model of Acute Myocardial Infarction.**  
J Bobi; N Solanes; R Fernández-Jiménez; C Galán-Arriola; A Paula Dantas; L Fernández-Friera; C Gálvez-Montón; E Rigol-Monzó; J Agüero; J Ramírez; M Roqué; A Bayés-Genís; J Sánchez-González; A García-Álvarez; M Sabaté; S Roura; **B Ibáñez**; M Rigol.  
*J Am Heart Assoc.* 2017;6:e005771 IF 4,5 Q1 article

194. **Bloodless reperfusion with the oxygen carrier HBOC-201 in acute myocardial infarction: a novel**



**platform for cardioprotective probes delivery.**

JM. García-Ruiz; C Galán-Arriola; R Fernández-Jiménez; J Agüero; J Sánchez-González; A García-Alvarez; M Nuno-Ayala; GP. Dubé; Z Zafirelis; GJ López-Martín; JA. Bernal; E Lara-Pezzi; V Fuster; **B Ibáñez\***.

***Basic Res Cardiol*** 2017;112:17 (pages 1-17) IF 5,7 Q1 article

**195. Myocardial Extracellular Volume Is not Associated With Malignant Ventricular Arrhythmias in High-risk Hypertrophic Cardiomyopathy**

JG. Mirelis, J Sánchez-González, E Zorio, T Ripoll-Vera, R Salguero-Bodes, D Filgueiras-Rama, E González-López, M Gallego-Delgado, R Fernández-Jiménez, MJ Soleto, J Núñez, G Pizarro, J Sanz, V Fuster, P García-Pavía, and **B Ibáñez\***.

***Rev Esp Cardiol*** 2017;70:933-940 IF 5,2 Q1 article

**196. Nutritional preconditioning by marine omega-3 fatty acids in patients with ST-Segment Elevation Myocardial Infarction: a METOCARD-CNIC trial substudy.**

A Sala-Vila; R Fernández-Jiménez; G Pizarro; C Calvo; JM García-Ruiz; L Fernández-Friera; MD Rodríguez; N Escalera; J Palazuelos; A Macías; B Pérez-Asenjo; A Fernández-Ortiz; E Ros; V Fuster; **B Ibáñez\***

***Int J Cardiol*** 2017; 228:828-833 IF 4,0 Q2 article

**197. Oxidized LDL is associated with metabolic syndrome traits independently of central obesity and insulin resistance**

Y Hurtado-Roca, H Bueno, A Fernandez-Ortiz, JM Ordovas, **B Ibáñez**, V Fuster, F Rodriguez-Artalejo, M Laclaustra.

***Diabetes*** 2017;66:474-482 IF 7,3 D1 article

**198. A 30-month worksite-based lifestyle program to promote cardiovascular health in middle-aged bank employees: design of the TANSNIP-PESA randomized controlled trial.**

JK Coffeng, HP van der Ploeg, JM Castellano, JM Fernández-Alvira, **B Ibáñez**, I García-Lunar, AJ van der Beek, A Fernández-Ortiz, A Moco-roa, L García-Leal, E Cárdenas, C Rojas-Murcia, MI Martínez-Castro, S Santiago, M Fernández-Gallardo, JM Mendiguren, S Bansilal, W van Mechelen, V Fuster.

***Am Heart J*** 2017;184:121-132 IF 4,2 Q2 article

**199. Targeting reperfusion injury in STEMI patients: trials and tribulations.**

Hausenloy DJ, Botker HE, Engstrom T, Erlinge D, Heusch G, **Ibanez B**, Kloner RA, Ovize M, Yellon DM, Garcia-Dorado D.

***Eur Heart J*** 2017;38:935-941 IF 23,4 D1 review

**200. Accuracy of Area at Risk Quantification by Cardiac Magnetic Resonance According to the Myocardial Infarction Territory.**

L Fernández-Friera, JM García-Ruiz, A García-Álvarez, R Fernández-Jiménez, J Sánchez-González, X

Rossello, S Gómez-Talavera, GJ López-Martín, G Pizarro, V Fuster, and **B Ibáñez\***.

*Rev Esp Cardiol* 2017;70:323-330 IF 5,2 Q1 article

**201. Magnetic resonance characterization of cardiac adaptation and myocardial fibrosis in pulmonary hypertension secondary to systemic-to-pulmonary shunt**

D Pereda; I García-Lunar; F Sierra; D Sánchez-Quintana; E Santiago; C Ballesteros; JF Encalada; J Sánchez-González; V Fuster; **B Ibáñez\***; A García-Álvarez\*. **\*Co-corresponding authors.**

*Circulation: Cardiovascular Imaging* 2016;9:e004566 IF 6,8 D1 article

**202. The CNIC: A Successful Vision in Cardiovascular Research**

Fuster V, **Ibáñez B**, Andrés V

*Circ Res.* 2016;119:785-9 IF 14,0 D1 editorial

**203. Circadian variability effectiveness of technical reperfusion and forecasting myocardial infarction ST elevation treated by angioplasty primary.**

MC Barneto; JR Garmendia; D Bautista; JV Beneit; A Fernandez-Ortiz; A Suarez-Barrientos; JL García-Klepzig; MD Aguilar; **B Ibanez**.

*Emergencias* 2016;28:327-332 IF 3,0 Q1 article

**204. Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension.**

A García-Álvarez; D Pereda; I García-Lunar; D Sanz-Rosa; R Fernández-Jiménez; J García-Prieto; M Nuño-Ayala; F Sierra; E Santiago; E Sandoval; P Campelos; J Agüero; G Pizarro; VI Peinado; L Fernández-Friera; JM García-Ruiz; JA Barberá; M Castellá; M Sabaté; V Fuster; **B Ibanez\***.

*Basic Res Cardiol* 2016;111(4):49 IF 5,3 Q1 article

**205. Association between a social-business eating pattern and early asymptomatic atherosclerosis.**

JL. Peñalvo, L Fernández-Friera, B López-Melgar, I Uzhova, B Oliva, JM Fernández-Alvira, M Laclaustra, S Pocock, A Mocoroa, JM. Mendiguren, G Sanz, E Guallar, S Bansilal, R Vedanthan, LJ Jiménez-Borreguero, **B Ibanez**, JM. Ordovás, A Fernández-Ortiz, H Bueno, V Fuster.

*J Am Coll Cardiol* 2016;68:805-14. IF 19,9 D1 article

**206. Leukocyte-Expressed  $\beta$ 2-Adrenergic Receptors are Essential for Survival Following Acute Myocardial Injury.**

LA. Grisanti, AM. Gumpert, CJ. Traynham, JE. Gorsky, AA. Repas, E Gao, RL. Carter, D Yu, J.W. Calvert, A Pun-García, **B Ibáñez**, JE. Rabinowitz, WJ. Koch, DG. Tilley.

*Circulation* 2016;134:153-67 IF 19,3 D1 article

**207. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery.**

Hausenloy DJ, Barrabes JA, Bøtker HE, Davidson SM, Di Lisa F, Downey J, Engstrom T, Ferdinandy P, Carbrera-Fuentes HA, Heusch G, **Ibanez B**, Iliodromitis EK, Inserte J, Jennings R, Kalia N, Kharbanda R, Lecour S, Marber M, Miura T, Ovize M, Perez-Pinzo MA, Piper HM, Przyklenk K, Schmidt MR, Redington A, Ruiz-Meana M, Vilahur G, Vinten-Johansen J, Yellon DM, Garcia-Dorado D.

**Basic Res Cardiol.** 2016;111:70. IF 5,3 Q1 review

**208. Early Administration of intravenous Beta blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention.**

Roolvink V, **Ibanez B**, Ottervanger JP, Pizarro G, van Royen N, Mateos A, Dambrink JH-E, Escalera N, Lipsic E, Albarran A, Fernández-Ortiz A, Fernández-Avilés F, Goicolea J, Botas J, Remkes W, Hernandez-Jaras MV, Kedhi E, Zamorano JL, Navarro F, Alfonso F, Garcia-Lledo A, Alonso J, van Leeuwen M, Nijveldt R, Postma S, Kolkman E, Gosselink M, de Smet B, Rasoul S, Piek JJ, Fuster V, van't Hof A.

**J Am Coll Cardiol** 2016;67:2705–15 IF 19,9 D1 article

**209. Impact of the timing of metoprolol administration during ongoing STEMI on infarct size and ventricular function.**

García-Ruiz JM; Fernández-Jiménez R; García-Alvarez A; Pizarro G; Galán-Arriola C; Fernández-Friera L; Mateos A; Nuno-Ayala M; Agüero J; Sánchez-González J; García-Prieto J; López-Melgar B; Martínez-Tenorio P; López-Martín G; Macías A; Pérez-Asenjo B; Cabrera JA; Fernández-Ortiz A; Fuster V; **Ibáñez B\***.

**J Am Coll Cardiol** 2016;67:2093-104. IF 19,9 D1 article

**210. 9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection.**

R. M. Bell, H. E. Bøtker, R. D. Carr, S. M. Davidson, J. M. Downey, D. P. Dutka, G. Heusch, **B. Ibanez**, R. Macallister, C. Stoppe, M. Ovize, A. Redington, J. M. Walker, D. M. Yellon

**Basic Res Cardiol** 2016;111:41. IF 5,3 Q1 review

**211. Accurate quantification of atherosclerotic plaque volume by 3D vascular ultrasound using the volumetric linear array method.**

López-Melgar B, Fernández-Friera L, Sánchez-González J, Vilchez JP, Cecconi A, Mateo J, Peñalvo JL, Oliva B, García-Ruiz JM, Kauffman S, Jiménez-Borreguero LJ, Ruiz-Cabello J, Fernández-Ortiz A, **Ibáñez B**, Fuster V.

**Atherosclerosis.** 2016;248:230-237. IF 4,2 Q1 article

**212. Systolic flow displacement using three-dimensional magnetic resonance imaging in an experimental model of ascending aorta aneurysm: impact of rheological factors**

Ayaon-Albarran A, Fernandez-Jimenez R, Silva-Guisasola J, Agüero J, Sanchez-Gonzalez J, Galan-Arriola C, Reguillo-Lacruz F, Maroto-Castellanos LC, **Ibanez B\***.

**Eur J Cardiothorac Surg** 2016 May 24: 1-8. ezw132 IF 3,8 Q1 article

**213. A novel systems-biology algorithm for the analysis of coordinated protein responses using quantitative proteomics.**

García-Marqués F, Trevisan-Herraz M, Martínez-Martínez S, Camafeita E, Jorge I, López JA, Méndez-Barbero N, Méndez-Ferrer S, Del Pozo MÁ, **Ibañez B**, Andrés V, Sánchez-Madrid F, Redondo JM, Bonzon-Kulichenko E, Vázquez J.

*Mol Cell Proteomics* 2016;15:1740-60 IF 6,5 D1 article

**214. Intratracheal gene delivery of SERCA2a ameliorates chronic post-capillary pulmonary hypertension in a large animal preclinical model.**

Aguero J, Ishikawa K, Hadri L, Santos-Gallego C, Fish K, Kohlbrenner E, Hammoudi N, Kho C, Lee A, **Ibanez B**, Garcia-Alvarez A, Zsebo K, Platakis M, Maron BA, Fuster V, Leopold J, Hajjar R.

*J Am Coll Cardiol* 2016;67:2032-46. IF 19,9 D1 article

**215. Cardiac extracellular volume detects amyloidotic cardiomyopathy and correlates with neurological impairment in Transthyretin-familial amyloidosis.**

M Gallego-Delgado, E Gonzalez-Lopez, F Muñoz, J Buades, L Galan, JL Muñoz-Blanco, J Sanchez-Gonzalez, **B Ibañez**, JG Mirelis, P Garcia-Pavia.

*Rev Esp Cardiol* 2016;69:923-930. IF 4,5 Q2 article

**216. Bimodal changes in infarct zone T2 relaxation times can be explained by the effects of myocardial haemorrhage, but “waves of edema” seem implausible”**

R Fernández-Jiménez; V Fuster; **B Ibanez\***.

*J Am Coll Cardiol* 2016;67:1869-70 IF 19,9 D1 letter

**217. Acute myocardial infarction and contrast-enhanced CMR: we need the whole map of the archipels, not just half of it !**

M Schaaf; N Mewton; **B Ibanez\***.

*JACC: Cardiovascular Imaging*. 2016;9:1015-6 IF 10,2 D1 letter

**218. QRS distortion in pre-reperfusion electrocardiogram is a bedside predictor of large myocardium at risk and infarct size (a METOCARD-CNIC trial substudy).**

MJ Valle-Caballero; R Fernández-Jiménez; R Díaz-Munoz; A Mateos; M Rodríguez-Álvarez; JA Iglesias-Vázquez; C Saborido; C Navarro; ML Dominguez; L Gorjón; JC Fontoira; V Fuster; JC García-Rubira; **B Ibanez\***.

*Int J Cardiol* 2016; 202: 666–673 IF 6,2 Q1 article

**219. Femoral and carotid subclinical atherosclerosis: association with risk factors and coronary calcium (Aragon Workers' Health Study).**

M Laclaustra; JA Casasnovas; A Fernández-Ortiz; V Fuster; M León-Latre; LJ Jiménez-Borreguero; M Pocovi; Y Hurtado-Roca; JM Ordovas; E Jarauta; E Guallar; **B Ibañez**; F Civeira.

*J Am Coll Cardiol* 2016;67:1263-74

IF 19,9

D1

article

**220. Fractional flow reserve and minimum Pd/Pa ratio during intravenous adenosine infusion: very similar but not always the same.**

Echavarría-Pinto M; Petraco R; van de Hoef TP; Gonzalo N; Nijjer S; Tarkin JM; **Ibañez B**; Sen S; Jimenez-Quevedo P; Nuñez-Gil IJ; Nombela-Franco L; Alfonso F; Fernández-Ortiz A; Macaya C; Piek JJ; Davies J; Escaned J.

*Eurointervention*. 2016;11:1013-9.

IF 5,2

Q1

article

**221. A clinical method for mapping and quantifying blood stasis in the left ventricle.**

L Rossini, P Martínez-Legazpi, V Vuc, L Fernández-Friera, Cs Pérez del Villar, S Rodríguez-López, Y Benito, MG Borja, D Pastor-Escuredo, R Yotti, MJ Ledesma-Carbayo, AM Kahn, **B Ibañez**, F Fernández-Avilés, K May-Newman, J Bermejo, JC del Álamo.

*J Biomech* 2016;49:2152-61

IF 2,7

Q2

article

**222. Imbalanced OPA1 processing and mitochondrial fragmentation causes heart failure in mice.**

T Wai, J García-Prieto, MJ. Baker, C Merkwirth, P Benit, P Rustin, FJ Rupérez, C Barbas, **B Ibañez\***, T Langer\* (\*co-corresponding authors).

*Science* 2015;350 (6265): aad0116 (pages 1-11).

IF 34,7

D1

article

**223. Fast T2 gradient-spin-echo (T2-GraSE) mapping for myocardial edema quantification: first in vivo validation in a porcine model of ischemia/reperfusion.**

R Fernandez-Jimenez; J Sanchez-Gonzalez; J Agüero; M Del Trigo; C Galan-Arriola; V Fuster; **B Ibanez\***

*J Cardiovasc Magn Reson* 2015;17:92

IF 5,7

D1

article

**224. Review and Updates in Regenerative and Personalized Medicine, Preclinical Animal Models, and Clinical Care in Cardiovascular Medicine**

E Barbato, PJ Barton, J Bartunek, S Huber, **B Ibanez**, DP Judge, E Lara-Pezzi, CM Stolen, A Taylor, JL Hall.

*J Cardiovasc Transl Res*. 2015;8:466-74.

IF 3,2

Q2

review

**225. Pathophysiology Underlying the Bimodal Edema Phenomenon after Myocardial Ischemia/Reperfusion**

R Fernández-Jiménez; J García-Prieto; J Sánchez-González, J Agüero; GJ López-Martín; C Galán-Arriola; A Molina-Iracheta; R Doohan; V Fuster; **B Ibanez\***

*J Am Coll Cardiol* 2015; 66:816-28.

IF 17,8

D1

article

**226. Combining baseline distal-to-aortic pressure ratio and fractional flow reserve in the assessment of coronary stenosis severity.**

TP van de Hoef , M van Lavieren , S Nijjer , **B Ibanez** , S Pocock , A Quiros , J Davies , M Meuwissen , P

Serruys , C Macaya , J Piek , J Escaned.

**JACC: Cardiovascular Interventions** 2015; 8:1681-91. IF 7.6 D1 article

**227. Prevalence, Vascular Distribution and Multi-territorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study.**

L Fernández-Friera; JL. Peñalvo; A Fernández-Ortiz; **B Ibanez**; B López-Melgar; M Laclaustra; B Oliva; A Mocoora; J Mendiguren; V Martínez de Vega; L García; J Molina; J Sanchez-Gonzalez; G Guzman; JC. Alonso- Farto; E Guallar; F Civeira; H Sillesen; S Pocock; JM. Ordovás; G Sanz; LJ Jiménez-Borreguero; V Fuster.

**Circulation** 2015;131:2104-2113. IF 17 D1 article

**228. Evolving therapies for myocardial ischemia/reperfusion injury.**

**B Ibanez\***, G Heusch, M Ovize, F Van de Werf. (\*Corr Author).

**J Am Coll Cardiol** 2015;65:1454-71. (**Review**). IF 17,8 D1 review

**229. Combination Proximal Pulmonary Artery Coiling and Distal Embolization Induces Chronic Elevations in Pulmonary Artery Pressure in Swine.**

J Aguero, K Ishikawa, K Fish, N Hammoudi, L Hadri, A García-Alvarez, **B Ibanez**, V Fuster, R Hajjar, JA. Leopold.

**PLOS ONE** 2015;10:e0124526. IF 3 Q1 article

**230. Exercise triggers arrhythmogenic right ventricular cardiomyopathy phenotype in mice expressing a disease-causing mutated version of human plakophilin-2 after single adeno-associated virus-mediated gene transfer.**

FM. Cruz, D Sanz-Rosa, M Roche-Molina, J García-Prieto, JM. García-Ruiz, G Pizarro, LJ. Jiménez-Borreguero, M Torres, A Bernad, J Ruíz-Cabello, V Fuster, **B Ibanez\***, J A. Bernal\*. (\*co-corresponding authors).

**J Am Coll Cardiol** 2015;65:1438-50. IF 17,8 D1 article

**231. Myocardial Edema After Ischemia/Reperfusion Is Not Stable and Follows a Bimodal Pattern: Advanced Imaging and Histological Tissue Characterization.**

R Fernández-Jiménez; J Sánchez-González; J Aguero; J García-Prieto; G J López-Martín; JM García-Ruiz; A Molina-Iracheta; X Rosselló; L Fernández-Friera; G Pizarro; A García-Álvarez; E Dall'Armellina; C Macaya; R Choudhury; V Fuster; **B Ibanez\***.

**J Am Coll Cardiol** 2015;65:315-23. IF 17,8 D1 article

**232. Impact of left ventricular hypertrophy on troponin release during acute myocardial infarction: new insights from a comprehensive translational study.**

Fernández-Jiménez R, Silva J, Martínez-Martínez S, López-Maderuelo MD, Nuno-Ayala M, García-Ruiz JM, García-Álvarez A, Fernández-Friera L, Pizarro TG, García-Prieto J, Sanz-Rosa D, López-Martin G, Fernández-Ortiz A, Macaya C, Fuster V, Redondo JM, **Ibanez B\***.

- J Am Heart Assoc.* 2015 Jan 21;4(1). pii: e001218 IF 5,1 Q1 article
233. **CAESAR: one step beyond in the construction of a translational bridge for cardioprotection.**  
R Fernández-Jiménez; **B Ibanez\***.  
*Circulation Research* 2015;116:554-556. IF 11,6 D1 editorial
234. **Optimization of dual-saturation single bolus acquisition for quantitative cardiac perfusion and myocardial blood flow maps.**  
J Sánchez-González; R Fernandez-Jiménez; ND Nothnagel; G López-Martín; V Fuster; **B Ibanez\***.  
*J Cardiovasc Magn Reson* 2015;17:21. IF 5,7 D1 article
235. **Association of Myocardial T1-Mapping CMR with Hemodynamics and Right Ventricular Performance in Pulmonary Hypertension.**  
A García-Álvarez, I García-Lunar, D Pereda, R Fernández-Jimenez, J Sánchez-González, J G. Mirelis, M Nuño-Ayala, D Sánchez-Quintana, L Fernández-Friera, JM. García-Ruiz, G Pizarro, J Agüero, P Campelos, M Castellá, M Sabaté, V Fuster, J Sanz, **B Ibañez\***.  
*JACC: Cardiovascular Imaging.* 2015;8:76-82. IF 7,8 D1 article
236. **Efficacy and Safety of Out-of-Hospital Intravenous Metoprolol Administration in Anterior ST-Segment Elevation Acute Myocardial Infarction: Insights From the METOCARD-CNIC Trial.**  
Mateos A, García-Lunar I, García-Ruiz JM, Pizarro G, Fernández-Jiménez R, Huertas P, García-Álvarez A, Fernández-Friera L, Bravo J, Flores-Arias J, Barreiro MV, Chayán-Zas L, Corral E, Fuster V, Sánchez-Brunete V, **Ibañez B\***.  
*Ann Emerg Med.* 2015;65:318-324 IF 5 D1 article
237. **Prasugrel in NSTEMI: Loading After Seeing.**  
**B Ibañez**, G Dangas.  
*J Am Coll Cardiol.* 2014; 64: 2572-2574. IF 16,5 D1 editorial
238. **Effects of fibrosis morphology on reentrant ventricular tachycardia inducibility and simulation fidelity in patient-derived models.**  
Ringenberg J, Deo M, Filgueiras-Rama D, Pizarro G, **Ibañez B**, Peinado R, Merino JL, Berenfeld O, Devabhaktuni V.  
*Clin Med Insights Cardiol.* 2014; 8: 1-13.
239. **Mechanisms of balloon angioplasty and repeat stenting in patients with drug-eluting in-stent restenosis.**  
Alfonso F, Sandoval J, Pérez-Vizcayno MJ, Cárdenas A, Gonzalo N, Jiménez-Quevedo P, **Ibañez B**, Núñez-Gil I, Rivero F, Escaned J, Fernández-Ortiz A, Macaya C.

*Int J Cardiol.* 2014;178C:213-220.

IF 4,0

**240. Long-Term Favorable Coronary Healing After Bioresorbable Scaffold Implantation: Insights From OCT.**

Gonzalo N, Dangas G, Ibanez B\*.

*J Am Coll Cardiol.* 2014; 64: 2357-9.

IF 16,5

D1

editorial

**241. Induction of sustained hypercholesterolemia by single adeno-associated virus (AAV)-mediated gene transfer of mutant hPCSK9.**

M Roche-Molina, D Sanz-Rosa, FM. Cruz, J García-Prieto, S López, R Abia, FJ.G. Muriana, V Fuster, B Ibañez, JA. Bernal.

*Arterioscler Thromb Vasc Biol.* 2015;35:50-9.

IF 6,0

Q1

article

**242. Early Intravenous Beta-Blockade Before Primary Percutaneous Coronary Intervention Gives Major Benefits, Apparently Without Side Effects.**

B Ibanez\*, V Fuster.

*J Am Coll Cardiol.* 2014;64:1864-5.

IF 16,5

D1

letter

**243. Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model.**

J Aguero, K Ishikawa, L Hadri, A Chaanine, C Santos-Gallego, K Fish, N Hammoudi, S Torquato, C Naim, B Ibanez, D Pereda, A Garcia-Alvarez, V Fuster, P Sengupta, J Leopold, R Hajjar.

*AJP-Heart and Circulatory Physiology.* 2014; 307: H1204-15.

IF 3,8

**244. Health and cost benefits associated with the use of metoprolol in heart attack patients.**

Fernández-Jiménez R, Ibanez B\*.

*Expert Rev Clin Pharmacol.* 2014 Sep 18:1-3.

IF 2.18 Q3

**245. Prehospital activation of cardiac catheterization teams in ST-segment elevation myocardial infarction.**

Franco E, Mateos A, Acebal C, Fernández-Ortiza A, Sánchez-Brunete V, García-Rubira JC, Fernández-Campos MJ, Macaya C, Ibanez B\*.

*Rev Port Cardiol* 2014; 33: 545-53.

IF 0,5

**246. Imaging Subclinical Atherosclerosis: Is it ready for prime time? A review**  
Fernández-Friera L, Ibañez B, Fuster V.

*J Cardiovasc Transl Res.* 2014 7:623-34

IF 3,0

**247. Rationale and Design of a Double-blind, Multicenter, Randomized, Placebo controlled Clinical**



**trial of Early Administration of Intravenous Beta-blockers in Patients with ST-elevation Myocardial Infarction before Primary PCI. EARLY Beta-blocker Administration before primary PCI in patients with ST-elevation Myocardial Infarction (EARLY-BAMI) trial.**

Roolvink V; Rasoul S; Ottervanger JP; Dambrink J-H E; Lipsic E; van der Horst I CC; de Smet B; Kedhi E; Gosselink M; Piek JJ; Sanchez-Brunete V; **Ibanez B**; Fuster V; van 't Hof AW.J.

*Am Heart J.* 2014;168:661-6.

IF 4,5

**248.  $\beta$ 3 adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytes.**

García-Prieto J; García-Ruiz JM; Sanz-Rosa D; Pun A; García-Alvarez A; Davidson SM; Fernández-Friera L; Nuno-Ayala M; Fernández-Jiménez R; Bernal JA; Izquierdo-Garcia JL; Jimenez-Borreguero J; Pizarro G; Ruiz-Cabello J; Macaya C; Fuster V; Yellon DM; **Ibanez B\***.

*Basic Res Cardiol.* 2014; 109:422-437.

IF 5,4

Q1

article

**249. Long term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial.**

Pizarro G, Fernández-Friera L, Fuster V, Fernández-Jiménez R, García-Ruiz JM, García-Álvarez A, Mateos A, Barreiro MV, Escalera N, Rodríguez MD, de Miguel A, García-Lunar I, Parra-Fuertes JJ, Sánchez-González J, Pardillos L, Nieto B, Jiménez A, Abejón R, Bastante T, Martínez de Vega V, Cabrera JA, López-Melgar B, Guzman G, García-Prieto J, Mirelis JG, Zamorano JL, Albarrán A, Goicolea J, Escaned J, Pocock S, Iñiguez A, Fernández-Ortiz A, Sánchez-Brunete V, Macaya C, **Ibanez B\***.

*J Am Coll Cardiol.* 2014;63:2356-62.

IF 16,5

D1

article

**250. Swine model of chronic postcapillary pulmonary hypertension with right ventricular remodeling: long-term characterization by cardiac catheterization, magnetic resonance and pathology.**

Pereda D, García-Alvarez A, Sánchez-Quintana D, Nuño M, Fernández-Friera L, Fernández-Jiménez R, García-Ruiz JM, Sandoval E, Agüero J, Castellá M, Hajjar RJ, Fuster V, **Ibañez B\***.

*J Cardiovasc Transl Res.* 2014 ;7(5):494-506.

IF 3,0

**251. The calcineurin variant CnA $\beta$ 1 improves post-infarction ventricular remodelling by promoting infarct vascularization.**

López-Olañeta MM, Villalba M, Gómez-Salineró JM, Jiménez-Borreguero LJ, Breckenridge R, Ortiz-Sánchez P, García-Pavía P, **Ibañez B**, Lara-Pezzi E.

*Cardiovasc Res.* 2014;102:396-406.

IF 5,9

**252. Impact of diastolic wall stress on the diagnostic value of visually interpreted dobutamine stress MR imaging.**

Mirelis J, Paetsch I, Jahnke, **Ibañez B**, Fleck E, Alonso-Pulpon LA, Fuster V, Gebker R.

*Int J Cardiol.* 2014;172:e39-42.

IF 4,0

253. **Metabolomics reveals metabolite changes in acute pulmonary embolism.**  
Bujak R, García-Álvarez A, Rupérez FJ, Nuño-Ayala M, García A, Ruiz-Cabello J, Fuster V, **Ibañez B**, Barbas C.

*J Proteom Res* 2014;13:805-16

IF 5,0

254. **Low coronary microcirculatory resistance associated to profound hypotension during intravenous adenosine infusion. Implications for the functional assessment of coronary stenosis.**

Echavarría M, Gonzalo N, **Ibañez B**, Petraco R, Jimenez-Quevedo P, Sen S, Nijjer S, Tarkin J, Alfonso F, Quiroz- Carretero A, Nuñez-Gil IJ, Bañuelos C, Fernández-Ortiz A, Macaya C, Davies J, Bon-Kwon K, Escaned J.

*Circulation CV Interventions*. 2014; 7: 35-42.

IF 6,2

255. **Animal Models of Tissue Characterization of Area at Risk, Edema and Fibrosis.**

Fernández-Jiménez R, Fernández-Friera L, Sánchez-González J, and **Ibañez B\***.

*Curr Cardiovasc Imaging Rep* 2014;7:9259

review

256. **Effect of early metoprolol on infarct size in ST-segment elevation myocardial infarction patients undergoing primary PCI: the METOCARD-CNIC trial.**

**Ibanez B\***, Macaya C, Sánchez-Brunete V, Pizarro G, Fernández-Friera L, Mateos A, Fernández-Ortiz A, García-Ruiz JM, García-Álvarez A, Iñiguez A, Jiménez-Borreguero LJ, López-Romero P, Fernández-Jiménez R, Goicolea J, Ruiz-Mateos B, Bastante T, Arias M, Iglesias-Vázquez JA, Rodríguez MD, Escalera N, Acebal C, Cabrera JA, Valenciano J, Pérez de Prado A, Fernández-Campos MJ, Casado I, García-Rubira JC, García-Prieto J, Sanz-Rosa D, Cuellas C, Hernández-Antolín R, Albarrán A, Fernández-Vázquez F, de la Torre-Hernández JM, Pocock S, Sanz G, Fuster V. (\*corresponding author)

*Circulation*. 2013;128:1495-1503.

IF 14,9

D1

article

257. **The Progression and Early detection of Subclinical Atherosclerosis (PESA) study: rationale and design.**

Fernández-Ortiz A, Jiménez-Borreguero LJ, Peñalvo JL, Ordovás JM, Moco-roa A, Fernández-Friera L, Laclaustra M, García L, Molina J, Mendiguren JM, López-Melgar B, de Vega VM, Alonso-Farto JC, Guallar E, Sillesen H, Rudd JH, Fayad ZA, **Ibañez B**, Sanz G, Fuster V.

*Am Heart J*. 2013 Dec;166(6):990-8

258. **Disturbed coronary hemodynamics in vessels with intermediate stenosis evaluated with fractional flow reserve. A combined analysis of epicardial and microcirculatory involvement in ischemic heart disease.**

Echavarría-Pinto M, Escaned J, Macías E, Medina M, Gonzalo N, Petraco R, Sen S, Jimenez-Quevedo P, Hernandez R, Mila R, **Ibañez B**, Nuñez-Gil IJ, Alfonso F, Bañuelos C, García E, Davies J, Fernández-Ortiz A, Macaya C.

*Circulation*. 2013;128:2557-66.

IF 14,9

259. **Noninvasive Monitoring of Serial Changes in Pulmonary Vascular Resistance and Acute Vasodilator Testing using Cardiac Magnetic Resonance.**

García-Álvarez A, Fernández-Friera L, García-Ruiz JM, Nuño-Ayala M, Pereda D, Fernández-Jiménez R, Guzmán G, Sanchez-Quintana D, Alberich-Bayarri A, Pastor-Escuredo D, Sanz-Rosa D, García-Prieto J, Mirelis JG, Pizarro G, Jimenez-Borreguero LJ, Fuster V, Sanz J, **Ibañez B\***.

*J Am Coll Cardiol.* 2013;62:1621-31.

IF 15,3

**260. Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension.**

Hadri L, Kratlian R G, Benard L, Maron B A, Dorfmüller P, Ladage De, Guignabert C, Ishikawa K, Aguero J, **Ibanez B**, Turnbull IC, Kohlbrenner E, Liang L, Zsebo K, Humbert M, Hulot J-S, Kawase Y, Hajjar RJ, Leopold JA.

*Circulation.* 2013;128:512-23.

IF 14,9

**261. Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention referral in patients with large intracoronary thrombus.**

Echavarría-Pinto M, Lopes R, Gorgadze T, Gonzalo N, Hernández R, Jiménez-Quevedo P, Alfonso F, Bañuelos C, Nuñez I, **Ibañez B**, Fernández C, Fernandez-Ortiz A, García E, Macaya C, Escaned J.

*Am J Cardiol.* 2013;111:1745-50.

IF 4,7

**262. Mutations in the NOTCH pathway regulator MIB1 cause left ventricular noncompaction cardiomyopathy.**

Luxán G, Casanova JC, Martínez-Poveda B, Prados B, D'Amato G, MacGrogan D, Gonzalez-Rajal A, Dobarro D, Torroja C, Martinez F, Izquierdo-García J L, Fernández-Friera L, Sabater-Molina M, Kong YY, Pizarro G, **Ibañez B**, Medrano C, García-Pavía P, Gimeno JR, Monserrat L, Jiménez-Borreguero LJ, de la Pompa JL.

*Nature Medicine.* (2013) 19: 193-201

IF 28,1

**263. Safety of lone thrombus aspiration without concomitant coronary stenting in selected patients with acute myocardial infarction.**

Escaned J, Echavarría-Pinto M, Gorgadze T, Gonzalo N, Armengol F, Hernández R, Jiménez-Quevedo P, Nuñez-Gil IJ, Pérez-Vizcayno MJ, Alfonso F, Bañuelos C, **Ibañez B**, García E, Fernández-Ortiz A, Macaya C.

*EuroIntervention* 2013;8:1149-56.

IF 3,3

**264. Inactivation of NF- $\kappa$ B inhibits vascular smooth muscle cell proliferation and neointima formation.**

Silvestre-Roig C, Fernández P, Esteban V, Pello OM, Indolfi C, Rodríguez C, Rodríguez-Calvo R; López-Maderuelo MD, Bauriedel G, Hutter R, Fuster V, **Ibañez B**, Redondo JM, Martínez-González J; Andrés V.

*Arterioscler Thromb Vasc Biol.* 2013;5:1036-45

**265. Imagining the Future of Diagnostic Imaging.**

Fernandez-Friera L, García-Álvarez A, **Ibañez B\***.

*Rev Esp Cardiol.* 2013;66:134-143.

**266. Synergistic Effect of LXR Activation and Simvastatin on Plaque Regression and Stabilization: an MRI study in a Model of Advanced Atherosclerosis.**

Chiara Giannarelli, Cimmino G, Connolly TM, **Ibañez B**, Garcia Ruiz JM, Alique M, Zafar MU, Fuster V, Feuerstein G, Badimon JJ.

*Eur Heart J*. 2012;33:264-73.

**267. Animal models of atherosclerosis.**

Fuster JJ, Castillo AI, Zaragoza C, **Ibañez B**, Andrés V.

*Prog Mol Biol Transl Sci*. 2012;105:1-23.

**268. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type).**

**Ibañez B**, Giannarelli C, Cimmino G, Santos-Gallego CG, Alique M, Pinero A, Vilahur G, Fuster V, Badimon L, Badimon JJ.

*Atherosclerosis*. 2012 Jan;220:72-7.

**269. Circadian Variations of Infarct Size in STEMI.**

**Ibañez B\***, Suarez-Barrientos A, Lopez-Romero P.

*Circ Res*. 2012;110(3):e22.

**270. Aragon workers' health study--design and cohort description.**

Casasnovas JA, Alcaide V, Civeira F, Guallar E, **Ibañez B**, Borreguero JJ, Laclaustra M, León M, Peñalvo JL, Ordovás JM, Pocovi M, Sanz G, Fuster V.

*BMC Cardiovasc Disord*. 2012 Jun 19;12:45

**271. The future: Therapy of Myocardial Protection.**

Sanz-Rosa D, García-Prieto J, **Ibañez B\***.

*Ann N Y Acad Sci*. 2012;1254:90-98.

**272. Troponin Release Overestimates Infarct Size in Presence of Left Ventricular Hypertrophy.**

Fernández-Jiménez R, López-Romero P, Suárez-Barrientos A, García-Rubira JC, Fernández-Ortiz A, Fuster V, Macaya C, **Ibañez B\***.

*J Am Coll Cardiol* 2012; 60: 640-1.

**273. Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term.**

Giannarelli C, Cimmino G, **Ibañez B**, Chiesa G, Garcia-Prieto J, Santos-Gallego CG, Alique-Aguilar M, Fuster V, Sirtori C, Badimon JJ.

*Thromb Haemost* 2012; 108: 1246-8.

**274. Automated segmentation and reconstruction of patient-specific cardiac anatomy and pathology from in vivo MRI.**

Ringenberg J, Deo M, Devabhaktuni V, Filgueiras-Rama D, Pizarro G, **Ibañez B**, Berenfeld O, Boyers P, Gold J.

*Measurement Science & Technology* 2012; 23: 125405.

**275. Early intravenous beta-blockers in patients with acute coronary syndrome-A meta-analysis of randomized trials.**

Chatterjee S, Chaudhuri D, Vedanthan R, Fuster V, **Ibañez B**, Bangalore S, Mukherje D.

*Int J Cardiol* 2013;168:915-21

**276. Study design for the "effect of METOprolol in CARDioproteCtioN during an acute myocardial InfarCtion" (METOCARD-CNIC): A randomized, controlled parallel-group, observer-blinded clinical trial of early pre-reperfusion metoprolol administration in ST-segment elevation myocardial infarction.**

**Ibañez B\***, Fuster V, Macaya C, Sanchez-Brunete V, Pizarro G, Lopez-Romero P, Mateos A, Jimenez-Borreguero J, Fernandez-Ortiz A, Sanz G, Fernandez-Friera L, Corral E, Barreiro MV, Ruiz-Mateos B, Goicolea J, Hernandez-Antolin R, Acebal C, Garcia-Rubira JC, Albarran A, Zamorano JL, Casado I, Valenciano J, Fernandez-Vazquez F, de la Torre JM, Perez de Prado A, Iglesias-Vazquez JA, Martinez-Tenorio P, Iniguez A. (\*corresponding author)

*Am Heart J.* 2012; 164: 473-480 e5.

**277. Tako-tsubo Syndrome and Heart Failure: Long-term Follow-up.**

Nunez-Gil IJ, Molina M, Bernardo E, **Ibañez B**, Ruiz-Mateos B, Garcia-Rubira JC, Vivas D, Feltes G, Luaces M, Alonso J, Zamorano J, Macaya C, Fernandez-Ortiz A.

*Rev Esp Cardiol.* 2012; 65: 996-1002.

**278. Ventricular Fibrillation after Correct Pacing in Digoxin Intoxication.**

Garcia-Rubira JC, Suarez A, **Ibañez B**.

*J Emerg Med.* 2012;42: e93-4.

**279. Systemic Fibrinolysis Through Intraosseous Vascular Access in ST-Segment Elevation Myocardial Infarction.**

Ruiz-Hornillos PJ, Martínez-Cámara F, Elizondo M, Jiménez-Fraile JA, Del Mar Alonso-Sánchez M, Galán D, García-Rubira JC, Macaya C, **Ibañez B\***.

*Ann Emerg Med.* 2011; 57: 572-574.

**280. The Cardioprotection Granted by Metoprolol is Restricted to its Administration Prior to Coronary reperfusion.**

**Ibañez B**, Cimmino G, Prat-González S, Vilahur G, Randolph H, García MJ, Fuster V, Sanz J, Badimon L, Badimon JJ.

*Int J Cardiol.* 2011; 147: 428-432.

**281. Carvedilol Administration in Acute Myocardial Infarction Results in Stronger Inhibition of Early Markers of Left Ventricular Remodeling than Metoprolol.**

Cimmino G†, **Ibañez B**†, Giannarelli C, Prat-González S, Hutter R, Garcia M, Sanz J, Fuster V, Badimon JJ.

*Int J Cardiol.* 2011;153:256-61. †Co-first authorship.

**282. Lethal myocardial reperfusion injury: A necessary evil?**

**Ibañez B**\*, Fuster V, Jiménez-Borreguero J, Badimon JJ.

*Int J Cardiol.* 2011;151:3-11

**283. Properties of Different Glycoprotein-IIb/IIIa Inhibitors: Do These Drugs Have a Class Effect?**

Fernández-Ortiz A, Núñez-Gil I, Ruiz-Mateos B, **Ibañez B**.

*Rev Esp Cardiol.* 2011;64(Supl 1):3-7.

**284. Clinical outcomes of patients with intramyocardial bridging diagnosed by multi-detector cardiac computed tomography.**

Marcos-Alberca P, Gonçalves A, Golfín CF, **Ibanez B**, Castilla E, Blanco E, Ferreiros J, Arrazola J, Macaya C, Zamorano J.

*Int J Cardiol.* 2011; 148: 123-5.

**285. Circadian Variations of Necrotic Size in Acute Myocardial Infarction.**

Suárez-Barrientos A, López-Romero P, Vivas D, Castro-Ferreira F, Núñez-Gil I, Franco E, Ruiz-Mateos B, García-Rubira JC, Fernández-Ortiz A, Macaya C, **Ibañez B**\*.

*Heart.* 2011; 97: 970-976.

**286. Heart failure and non-ST-segment elevation myocardial infarction: a review for a widespread situation.**

Franco E, Núñez-Gil IJ, Vivas D, Ruiz Mateos B, **Ibanez B**, Gonzalo N, Macaya C, Fernández Ortiz A.

*Eur J Intern Med.* 2011 Dec;22(6):533-40.

**287. Modulation of the beta-adrenergic system during acute myocardial infarction: rationale for a new clinical trial.**

**Ibañez B**\*, Fuster V, Macaya C, Jiménez-Borreguero J, Iñiguez A, Fernández-Ortiz A, Sanz G, Sánchez-Brunete V.

*Rev Esp Cardiol.* 2011 Jul;64 Suppl 2:28-33.

**288. A New Oral Antiplatelet Agent with Potent Antithrombotic Properties: Comparison of DZ-697b with Clopidogrel in a Randomized Phase-I Study.**

Zafar MU, Ibañez B, Choi B G, Vorchheimer DA, Pinero A, Jin X, Sharma RK, Badimon JJ.

*Thromb Haemost.* 2010;103:205-12.

**289. Increasing High-Density Lipoprotein as a Therapeutic Target in Atherothrombotic Disease.**  
Badimón JJ, Ibañez B.

*Rev Esp Cardiol.* 2010;63:323-333.

**290. Recombinant Apolipoprotein A-I Milano Rapidly Reverses Aortic Valve Stenosis and decreases leaflet inflammation in an experimental rabbit model.**

Speidl WJ, Cimmino G, Ibañez B, Elmariah S, Hutter R, Garcia MJ, Fuster V, Goldman ME, Badimon JJ.

*Eur Heart J.* 2010; 31: 2049-2057.

**291. Ischaemic conditioning for myocardial salvage after AMI.**

Ibañez B, Fuster V.

*Lancet.* 2010;375(9727):1691.

**292. Contrast-Enhanced Ultrasound Imaging Detects Intraplaque Neovascularization in an Experimental Model of Atherosclerosis.**

Giannarelli C, Ibañez B, Cimmino G, Garcia -Ruiz JM, Fata F, Bianchini E, Zafar MU, Fuster V, Garcia MJ, Badimon JJ.

*JACC: Cardiovascular Imaging.* 2010; 3: 1256-64.

**293. Quantification of Serial Changes in Plaque Burden Using Multi-Detector Computed Tomography in Experimental Atherosclerosis.**

Ibañez B, Cimmino G, Bénézet-Mazuecos J, Santos Gallego CG, Pinero A, Prat-González S, Speidl WS, Fuster V, García MJ, Sanz J, Badimon JJ.

*Atherosclerosis.* 2009; 202: 185-91.

**294. Diagnosis of Atherosclerosis by Imaging.**

Ibañez B, Badimon JJ, García MJ.

*Am J Med.* 2009;122(1 Suppl):S15-25.

**295. Up-Regulation of Reverse Cholesterol Transport Key Players and Rescue from Global Inflammation by ApoA-IMilano.**

Cimmino G\*, Ibañez B\*, Vilahur G, Speidl WS, Fuster V, Badimon L, Badimon JJ.

*J Cell Mol Med.* 2009;13:3226-35. \*Co-first authorship

296. **Genesis and dynamics of atherosclerotic lesions: implications for early detection.**  
Badimon JJ, Ibañez B, Cimmino G.

*Cerebrovasc Dis.* 2009; 27 Suppl 1:38-47.

297. **Safe and sustained over-expression of functional ApoA-I/HDL in ApoA-I null mice by muscular AAV8 gene transfer.**

Cimmino G, Chen W, Speidl WS, Giannarelli C, Ibañez B, Fuster V, Hajjar R, Walsh CE, Badimon. JJ.

*Journal of Cardiovascular Pharmacology* 2009; 54:405-11.

298. **Diabetes and Cardiovascular Disease.**

Fuster V, Ibañez B.

*Rev Esp Cardiol.* 2008; 8: C35-C44.

299. **Tako-tsubo Syndrome: A New entity or New Form of Presentation of an Old One? An Electrocardiographic Analysis.**

Ibañez B, Pinero A, Zafar MU, Navarro F, Benezet-Mazuecos J, Farre J.

*Int J Cardiol.* 2008;126:281-3.

300. **Rapid Change in Plaque Size, Composition and Molecular Footprint Following Recombinant ApoA-IMilano (ETC-216) Administration. Magnetic Resonance Imaging Study in an Experimental Model of Atherosclerosis.**

Ibañez B, Vilahur G, Cimmino G, Speidl WS, Pinero A, Choi BG, Zafar MU, Santos-Gallego CG, Krause B, Badimon L, Fuster V, Badimon JJ.

*J Am Coll Cardiol.* 2008; 51:1104-1109.

301. **Ovariectomy Increases Vascular Calcification Via the OPG/RANKL Cytokine Signaling Pathway.**

Choi BG, Vilahur G, Cardoso L, Fritton CJ, Ibañez B, Zafar UM, Yadegar D, Speidl WS, Schaffler MB, Fuster V, and Badimon JJ.

*Eur J. Clin Invest.* 2008; 38:211-7.

302. **Selective Estrogen Receptor Modulation Influences Atherosclerotic Plaque Vulnerability in a Rabbit Menopause Model.**

Choi BG, Vilahur G, Zafar MU, Cardoso L, Yadegar D, Ibañez B, Tunstead J, Viles-Gonzalez JF, Schaffler MB, Fuster V, Badimon JJ.

*Atherosclerosis.* 2008; 201: 76-84.

303. **Clinical Implications of Clopidogrel Resistance.**



De Miguel A, **Ibañez B**, Badimon JJ.

***Thrombosis and Haemostasis***. 2008;100:196-203.

304. **Cyclosporine in acute myocardial infarction.**

**Ibañez B\***, Badimon JJ.

***N Engl J Med***. 2008; 359(21):2287.

305. **Danger to the ventricular myocardium from prolonged ablation procedures combined with a long-lasting catecholamine infusion for provocative arrhythmia testing.**

Farre J, **Ibañez B**.

***Europace***. 2008; 10(12):1361-2.

306. **HDL-cholesterol: Is it really good? Differences between apoA-I and HDL.**  
Santos-Gallego CG, **Ibañez B**, Badimon JJ.

***Biochemical Pharmacology***. 2008; 76: 443-452.

307. **Validation Study of a Semi-Automated Program for Quantification of Atherosclerotic Burden.**

Choi B.G, Novoselsky C.A, Vilahur G, Viles-Gonzalez JF, Zafar M.U, **Ibañez B**, Fuster V, Badimon JJ.

***J Cardiovasc Magn Reson***. 2007; 9:615-20.

308. **Novel Imaging Techniques for Quantifying Overall Atherosclerotic Burden.**

**Ibañez B**, Pinero A, Orejas M, Badimon JJ.

***Rev Esp Cardiol***. 2007; 60:299-309.

309. **A Novel Anti-Ischemic Nitric Oxide Donor (LA419) Reduces Thrombogenesis in Healthy Human Subjects.**

Zafar MU, Vilahur G, Choi BG, **Ibañez B**, Salas E, Badimon JJ.

***J Thromb Haemost***. 2007; 5:1195-200.

310. **Early Metoprolol Administration Before Coronary Reperfusion Results in Increased Myocardial Salvage: Analysis of Ischemic Myocardium at Risk Using Cardiac Magnetic Resonance.**

**Ibañez B**, Prat S, Speidl WS, Vilahur G, Pinero A, Cimmino G, Garcia MJ, Fuster V, Sanz J, Badimon JJ.

***Circulation***. 2007; 115:2909-16.

311. **Plaque progression and regression in atherothrombosis.**

**Ibañez B**, Vilahur G, Badimon JJ.

***J Thromb Haemost***. 2007; 5 (Suppl. 1): 292-9.

**312. Myocardial reperfusion injury.**

**Ibañez B\***, Cimmino G, Badimon JJ.  
*N Engl J Med.* 2007; 357(23):2409.

**313. Utility of in-hospital cardiac remote telemetry in patients with unexplained syncope.**

Benezet-Mazuecos J, **Ibañez B**, Rubio JM, Navarro F, Martín E, Romero J, Farre J.  
*Europace.* 2007; 9: 1196-201.

**314. Resident human cardiac stem cells: role in cardiac cellular homeostasis and potential for myocardial regeneration.**

Torella D, Ellison GM, Mendez-Ferrer S, **Ibañez B**, Nadal-Ginard B.  
*Nat Clin Pract Cardiovasc Med.* 2006;3 Suppl 1:S8-S13.

**315. Tako-tsubo syndrome: a Bayesian approach in relation to its pathogenesis.**

**Ibañez B\***, Benezet-Mazuecos J, Navarro F, Farre J.  
*Mayo Clin Proc.* 2006;81:732-735.

**316. Tako-tsubo syndrome: a form of spontaneous aborted myocardial infarction?**

**Ibañez B\***, Choi BG, Navarro F, and Farre J.  
*Eur Heart J.* 2006;27:1509-10.

**317. Measures of Thrombosis and Fibrinolysis.**

Choi BG, Vilahur G, **Ibañez B**, Zafar MU, Rodríguez J, Badimon JJ.  
*Clin Lab Med.* 2006;26:655-78.

**318. Pharmacology of thienopyridines. Rationale for dual pathway inhibition.**

**Ibañez B**, Vilahur G, Badimon JJ.  
*Eur Heart J Suppl.* 2006;8:G3-G9.

**319. Severe hypothermia showing Osborn waves associated with transient atrial fibrillation and ST segment depression.**

Benezet-Mazuecos J, **Ibañez B**, Farre J.  
*Heart.* 2006 Nov;92(11):1666.

**320. Tako-tsubo transient left ventricular apical ballooning: is intravascular ultrasound the key to resolve the enigma?**

**Ibañez B\***, Navarro F, Córdoba M, Marcos-Alberca P and Farré J.

*Heart*. 2005; 91: 102-4. IF 3,3 Q1

**321. Transient left ventricular apical ballooning.**

**Ibañez B**, Navarro F, and Farré J.

*Ann Intern Med*. 2005;142:677-8.

**322. Atypical left bundle branch block in dilative "burned-out" phase of hypertrophic cardiomyopathy.**

Benezet-Mazuecos J, **Ibañez B**, Farre J.

*Pacing Clin Electrophysiol*. 2005;28:1357-9.

**323. Multicavitated left atrial myxoma mimicking a hydatid cyst.**

**Ibanez B**, Marcos-Alberca P, Rey M, de Rabago R, Orejas M, Renedo G, Farre J.

*Eur J Echocardiogr*. 2005 Jun;6(3):231-3.

**324. Left Main Coronary Artery Occlusion in Patient with Solitary Coronary Ostium in the Right Aortic Sinus.**

**Ibañez B**, Cordoba M, and Farré J.

*Heart*. 2004; 90:946. IF 3,3 Q1

**325. Incomplete myocardial rupture after coronary embolism of an isolated single coronary artery.**

Pindado J, Marcos-Alberca P, Rey M, Rábago R, de Diego C, **Ibañez B**, Córdoba M, Farré J.

*Eur J Echocardiogr*. 2005 Jan;6(1):72-4.

**326. Cardiac granulocytic sarcoma (chloroma): In vivo diagnosis with transesophageal echocardiography.**

Marcos-Alberca P, **Ibañez B**, Rey M, Roman A, Rabago R, Orejas M, Tomas JF, Farré J.

*J Am Soc Echocardiogr*. 2004; 17: 1000-2. IF 1,4 Q3

**327. Tako-tsubo syndrome associated with a long course of the left anterior descending coronary artery along the apical diaphragmatic surface of the left ventricle].**

**Ibañez B**, Navarro F, Farré J, Marcos-Alberca P, Orejas M, Rabago R, Rey M, Romero J, Iniguez A, Córdoba M.

*Rev Esp Cardiol*. 2004;57(3):209-16. IF 1,8 Q2 article

## Metrics updated June 2022

### Scholar

H index= 71

i10 index = 244

Total number of citations = 48800

5-year H index= 58

5-year i10 index = 201

5-year number of citations = 43229

### Web of Science Researcher ID (J-6993-2014)

H index= 55

Citations per article = 62,57

Total number of citations = 21341

**Research ID:** <http://www.researcherid.com/rid/J-6993-2014>

**ORCID:** <https://orcid.org/0000-0002-5036-254X>

**Scopus ID:** 13907649300

**Publons:** <https://publons.com/researcher/2499409/borja-ibanez/metrics/>

## Research Support

- 2023-2026: Madrid Regional R&D grant for technology development and biomedicine. “*Madrid Network in Molecular Imaging (RENIM-CM)*”. “Ayudas para la realización de Programas de Actividades de I+D entre Grupos de Investigación de la Comunidad de Madrid en Tecnologías y en Biomedicina”. Funding body: Comunidad Autónoma de Madrid. Title and reference: RED MADRILEÑA DE NANOMEDICINA EN IMAGEN MOLECULAR (RENIM-CM). Project ID P2022/BMD-7403.  
**€ 827.000,00 total budget (PRINCIPAL INVESTIGATOR OF 1 GROUP, local Budget €171.000).**
- 2023-2025: CaixaResearch Health “A DIRECT Quantitative assessment of Heart disease with magnetic resonance imaging (*DIREQT2Heart*)”, La Caixa Foundation. Project ID: HR22-00533.  
**€ 993.609 total budget (local budget € 204.492).**  
**PRINCIPAL INVESTIGATOR**
- 2022-2025: Independent Clinical Research Project “*Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN trial)*”, Spanish National Institute of Health Carlos III (Investigación Clínica Independiente, ICI, Instituto de Salud Carlos III, ISCiii). Project ID: ICI21/00088  
**€ 644.600**  
**PRINCIPAL INVESTIGATOR COORDINATOR**
- 2021-2025: Horizon 2020 SC1-BHC-08-2020 “*Remote Ischemic Conditioning in Lymphoma Patients Receiving Anthracyclines*” (RESILIENCE). Project ID 945118  
**€ 5.998.388 total budget (local budget € 1.725.938).**  
**PRINCIPAL INVESTIGATOR COORDINATOR**
- 2021-2025: EU European Cooperation in Science & Technology COST INNOVATORS GRANT “*Improving Preclinical Assessment of Cardioprotective Therapies*” (IMPACT). Project ID CA16225  
**€ 125.000 total budget.**  
**COLLABORATOR**
- 2021-2025: Horizon 2020 SC1-BHC-08-2020 “*Rituximab in patients with acute myocardial infarction. A phase 2 placebo-controlled randomised clinical trial*” (RITA-MI 2)”. Project ID 899991  
**€ 6.583.215 total budget (local budget € 383.500). Local PRINCIPAL INVESTIGATOR.**
- 2021-2024: Health Research Projects (proyectos de investigación en salud. Fondo de investigación sanitaria), PI21/01631. “*Efectos Clínicos y Fisiológicos del Metoprolol en el Síndrome de Distrés Respiratorio Agudo. METDIS*”. **€101.640 (COLLABORATOR).**
- 2021-2022: Spanish Society of Cardiology Basic Research Grant 2020. “*Empagliflozina in hybERnatinG mYocardium. A swine model (ENERGY)*”. **€15.000. (PI).**
- 2021-2023: Ayudas investigación Fundación Francisco Soria Melguizo 2019 “Prevalencia de secuelas cardiacas tras infección por SARS-CoV-2. Estudio CAR-VID”.  
**€ 449.725,9 COLLABORATOR**
- 2020-2022: Ministry of Science and Innovation R&D projects call “RETOS 2019” (Programa Estatal, Proyectos I+D+i Ministerio Ciencia e Innovación, modalidad **RETOS 2019**). “*Reappraisal of ischemia/reperfusion injury targets (RECENTRE)*”. Project ID: PID2019-107332RB-I00.  
**€ 375.000,00. PRINCIPAL INVESTIGATOR.**
- 2019-2024: **ERC Consolidator Grant (ERC CoG).** “Novel mitochondria-targeted therapies for cancer treatment-induced cardiotoxicity (MATRIX). Project ID: 819775.  
**€ 1.999.370. PRINCIPAL INVESTIGATOR.**
- 2020-2024: Horizon 2020 SC1-BHC-25-2019 “Implementation of personalised risk prediction and prevention of sudden cardiac death after myocardial infarction” (PROFID). Project ID 847999. **€ 19.884.569,75 total budget (local budget € 83.500). Local PRINCIPAL INVESTIGATOR.**
- 2020-2024: Horizon 2020 SC1-BHC-07-2019. “New-generation cardiac therapeutic strategies directed to the activation of endogenous regenerative mechanisms” (REANIMA). Project ID 874764, **€ 8.000.000 total budget (local budget €1.380.000). COLLABORATOR**

- 2020-2014: Horizon 2020 SC1-BHC-25-2019. "Personalized Prevention for Coronary Heart Disease" (COROPREVENTION). Project ID 848056. **€ 19.970.828 total budget (local budget €228.750). Local PRINCIPAL INVESTIGATOR.**
- 2020-2021: Spanish Society of Cardiology Basic Research Grant 2020. "Post-myocardial infarction cardiac regeneration by in-vivo cellular reprogramming". **€15.000. (Co-PI).**
- 2019-2021: Ayuda para la contratación de técnico de laboratorio (PEJ-CAM-2018). **€ 38.000. PRINCIPAL INVESTIGATOR/SUPERVISOR**
- 2018-2021: Madrid Regional R&D grant for technology development and biomedicine. "Madrid Network in Molecular Imaging (RENIM-CM)". "Ayudas para la realización de Programas de Actividades de I+D entre Grupos de Investigación de la Comunidad de Madrid en Tecnologías y en Biomedicina". Funding body: Comunidad Autónoma de Madrid. Title and reference: RED MADRILEÑA DE NANOMEDICINA EN IMAGEN MOLECULAR (RENIM-CM). Project ID B2017/BMD-3867. **€ 857.843,00 total budget (PRINCIPAL INVESTIGATOR OF 1 GROUP, local Budget €128.001,57).**
- 2017-2019: Horizon 2020 European Research Area Network on Cardiovascular Diseases (ERA-CVD) Joint Transnational Call (JTC2016 / APCIN-ISCI-2016.). AC16/00021 "Heart Failure Rescue by Nutritional Approaches: relevance of mitochondrial substrate utilization-FAT4HEART". Global funding **€643.178 (PRINCIPAL INVESTIGATOR coordinator)**. Local funding €149.798
- 2018-2019: Health Research Projects, modality technological development-FIS DTS. Ref #DTS17/00136. "Development of a novel ultra-rapid 3D cardiac magnetic resonance sequence for clinical application". **€77.550 (PRINCIPAL INVESTIGATOR).**
- 2017-2019: CNIC Intramural Grants Program - Severo Ochoa (IGP-SO) 2016. Project ID10-2016 IGP. "The gut microbiome and its related metabolites in the progression of atherosclerosis". **€300.000. (Co-PRINCIPAL INVESTIGATOR).**
- 2017-2018: Spanish Society of Cardiology Basic Research Grant. "Cardioprotective effect of ultra-short acting betablockers in a porcine model of ischemia/reperfusion". **€20.000. (PRINCIPAL INVESTIGATOR).**
- 2017-2018: Spanish Society of Cardiology Translational Research Grant. "Early detection of anthracyclines-induced cardiotoxicity and fibrosis evaluation by multiparametric cardiac magnetic resonance: translational study in a large animal model". **€20.000. (PRINCIPAL INVESTIGATOR).**
- 2017-2018: Spanish Society of Cardiology Basic Research Grant. "Strategies to optimize the therapeutic potential of endothelial progenitor cells: combination therapy and rejuvenation". **€20.000. (Collaborator).**
- 2018-2020 Fundació La Marató de TV3. "School-based behavioural intervention to face obesity and promote cardiovascular health among Spanish adolescents: a cluster-randomized controlled trial". **€125.000. (Collaborator).**
- 2016-2019 Ayudas Fundación BBVA a Equipos de Investigación Científica Convocatoria 2016. "Fat diet for heart failure Reversal: a conceptual change." **€119.790 (PRINCIPAL INVESTIGATOR).**
- 2017-2019: Health Research Projects (proyectos de investigación en salud. Fondo de investigación sanitaria), PI16/02110. "Selective blockade of beta1 adrenergic receptors as a therapy for acute cardiovascular disease in the light of a novel mechanism of action – a comprehensive translational study". **€195.415 (PRINCIPAL INVESTIGATOR).**
- 2017-2020: CIBER cardiovascular.
- 2017-2019: CM16/00109 Rio Hortega Instituto de salud Carlos III. Trainee: Luis Rodriguez Esparragoza Fernández. PI Supervisor: Borja Ibáñez. Institution of execution: Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz. **€53.732 (PRINCIPAL INVESTIGATOR Supervisor).**
- 2017-2019: Proyecto Integrado de Excelencia (PIE 16/00021). "Athero-Brain: Heart to Head (H2H) Study". **€630.300. (Collaborator).**

- 2017-2019: Marie Skłodowska-Curie Individual Global Fellowship (MSCA-IF-2015-EF). “Comprehensive Lifestyle Intervention Project (CLIP)”. Trainee: RoProject ID 707642. **€257.191. (PRINCIPAL INVESTIGATOR Supervisor).**
- 2016-2017: Spanish Society of Cardiology Translational Research Grant. “Validation of the new 3D CMR sequence “VF 3D BRISA” resulting in a massive reduction in the time of scan of a cardiac study”. **€20.000. (PRINCIPAL INVESTIGATOR).**
- 2016-2018: Fundació La Marató de TV3. “ $\beta$ 3adrenergic agonist Treatment in Patients with Chronic Heart Failure and Secondary Pulmonary Hypertension: a Randomized Placebo-Controlled Phase 2 Clinical Trial”. **€101.000. (Co-PRINCIPAL INVESTIGATOR, WP3).**
- 2016-2017: Acciones de dinamización “Redes de Excelencia” 2015 (SAF2015-71613-REDI). “Imagen multimodal y traslacional (IMUTRANS)”. **€137.000. (Co-PRINCIPAL INVESTIGATOR).**
- 2014-2016: Health Research Projects (proyectos de investigación en salud. Fondo de investigación sanitaria), PI13/01979. “Characterization of the dynamic changes in tissue composition of the myocardium after ischemia/reperfusion by using advanced imaging technology”. **€145.200 (PRINCIPAL INVESTIGATOR).**
- 2014-2016: Projects "EXPLORA CIENCIA" National program for boosting scientific research of excellence. National subprogram for knowledge generation (SAF2013-49663-EXP). “Infarto agudo de miocardio: detener la isquemia sin restablecer el flujo sanguíneo. desafío a un paradigma universal”. **€99.220 (PRINCIPAL INVESTIGATOR).**
- 2013-2017: FP7-PEOPLE-2013-ITN. “Next generation training in cardiovascular research and innovation-Cardionext”. €2.736.019 total project, B. Ibañez’s group **€368.948,40 (Co-PRINCIPAL INVESTIGATOR).**
- 2013-2014: Spanish Society of Cardiology Basic Research Grant. “Role of colchicine in the homeostasis of atherosclerotic plaques in a rabbit model”. **€25.000. (PRINCIPAL INVESTIGATOR).**
- 2013-2016: MINECO. Acciones de dinamización de carácter internacional "europa investigación". Project ID EUIN2013-50881. Proyecto Optimización de la administración de metoprolol durante el infarto agudo de miocardio como una terapia de bajo coste para la prevención de la insuficiencia cardíaca crónica. **€25.000. (PRINCIPAL INVESTIGATOR).**
- 2013-2017: Spanish Cardiovascular Network. Project ID RD 12/0042/0054. Program 4: HISPANICVS. WP8 “Evaluation of diffuse fibrosis in cardiomyopathies by Magnetic Resonance Imaging”. B Ibañez’s group **€116.913,82 (PRINCIPAL INVESTIGATOR of WP8).**
- 2013-2015: Fundació La Marató de TV3. “Allogenic adipose tissue-derived stem cells therapy in a porcine model of myocardial infarction: paracrine mechanisms, immune response and functional effects at short and long-term follow-up. **€150.000. (PRINCIPAL INVESTIGATOR of WP3).**
- 2013-2014: CM12/00211 Rio Hortega Instituto de salud Carlos III. Trainee: Rodrigo Fernández. Borja Ibañez. Institution of execution: Centro Nacional de Investigaciones Cardiovasculares. **€56.000 (PRINCIPAL INVESTIGATOR Supervisor).**
- 2012-2013: Spanish Society of Cardiology Basic Research Grant. “Utility of cardiac magnetic resonance to monitor changes in pulmonary vascular resistances and early detection of right ventricular dysfunction in pulmonary hypertension”. **€25.000. (PRINCIPAL INVESTIGATOR).**
- 2012-2015 FP7/2007-2013. LiPhos - Living Photonics: Monitoring light propagation through cells (STREP Project, Grant Agreement No 317916). €3.200.000 total project, **CNIC: €310.250 (Co-PRINCIPAL INVESTIGATOR CNIC)**
- 2011-2013: Health Research Projects (proyectos de investigación en salud. Fondo de investigación sanitaria). PI10/02268. “Beta-Adrenergic System Modulation and Cardioprotection in Myocardial infarction: a translational round trip” **€197.230 (PRINCIPAL INVESTIGATOR).**
- 2011-2013: Master research agreement, Philips Iberica. “Role of T1W mapping in the evaluation of patients with acute myocardial infarction”. **€44.286 (PRINCIPAL INVESTIGATOR)**
- 2011-2013: Fundacion Mutua Madrileña (AP8695-2011). “Role of  $\beta$ 1 blockade before coronary reperfusion: clinical trial of early pharmacological intervention in acute myocardial infarction”. **€80.800 (PRINCIPAL INVESTIGATOR).**

- 2010-2013: CNIC translational grant. Ischemia-Reperfusion Injury: Novel Insights into beta-blockade Salvage Mechanisms in Acute Myocardial Infarction. Translating pre-clinical research into human care” **€448.385 (PRINCIPAL INVESTIGATOR)**.
- 2011-2012: Ministerio de Sanidad y Política Social FIC1 (EC10-042). “Cardioprotective effect of metoprolol in ST-segment elevation acute myocardial infarction, METOCARD-CNIC trial”. **€56.000 (PRINCIPAL INVESTIGATOR)**.
- 2007-2010: Effects of the LXR Modulator WAY-252623 on a Rabbit Model of Advanced Atherosclerosis: In vivo High-Resolution MRI, Biomarker, and Profiling Study. Sponsor: Wyeth Pharmaceuticals. **(Co-I)**.
- 2007-2009: GSK-USA Collaborative Research Project. Effect of carvedilol on acute myocardial infarction. Salvaged Myocardium and apoptosis **(Co-PRINCIPAL INVESTIGATOR)**.
- 2006-2008: Grant from the Working on Ischemic Heart Disease of the Spanish Society of Cardiology. Effect of the HDL-raising in the composition of the atherosclerotic plaque **(Co-PRINCIPAL INVESTIGATOR)**.
- 2005-2008: Effect of ETC-216 (HDL-apoA-<sub>Milano</sub>) on plaque volume and composition in a rabbit model of atherosclerosis. Sponsor: Pfizer R&D. **(Co-I)**.
- 2006-2007: Grant from the American Society of Echocardiography. Mechanisms of diastolic heart failure after myocardial infarction in a pig model of ischemia-reperfusion: Relationship between extent of myocardial scarring, infarct location and left ventricular relaxation and stiffness **(Co-PRINCIPAL INVESTIGATOR)**.



## Patents

- Title: Use of selective 3 agonists for the treatment of pulmonary hypertension.  
Inventors: B Ibanez, A García-Alvarez, V Fuster.  
Patent number: P201231343  
Priority: Spain, Date of priority: 28/08/2012. Status: *entered into national phases in EP, JP, US*.  
Applicant: CNIC
- Title: Method and system for generating MR images of a moving object in its environment.  
Inventors: Javier Sánchez-González, Nils Nothnagel, Borja Ibañez, Rodrigo Fernandez, Valentín Fuster.  
Patent number: EP14192290  
Priority: Europe. Date of priority: 07/11/2014. Status: *entered into national phases in CN, EP, IN, JP, US*.  
Applicants: Koninklijke Philips N.V. and CNIC.
- Title: Oxygen carrying blood substitutes and their use as delivery vehicles.  
Inventors: Borja Ibáñez, Jose Manuel Garcia-Ruiz, Jaume Agüero, Rodrigo Fernandez-Jimenez, Valentín Fuster, Enrique Lara, Juan Bernal, Carlos Galan, Enda Clinton.  
Patent number: EP17382040  
Priority: Europe. Date of priority: 28/01/2017. Status: PCT.  
Applicant: CNIC
- Title: AAV vectors for the treatment of ischemic and non-ischemic heart disease.  
Inventors: Enrique Lara Pezzi, Borja Ibáñez Cabeza, Enda Joseph Clinton, Jesús María Gómez Salinero, María Villalba Orero, David Sanz Rosa, Juan Antonio Bernal Rodríguez.  
N° EP14155721.5.  
Priority: Europe, Date of priority: 19/02/2014. Status: abandoned.  
Applicant: CNIC

## Invited presentations to international conferences (selected from > 70).

- 12/2022:** Invited Speaker at the American College of Cardiology 55<sup>th</sup> Annual NY Cardiovascular Symposium, “*Evolving Strategies for Acute Coronary Syndromes. Differences Between US and European Clinical Practice Guidelines*”. New York, USA. Dec 9-11 2022.
- 08/2022:** Invited Speaker at the European Society of Cardiology (ESC) annual meeting. ESC Congress 2022 Barcelona. “Coronary CT angiography should be the first line investigation in a patient over 70 years with suspected angina – the final word.”. August 29<sup>th</sup> 2022
- 08/2022:** Invited Speaker at the European Society of Cardiology (ESC) annual meeting. ESC Congress 2022 Barcelona. “Atypical chest pain one year after coronary stenting”. August 28<sup>th</sup> 2022
- 08/2022:** Invited Speaker at the European Society of Cardiology (ESC) annual meeting. ESC Congress 2022 Barcelona. “*Diagnosing subclinical atherosclerosis using quantitative proteomics when imaging is not available*”. August 26<sup>th</sup> 2022
- 05/2022:** Invited Speaker at the Course “The Cancer: Non-Hodgkin Lymphomas: From Biology to Treatment”, (Advanced Health Education, NOVA Medical School). May 18-19, 2022, Lisbon, Portugal.
- 05/2022:** Invited Speaker at the 11th Biennial Hatter Cardiovascular Institute Workshop “Cardio, Renal & Neuro Protection, “*Remote Ischemic Conditioning and cardiotoxicity - Rationale & design*”. South Africa. 2022.
- 04/2022:** Invited Speaker at the American College of Cardiology 71st Annual Scientific Session, “*STEMI & NSTEMI Pathophysiological & Clinical Advances: European Versus American Guidelines*”. Washington, USA. April 3<sup>rd</sup> 2022.
- 03/2022:** Invited Speaker at the CardioVascular Research Cluster (CVRC), University of Bern-Inselspital, “*Translational research at CNIC: from mechanisms to clinical trials*”. Bern, Switzerland. March 24<sup>th</sup> 2022.
- 02/2022:** Invited Speaker at the Dublin Cardiovascular Research Forum, Cardiovascular Research institute “*Anthracycline-induced cardiotoxicity: mechanisms, early diagnosis and prevention*”. Dublin, Ireland. February 3<sup>rd</sup> 2022.
- 02/2022:** Invited Speaker at the 25th Annual Scientific Sessions, Virtual – SCMR (Society for Cardiovascular Magnetic Resonance). “*CNIC-Philips partnership: CMR & beyond*”. Virtual Session. February 3<sup>rd</sup> 2022.
- 02/2022:** Invited Speaker at the MonteHeart lecture series, Montefiore Hospital. MonteHeart Multimodality Imaging Lecture “*ESSOS: a new approach to reduce CMR scan time*”. New York, USA. February 18<sup>th</sup> 2022.
- 12/2021:** Invited Speaker at the American College of Cardiology 54<sup>th</sup> Annual NY Cardiovascular Symposium, “*New 3-Dimensional Ultrafast Cardiac MRI in < 1 Minute Acquisition Time From Experimental to Clinical Validation*”. Virtual Symposium. New York, USA. Dec 11<sup>th</sup> 2021.
- 12/2021:** Invited Speaker at the American College of Cardiology 54<sup>th</sup> Annual NY Cardiovascular Symposium, “*STEMI – Pathophysiological & Clinical Advances in 2021 European vs American Guidelines 2020*”. Virtual Symposium. New York, USA. Dec 11<sup>th</sup> 2021.
- 10/2021:** Invited Speaker at the 8th EU-CARDIOPROTECTION COST Action WG Meeting, “*Challenges with setting-up up a pig AMI network*”. Mallorca, Spain. Oct 13<sup>th</sup> 2021.
- 06/2021:** Invited speaker at the 13th International Symposium on Pharmaceutical Sciences (ISOPS-13). “*Modulation of Beta Adrenergic System For Exacerbated Inflammation*” Virtual meeting, Ankara-

Turkey. June 22<sup>nd</sup> 2021

- 06/2021:** Invited speaker at the international congress of the Interamerican Society of Cardiology (SIAC 2021). "SCA con enfermedad de múltiples vasos. Revascularización completa endovascular: ¿En qué momento?" Virtual meeting, June 9<sup>th</sup> 2021
- 04/2021:** Invited speaker at the Annual meeting of the German Cardiac Society (DGK) 2021. "STEMI – Current treatment". Virtual meeting, April 7<sup>th</sup> 2021
- 03/2021:** Invited speaker at the international congress of the Mexican Society of Cardiology. "The use of beta-blockers in the prevention of adverse post-infarct remodeling". Virtual meeting, March 19<sup>th</sup> 2021
- 12/2020:** Invited speaker at the International Forum on Translational Medicine, National Center on Translational Medicine, Shanghai, China. "Cardiovascular translational Research in XXI Century: from disease to health. The CNIC's vision". Virtual meeting, December 18<sup>th</sup> 2020
- 11/2020:** Invited speaker at the international congress on Acute Coronary Syndromes (SICA 2020), Instituto Nacional de Cardiología Ignacio Chavez, Mexico. "¿Qué hay nuevo desde las guías STEMI ESC 2017?" Virtual meeting, November 26<sup>th</sup> 2020
- 11/2020:** Invited speaker at the annual congress of the Mexican Society of Interventional Cardiology (SOCIME). "Beyond ESC STEMI guidelines". Virtual meeting, November 22<sup>nd</sup> 2020
- 11/2020:** Guest lecture of the CRC1116. "Applying lessons learned in ischemia/reperfusion to anthracycline-induced cardiotoxicity". Dusseldorf, Germany (Virtual), November 5<sup>th</sup> 2020
- 11/2020:** Invited Speaker at the American Heart Association (AHA) Scientific Sessions 2020. A Virtual Experience. "Strategies to Reduce Anthracycline-Induced Cardiotoxicity: The Matrix EU Study". November 13<sup>rd</sup> 2020
- 08/2020:** Invited Speaker at the European Society of Cardiology (ESC) annual meeting. ESC Congress the Digital Experience 2020. Amsterdam, The Netherlands (Virtual). "New data since the last ESC Guidelines on STEMI". August 31<sup>st</sup> 2020
- 06/2020:** Invited Speaker at the European Hematology Association (EHA) 25th Annual Congress, "Anthracycline-induced cardiac toxicity in animal models and the role of cardiac MRI in monitoring the damage focused in older adults with lymphoma". Virtual Congress 2020.
- 12/2019:** Invited Speaker at the American College of Cardiology 52<sup>nd</sup> Annual NY Cardiovascular Symposium, "Evolving Cardiac MRI - Clinical and Research Applications: Post Myocardial Infarction, Early Chemotherapy Toxicity". New York, USA. Dec 2019.
- 11/2019:** Invited speaker at the Cardiovascular Program and Cardiovascular Research Meeting "Mitochondria as a therapeutic target in anthracycline-induced cardiotoxicity", Yasuragi Hasseludden, Sweden, 28th-29th November 2019.
- 11/2019:** Invited speaker at the "ESC in Asia" meeting. Joint meeting European Society of Cardiology (ESC) & Asian Pacific Society of Cardiology (APSC). "Management of STEMI and Multivessel Disease". Singapore, November 9<sup>th</sup> 2019
- 11/2019:** Invited speaker at the "ESC in Asia" meeting. Joint meeting European Society of Cardiology (ESC) & Asian Pacific Society of Cardiology (APSC). "Myocardial revascularization- New ESC Guidelines". Singapore, November 9<sup>th</sup> 2019
- 11/2019:** Invited speaker at the "ESC in Asia" meeting. Joint meeting European Society of Cardiology (ESC) & Asian Pacific Society of Cardiology (APSC). "Highlights of the ESC Congress 2019 II: Intervention". Singapore, November 8<sup>th</sup> 2019
- 09/2019:** Invited Speaker at the European Society of Cardiology (ESC) annual meeting. "STEMI patient with

- multivessel disease: What to the Guidelines say". Paris, France, September 3<sup>rd</sup> 2019
- 09/2019:** Hot Line Session Discussant "16 years follow-up of the DANAMI-2". European Society of Cardiology (ESC) annual meeting. Paris, France, September 2<sup>nd</sup> 2019
- 09/2019:** Invited Speaker at the European Society of Cardiology (ESC) annual meeting. "Ace-inhibitors and betablockers after acute coronary syndromes: for whom and for how long". Paris, France, September 2<sup>nd</sup> 2019
- 09/2019:** Invited Speaker at the European Society of Cardiology (ESC) annual meeting. "Journal of the American College of Cardiology's Year in Cardiology: four challenges to enhance major health factors: Cholesterol". Paris, France, September 1<sup>st</sup> 2019
- 08/2019:** Special Scientific Seminar, School of Medicine of Essen "Mitochondria-targeted therapies for anthracycline induced cardiotoxicity". Essen, Germany, August 27<sup>th</sup> 2019
- 08/2019:** Guest lecture of the IRTG 1902, SFB 1116 and CARID "Beta-adrenergic System Modulation to reduce ischemia/reperfusion injury". Dusseldorf, Germany, August 28<sup>th</sup> 2019
- 05/2019:** Opening Lecture at the Congreso AsturGalaico of Cardiology, "Present and future of Cardiovascular Research in Spain: Role of the National Center for Cardiovascular Research". Avilés, Spain, May 2019.
- 02/2019:** Keynote Lecture at the 4<sup>rd</sup> EU-CARDIOPROTECTION COST Action CA16225. Closing Keynote lecture "CMR in clinical cardioprotection studies". Kragujevac, Serbia, February 2019.
- 11/2018:** Invited Speaker at the American Heart Association (AHA) Scientific Sessions 2018. "PCI strategy in multi vessel disease: How and when?", Chicago, USA, November 2018
- 10/2018:** Invited Speaker at the Eurothrombosis meeting (organized by the ESC working group on thrombosis). "Targeting microvascular obstruction in primary PCI: when and how". Barcelona October 2018.
- 06/2018:** Invited Speaker at the Workshop on Cardiovascular Medicine at the 52<sup>th</sup> Annual Scientific meeting of the European Society for Clinical Investigation, Barcelona June 2018. "Immunodulation in Myocardial Infarction"
- 09/2018:** Invited Speaker at the Ukrainian National congress of cardiology. "The Cardiovascular Polypill: Innovation in improving adherence and cost effectiveness of secondary prevention worldwide". Kiev, Ukraine September 2018
- 08/2018:** Invited Speaker at the European Society of Cardiology (ESC) annual meeting. "Managing STEMI in patients on oral anticoagulation" Munich, Germany, August 2018
- 03/2018:** Invited Speaker at the 'ESC in Arabia' 2018 at the 29<sup>th</sup> Saudi Heart Association Scientific Session (SHA29) "STEMI and Pregnancy, What do ESC Guidelines Say?", Riyadh, Saudi Arabia, March 2018
- 12/2017:** Invited Speaker at the American College of Cardiology "50<sup>th</sup> Annual NY Cardiovascular Symposium", New York, USA, Dec 2017. "STEMI 1 – Timing, Mechanical Type and Pharmacology of Reperfusion: Three Main Challenges to Decrease Infarct Size and Increase Viability".
- 11/2017:** Invited speaker at the 2<sup>nd</sup> MOLECULAR IMAGING WORKSHOP 2017, San Sebastián, Spain. "Role of CMR in post-myocardial infarction tissues characterization".
- 11/2017:** Invited Speaker at the 47<sup>th</sup> Annual CardioCon2017, Hyderabad Pakistan, November 2017. Session Pakistan Cardiac Society-European Society of Cardiology (PCS-ESC) JOINT SESSION "New 2017 STEMI guidelines: what is new?".
- 09/2017:** Invited Speaker at the 19<sup>th</sup> Scientific Annual Congress of Chinese Society of Cardiology (CSC 2017), Taiyuan, China, September 2017. "Dual antiplatelet therapy (DAPT): when, how and till

when?”

- 09/2017:** Invited Speaker at the IV Congreso Internacional De Cardiología Fundacion Clinica Shaio, Bogotá, Colombia, September 2017. Three invited talks “Daño por isquemia/repercusión en el infarto con elevación de segmento ST: una espada de doble filo”, “Novedades de tratamiento de STEMI en 2017”, & “Identificación de aterosclerosis subclínica por imagen como herramienta para re-estratificación del riesgo cardiovascular”.
- 06/2017:** Invited Speaker at the Chinese Northeast Cardiovascular Forum (NCF), Shenyang, China, June 2017. “Ischemia, Reperfusion & Remodeling in JACC Family”.
- 06/2017:** Invited Speaker at the XXV Annual meeting of the Czech Society of Cardiology, Brno, Czech Republic, May 2017. Joint Session CSC-ESC. “STEMI treatment - New evidence which may be considered for future ESC guidelines”.
- 03/2017:** Invited Speaker at the 49th Annual Scientific Meeting The Heart Association of Thailand: Cardiology on the move, Huahin, Thailand, March 2017. “ESC STEMI 2017”.
- 1/2017:** Invited Speaker at the American College of Cardiology Cardiovascular Symposium India, Mumbai Jan 2017. Session II: Acute Coronary Syndromes. “STEMI 1 - Timing to Reperfusion / Reperfusion Injury. The two Priority Challenges to Decrease Infarct Size”.
- 12/2016:** Invited Speaker at the American College of Cardiology “49<sup>th</sup> Annual NY Cardiovascular Symposium”, New York, USA. Dec 2016. Session II: Acute Coronary Syndromes. “STEMI 1 - Timing to Reperfusion / Reperfusion Injury A Multi-Layer Challenge to Decrease Infarct Size”.
- 06/2016:** Invited Speaker at the Workshop “Looking beyond primary angioplasty in STEMI: myocardial cardioprotection at the crossroads”, Bologna Italy June 2016. Session Cardiac Magnetic Resonance (CMR) imaging in cardioprotection trials: a controversial matter. “Area at risk quantification by CMR is another source of bias and should not be used in clinical trials”.
- 05/2016:** Invited Speaker at the conference “Ischemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery”. Barcelona May 2016. “Pharmacological prevention of reperfusion injury: Beta-blockers”
- 3/2016:** Invited Speaker at the American College of Cardiology 65th Annual Scientific Session, Chicago, Illinois. Session: Cardiovascular Update for the Clinician. Session: Coronary artery disease-challenges in 2016. “STEMI - Timing to Reperfusion / Reperfusion Injury. A Multilayer Challenge to Decrease Infarct size”.
- 01/2016:** Invited Speaker at the 9th Biennial Hatter Cardiovascular Institute Workshop “Cardioprotection”. Botswana. 2016. World leaders in reperfusion injury.
- 3/2015:** Invited Speaker at the American College of Cardiology 64th Annual Scientific Session, San Diego, California. 2015. Session: Cardiovascular Update for the Clinician. Session: Athero-thrombogenesis and Acute Coronary Syndromes. “STEMI - Evolving Early Therapies for Ischemia/Reperfusion Injury. Integrating “Time is Muscle” with “Therapy Strategy is Muscle”.
- 1/2015:** Invited Speaker at the American College of Cardiology Cardiovascular Symposium India, Mumbai Jan 2015. Session II: Acute Coronary Syndromes. “STEMI: Evolving Early Therapies of “STEMI – Time to Reperfusion/Reperfusion Injury: A Double Challenge to Decrease Infarct Size”.
- 12/2014:** Invited Speaker at the American College of Cardiology “47<sup>th</sup> Annual NY Cardiovascular Symposium”, New York, USA. Dec 2014. “Acute Coronary Syndromes. “STEMI: Evolving Early Therapies of “Myocardial Ischemia/ Reperfusion Injury” Protection Preconditioning (Inflation/Deflection) and Beta- blockers in the Ambulance, Cyclosporin A”.
- 11/2014:** Invited Speaker at the annual Scientific Sessions if the American Heart Association, Chicago Nov 2014. Session “Groundbreaking studies 2013”.

- 05/2014:** Invited Speaker Plenary Session “Can we increase myocardial salvage in the primary PCI era?” at the EuroPCR symposium, Paris May 2014. “Preservation of microcirculatory integrity in patients with acute myocardial infarction with pharmacological agents”.
- 03/2014:** Late Breaking Clinical trials presentation. American College of Cardiology Sessions, Washington.
- 09/2013:** Keynote lecture, opening session at the First Experts Meeting on Intensive Care. “*Early i.v.  $\beta$ -Blocker in Acute Myocardial Infarction for Myocardial Salvage*”. Salzburg, Austria.
- 08/2012:** Invited Speaker at the 7th Biennial Hatter Cardiovascular Institute Workshop “*Cardioprotection: From novel targets to clinical application*”. South Africa. World leaders in reperfusion injury.
- 03/2012:** Invited Speaker at the University College London (UCL) Cardiovascular Lecture Series, London.
- 12/2011:** Invited Speaker at the American College of Cardiology “*44<sup>th</sup> Annual NY Cardiovascular Symposium*”, New York, USA.
- 11/2011:** Invited Speaker at the New York Academy of Sciences meeting: “*Evolving Challenges in Promoting Cardiovascular Health*”.
- 11/2010:** Invited Speaker at the American Heart Association Scientific Sessions. Chicago, USA.
- 11/2010:** Invited Speaker at the American Heart Association Resuscitation Science Symposium. Chicago.
- 12/2008:** Invited Speaker at the Working Group of Thrombosis of the European Society of Cardiology “Eurothrombosis Science”.

## Mentorship and Training: PhD thesis and postdoctoral fellows.

PhD THESIS SUPERVISED.

1. **Susana Prat-González.** PhD thesis title "Efecto cardioprotector del metoprolol en la reperfusión coronaria: análisis del miocardio isquémico". University: Universidad Autonoma de Barcelona. Date: Jun 8 **2012**

<http://hdl.handle.net/10803/126399>

2. **Eduardo Pozo Osinalde.** PhD thesis title "Evaluación de la infiltración miocárdica en amiloidosis mediante cardioresonancia magnética". University: Universidad Complutense de Madrid. Date: Jan 25<sup>th</sup> **2016**.

<https://eprints.ucm.es/id/eprint/44719/>

3. **Beatriz López Melgar.** PhD thesis title "Ecografía vascular tridimensional, un nuevo método para la detección y la cuantificación de la aterosclerosis subclínica". University: Universidad Complutense de Madrid. Date: Feb 2<sup>nd</sup> **2016**.

<https://eprints.ucm.es/id/eprint/41475/>

4. **Nils Nothnagel.** PhD thesis title "Development of novel quantitative medical imaging techniques for MPI and MRI". University: Universidad Carlos III de Madrid. Date: Sept 30<sup>th</sup> **2016**.

<http://hdl.handle.net/10016/23851>

5. **Gonzalo Pizarro.** PhD thesis title "Cardioprotection exerted by metoprolol in STEMI. Evaluation by cardiac magnetic resonance in the context of the METOCARD-CNIC trial". University: Universidad Europea de Madrid (UEM). Date: April 6<sup>th</sup> **2017**.

<http://hdl.handle.net/11268/6966>

6. **Jaume Agüero.** PhD thesis title "Novel heart failure preclinical models: characterization by advanced imaging techniques and new therapies application". University: Universidad Autónoma de Madrid. Date: May 30<sup>th</sup> **2017**.

<http://hdl.handle.net/10486/679885>

7. **Cristina Barneto.** PhD thesis title "Cronopatología del infarto de miocardio y moduladores cronobiológicos en la efectividad de la estrategia terapéutica". University: Universidad Complutense de Madrid. Date: July 14<sup>th</sup> **2017**.

<https://eprints.ucm.es/id/eprint/49842/>

8. **Antonio Piñero.** PhD thesis title "Administración pre-reperfusión del agonista de receptores adrenérgicos beta-3 "mirabegron" en un modelo porcino de infarto: efecto sobre tamaño de infarto, remodelado ventricular y función cardiaca". University Autónoma de Madrid. Date: September 22<sup>nd</sup> **2017**.

<http://hdl.handle.net/10486/682964>

9. **Alberto Cecconi.** PhD thesis title "Efectos de la colchicina sobre la placa aterosclerótica: estudio en un modelo de aterosclerosis en conejo". University Complutense de Madrid. Date: November 15<sup>th</sup> **2017**.

<https://eprints.ucm.es/id/eprint/50132/>

10. **Jaime García-Prieto.** PhD thesis title "Role of  $\beta$ -adrenergic modulation in myocardial ischemia/reperfusion injury. Mechanisms underlying cardioprotection". University: Universidad Autónoma de

Madrid. Date: December 18<sup>th</sup> 2017.

<http://hdl.handle.net/10486/681489>; <http://hdl.handle.net/20.500.12105/8347>

**11. Rodrigo Fernández-Jiménez.** PhD thesis title “Temporal dynamics and pathophysiology of the edematous response after acute myocardial infarction: a translational journey”. University: Universidad Autónoma de Madrid. Date: December 20<sup>th</sup> 2017.

<https://repositorio.uam.es/handle/10486/681476>; <http://hdl.handle.net/20.500.12105/8346>

**12. Ali Ayaon.** PhD thesis title “odelo experimental de aneurisma de la arteria aorta ascendente: estudio de los factores reológicos”. University: Universidad Complutense de Madrid. Date: July 5<sup>th</sup> 2018.

<https://eprints.ucm.es/id/eprint/50941/>

**13. Daniel Pereda.** PhD thesis title “Modelos experimentales traslacionales de hipertensión pulmonar y su aplicación para desarrollar nuevas estrategias diagnósticas terapéuticas”. University: Universidad Autónoma de Barcelona. Date: October 16<sup>th</sup> 2019.

<https://www.educacion.gob.es/teseo/imprimirFicheroTesis.do?idFichero=8RmcMVT8Mrw%3D>

**14. Jean Paul Vilchez.** PhD thesis title “Correlación entre la ecografía vascular 3d, resonancia magnética y tomografía por emisión de positrones en la detección y caracterización de la aterosclerosis en aorta de conejo”. University: Universidad Complutense de Madrid. Date: November 25<sup>th</sup> 2019.

<https://eprints.ucm.es/id/eprint/59205/>

**15. Andrés Pun.** PhD thesis title “The role of the  $\beta$ 3-adrenergic receptor in animal models of cardiac injury”. University: Universidad Autónoma de Madrid. December 20<sup>th</sup> 2019

<http://hdl.handle.net/20.500.12105/9030>

**16. Carlos Galán.** PhD thesis title “Early identification of myocardial dysfunction in subjects receiving chemotherapy”. University: Universidad Autónoma de Madrid. February 21<sup>st</sup> 2020

<http://hdl.handle.net/20.500.12105/10730>

**17. Inés García-Lunar.** PhD thesis title: “Efecto de la denervación arterial pulmonar en un modelo experimental traslacional de hipertensión pulmonar postcapilar crónica”. University: Universidad Europea de Madrid. June 15<sup>th</sup> 2020

<http://hdl.handle.net/11268/9532>

**18. Aida Suárez Barrientos.** PhD thesis title: “Influencia del ritmo circadiano en el tamaño del infarto y estrategias de cardioprotección”. University: Universidad Autónoma de Madrid. July 1<sup>st</sup> 2020

<http://hdl.handle.net/10486/692419>

**19. Juan Martínez-Milla.** PhD thesis title “Miocardio hibernado: caracterización con imagen multimodal de un Modelo de animal grande y estudio piloto del papel terapéutico de dieta rica en grasa”. University: Universidad Autónoma de Madrid. University: Universidad Autónoma de Madrid. September 28<sup>th</sup> 2020

<http://hdl.handle.net/10486/693066>

**20. Ana Devesa.** PhD thesis title “Prevalencia de amiloidosis cardiaca por transtiretina en pacientes con insuficiencia cardiaca con fracción de eyección preservada sin hipertrofia ventricular izquierda”. University: Universidad Autónoma de Madrid. October 23<sup>rd</sup> 2020.

<http://hdl.handle.net/10486/693812>

**21. Joaquim Bobí.** PhD thesis title “Terapia con células madre mesenquimales derivadas del tejido adiposo alógenicas en un modelo porcino de infarto agudo de miocardio”. Universidad de Barcelona. December



17th 2020.

[http: PENDING](#)

**22. Raquel Díaz Muñoz.** PhD thesis title “Efecto del metoprolol intravenoso en el electrocardiograma del paciente con infarto agudo de miocardio con elevación del segmento ST antes de la reperfusión”. Universidad Autónoma de Madrid. January 15<sup>th</sup> 2021

[http: PENDING](#)

**23. Tiago Ferreira Silva.** PhD thesis title “3D single breath-hold MR methodology for measuring parametric cardiac mapping on a 3T clinical scanner”. Universidad Carlos III de Madrid. May 27<sup>th</sup> 2021

[http: PENDING](#)

**24. Austin Benn.** PhD thesis title “A Common Space Approach to Comparative Neuroimaging Extends the Translational Niche of the Pig In Neuroscience”. Universidad Autónoma de Madrid. July 28<sup>th</sup> 2021

[http: PENDING](#)

**25. Eduardo Arroyo Úcar.** PhD thesis title “Preacondicionamiento isquémico en la función vasomotora de la arteria radial evaluada mediante tomografía de coherencia óptica”. Universidad Europea de Madrid. September 10<sup>th</sup> 2021

[http: PENDING](#)

**26. Borja Ruiz-Mateos.** PhD thesis title “Utilidad del electrocardiograma de 12 derivaciones para localizar la arteria responsable del infarto de miocardio inferior con elevación del ST”. Universidad Autónoma de Madrid. September 13<sup>th</sup> 2022

[http: PENDING](#)

**27. Elena Díaz Peláez.** PhD thesis title “Evolving In Cardiac Magnetic Resonance Imaging: Clinical And Research Applications Of Tisular Carachterization In Myocardial Infarction And Cardiotoxicity”. Universidad de Salamanca. November 23<sup>rd</sup> 2022

[http: PENDING](#)

**28. Rocío Villena-Gutiérrez.** PhD thesis title “The role of Yme1l in the progression of heart failure. Nutritional approaches for prevention”. Universidad Autónoma de Madrid. January 26<sup>th</sup> 2023

[http: PENDING](#)

**29. Agustín Clemente.** PhD thesis title “Translational and Mechanistic Study about Beta-1-Adrenergic Receptor Modulation on Neutrophils as a Therapy against Ischemia/Reperfusion Injury”. University: Universidad Autónoma de Madrid. February 24<sup>th</sup> 2023

[http: PENDING](#)

PhD THESIS ONGOING (UNDER CURRENT SUPERVISION).

**30. Sandra Gómez-Talavera.** PhD thesis title “XXX”. University: Universidad Autónoma de Madrid. Year (anticipated): 2023

**31. Anabel Díaz-Guerra Priego.** PhD thesis title “MATRIX.....”. University: Universidad Autónoma de

Madrid. Year (anticipated): 2024

**32. Miguel Fernández-Tocino.** PhD thesis title “RECENTRE...”. University: Universidad Autónoma de Madrid. Year (anticipated): 2025

**33. Danielle Medina-Hernández.** PhD thesis title “INPHINIY. EMPADOX...”. University: Universidad Autónoma de Madrid. Year (anticipated): 2025

#### POSTDOCTORAL FELLOWS SUPERVISION.

- 1. Ana García Álvarez, MD, PhD.** Period as supervisor: 2012-2015. Current position: Chief of Cardiology Department and head of Heart Failure Unit, Hospital Clinic Barcelona & Group leader at the Instituto de Investigación Biomédica Agustí Pi i Sunyer, Barcelona.
- 2. David Sanz-Rosa, PhD.** Period as supervisor: 2010-2015. Current position: Assistant Professor & methodological advisor, Centro de Excelencia de Investigación en Salud, Deporte y Ciencias de la Vida Escuela de Doctorado e Investigación. Universidad Europea de Madrid.
- 3. Rodrigo Fernández-Jiménez, MD PhD.** Period as supervisor: 2012-present. Current Position: Group Leader (Assistant Health Scientist) at the Spanish Center for Cardiovascular Research (CNIC).
- 4. Eduardo Oliver, PhD.** Period as supervisor: 2016-present. Current position: Group Leader, Centro de Investigaciones Biológicas Margarita Salas | CSIC, Spain.
- 5. Carlos Galán-Arriola, MD PhD.** Period as supervisor: 2020-. Current position: Permanent Scientific Collaborator, CNIC.
- 6. Ana Devesa, MD PhD.** Period as supervisor: 2016-2021present. Current position: Postdoctoral fellow, Icahn School of Medicine at Mount Sinai, New York, USA.
- 7. Laura Cádiz, PhD.** Period as supervisor: 2021-. Current position: Postdoctoral fellow, CNIC.